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But there are times when it needs a little help.
The liver is an extraordinary organ.
The best of Royal Canin’s expertise for absolute Hepatic Support.
Royal Canin Hepatic Canine and Feline support and protect the liver
while providing appropriate nutrition for the whole body.
Dear FECAVA Member,
Please find attached your FECAVA 
Membership Card.
One of the main benefits of your membership 
is that you can attend not only your own 
association’s conferences, but also benefit 
from a reduced delegate fee at the courses 
and conferences of other FECAVA member 
associations. Colleagues from associations 
under the umbrella of FECAVA’s CE 
programme can expect a further reduction 
at some larger congresses and they can 
benefit from free or considerably subsidised 
FECAVA-organised courses in their own 
country. These benefits require you to be 
a member of your own national FECAVA 
associated organisation. In order to help you 
and the organisers of veterinary conferences 
to identify you as a member of a FECAVA 
organisation, we have enclosed your own 
membership card. Please add your personal 
details on the back of your card to avoid any 
misuse.*
You will not need the attached card, if your 
own national companion animal association 
has already issued you with a membership 
card that clearly displays the FECAVA logo on 
the front of the card.
The attached card is valid for three years 
and replacement cards can be ordered 
from our Brussels office on payment of an 
administration fee.
Please note the list of other benefits of 
FECAVA membership on the back of the card 
and do visit the FECAVA website at www.
fecava.org for more details on benefits and 
discounts for which you might need your 
membership card in the future.
*) Please note that individual conference 
organisers might ask you for further proof of 
your membership.
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     Editorial
FECAVA was founded and EJCAP ﬁ rst published 21 years ago and both can now deﬁ nitely be said to have come of 
age! One of the principal aims of the new Federation was to bring together, for the beneﬁ t of all members, the vast 
amount of expertise and knowledge available in Europe. Europe at 820 million has a population greater than North 
America’s 520 million. It follows that the potential clinical base and pool of knowledge at least rivals that of North 
America. Because of language and cultural differences however, veterinarians in different parts of Europe had a limited 
idea of what advances were being made in other neighbouring countries. In order to address this problem FECAVA 
founded EJCAP where the best published work from all member countries could be published following selection 
and translation into English. More recently other scientiﬁ c work originating in Europe has been made available to 
EJCAP readers. This includes Commissioned material, original work articles, papers based on FECAVA lectures, Book 
reviews, a Calendar of Continuing Education opportunities and news items, each helping readers to take advantage of 
the best in Europe.
This is the forty third issue of EJCAP and it will be the last to be published in hard copy format.  To have the Journal 
available in both hard copy and online formats would have been the ideal arrangement but the cost of distribution of 
the printed Journal was becoming such a burden for some associations that the decision was taken that future issues 
will be available online only. 
What has become increasingly apparent as we have worked towards the production of an online publication next year 
is the prospect of a much richer Journal, with lots of exciting add-ons and hyperlinks. Moreover, the online format will 
allow us to address one problem that the Journal has always presented for some of our readers - the fact that not all can 
beneﬁ t fully from a journal that is not produced in their native language.  Online publication will allow the production 
of a journal with multilingual elements, tailored to meet the needs of all members. There can be no doubt that on-line 
publication is the way forward in this digital age.
I urge all readers to read Monique Megens introduction to the online Journal on page 131 of this issue and you will 
then understand why those of us involved in developing this project are convinced of the beneﬁ ts of online publication.
My e-mail is always open to constructive suggestions as to how we can meet your own requirements as we move to the 
online format. Interactive questionnaires will also regularly appear in the online issues. 
Be excited and ready to view the ﬁ rst online issue in April 2012
Keith Davies, Editor EJCAP
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FECAVA NEWS
FECAVA NEWS
The FECAVA Council, committee and 
working group meetings took place in 
Moscow from 14th – 16th April this year 
at the invitation of our Russian member, 
the Russian Small Animal Veterinary 
Association (RSAVA).
The Council was welcomed to Moscow by 
Dr. Serguey Sereda, the RSAVA President 
who expressed how important the 
support and collaboration of Europe is for 
Russia. He explained that RSAVA 
members presently faced immense 
difficulties due to recently enacted 
medicines legislation, which essentially 
meant that they could not legally use any 
anesthetics and analgesics.  He asked for 
FECAVA’s help in effecting sensible 
changes to this situation.
FECAVA News is brought together by Simon Orr, FECAVA President Elect
From left to right - Dr. Alexander Tkachov Jr. (FECAVA 
Director for RSAVA), Dr. Serguey Sereda (RSAVA President) 
and Dr. Johan van Tilburg (FECAVA President)
The tour guide standing behind Stalin’s 
desk in front of a map showing the situation 
as the Germans approached the city.
From left to right 
- Dr. Miloš Urban 
(FECAVA Director 
for CSAVA), Ulrike 
Tewes (FECAVA 
Secretariat) and Dr. 
Wolfgang Dohne 
(FECAVA Director for 
BSAVA) in front of St. 
Basils Cathedral in Red 
Square
FECAVA Council visits Russia for the first time
The FECAVA Board had a meeting on 
9th-10th June in Palermo, which gave it a 
chance to network with the FVE and 
UEVP Boards and delegates attending 
their assembly meetings.
All the meetings, including the FECAVA 
Board meeting, took place in the rather grand 
Palazzo dei Normanni or Royal Palace of 
Palermo.  However, not all attendees seemed 
very interested in what was being discussed!
 
The UEVP General Assembly meeting 
took place the day before the FVE 
meeting and the items of relevance to 
The FECAVA Board joined the FVE and UEVP delegates in Palermo
On Thursday 14th April, delegates were 
taken on a visit to Stalin’s bunker to the 
east of Moscow, from where Stalin 
directed operations against the German 
armies as they approached the city of 
Moscow.  An informative guide gave the 
audience some idea of the momentous 
events that took place in the second half 
of 1941 during Operation Barbarossa.
Although meetings occupied most of the 
time from Thursday through to the 
Council meeting on Saturday, some 
managed to find time to visit the city of 
Moscow and see some of the famous sites 
including Red Square and the Kremlin.
FECAVA is very grateful to RSAVA for 
making the visit possible and for the 
tremendous organisation and hospitality 
offered during the meeting.
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FECAVA Hygiene 
Poster receives 
endorsement at 
the FVE Meeting in 
Palermo
Nancy De Briyne, Deputy Executive 
Director of FVE, gave the FVE Assembly 
meeting in Palermo an update on the 
development of the Community Animal 
Health Law.  She closed her presentation 
explaining that a previous EU Veterinary 
Week had been on the subject of 
Biosecurity. She then presented the 
FECAVA Hygiene poster and invited 
everybody to take a copy. 
Nancy De Briyne, Deputy Executive 
Director of FVE. Photograph courtesy of 
Karin de Lange / Aksent
An update on the 
European Board for 
Veterinary Professional 
Development
The European Board for Veterinary 
Professional Development (EBVPD) held 
its inaugural meeting in Brussels on 
April 6th. The first task was the 
establishment of statutes together with a 
mission statement and strategy. The 
statutes are now drafted and the new 
Board agreed to meet again on 21st 
September 2011.
The Board comprises FVE, UEVP, 
FECAVA (as a co-opted member), the 
European Association of Establishments 
for Veterinary Educational 
Establishments (EAEVE) and the 
European Board for Veterinary 
Specialisation (EBVS). It is envisaged that 
other groups (e.g. the statutory bodies) 
will be involved in the near future.  
Andrew Byrne (FECAVA/UEVP) was 
elected by the Board as Chairman.
FECAVA were discussed in both 
meetings and are summarised below.
An election was held for the UEVP Board 
and the following results were declared:
Re-elected as President 
 Zsolt Pinter (Hungary)
Re-elected as General Secretary 
 Andrew Robinson (UK)
Re-elected as Treasurer 
 Anne Ceppi (Switzerland)
Re-elected as Vice-Presidents 
 Andrew Byrne (Republic of Ireland)
 Thierry Chambon (France)
  Rens van Dobbenburgh (The 
Netherlands)
Zsolt Pinter
UEVP President
The FVE Assembly was opened and 
delegates were welcomed to Palermo, by 
FVE President Dr Walter Winding and 
Fedrazione Nazionale Ordini Veterinari 
Italiani President, Dr Gaetano Penocchio.
FVE Executive Director, Jan Vaarten 
updated the Assembly on recent FVE 
activities and priorities, which had 
included: 
a. The One Health initiative.
b.  Strengthening links with the medical 
profession.
c.  The Medicines and the Medicated 
Feed Directives.
d.  Responsible use of antimicrobials, in 
particular the FVE response to the 
amendment to the European 
Parliament Antimicrobial Resistance 
Resolution and participation in EU 
AMR Day.
e.  Animal Welfare issues including the 
BEVA / FEEVA work on transporting 
horses, the declaration on pig 
castration and the work on responsible 
animal ownership.
He also noted that FVE has undertaken 
considerable work in relation to 
veterinary education and research, 
including having responded to the 
consultation on the revision of the 
Recognition of Professional Qualification 
Directive, worked on the European Board 
of Veterinary Professional Development 
and been a part of the CALLISTO project 
on the transmission of zoonotic diseases 
from companion animals.
The President, Walter Winding, 
introduced the paper ‘Report on 
reflections on the structure of FVE’ 
noting that the FVE was looking at the 
relationship between the FVE and its 
sections and branches, to establish 
whether working practices and 
collaboration could be improved. The 
FVE was also considering its relationship 
with other European organisations such 
as FECAVA. The paper was not proposing 
a change of structure, but was a reflection 
on how the current structure worked and 
could be developed.
Simon Orr, the FECAVA Vice-President, 
noted that FECAVA has a good working 
relationship with FVE and ask that it be 
allowed to feed into any discussions that 
would take place in the future.
An election was held for the position of 
FVE President and four positions of 
Vice-President and the following results 
were declared:
Elected as President – 
 Christophe Buhot (France)
Elected as Vice- Presidents
 Robert Huey (UK)
 Karin Ostensson (Sweden)
 Rafael Laguens (Spain)
 Hans Joachim Gotz (Germany)
 
Christophe Buhot
FVE President
Christophe Buhot stated that it was an 
honour to be elected as President and 
informed the Assembly that during his 
term of office he wished to:
•  Ensure that the FVE remained 
independent and proactive.
•  Strengthen the diversity of knowledge 
and culture within FVE.
•  Address the ‘big five’ issues: 
Antimicrobial Resistance, education, 
the Medicines Directive, the Animal 
Health Law and the Animal Welfare 
Law.
• Improve communications within FVE.
•  Ensure the profession was recognised 
and the veterinary surgeon was 
acknowledged as the most qualified 
person to address animal health.
	  
126
FECAVA NEWS
FVE (the Federation of veterinarians of 
Europe) has asked FECAVA to take a 
significant role in a major project 
concerning zoonosis.
Zoonotic pathogens continue to pose a 
significant health risk to humans. In the 
past few decades we have witnessed 
several events where pathogens crossed 
the barriers from their regular animal 
host to humans via contact or vectors or 
via food, causing large outbreaks in the 
human population. About 60% of 
infectious diseases in humans originate 
in animals and about 75 % of emerging 
diseases are zoonotic. In addition, food 
animals are also at risk of emerging 
pathogens mainly originating from other 
animal species.
An increasing number and range of 
companion animals – defined as any 
domesticated or domestic-bred animals 
kept by humans for company, amusement 
or psychological support including dogs, 
cats, horses, birds, rabbits, ferrets, guinea 
pigs, reptiles and ornamental fish – are 
being kept in close interaction with 
human beings and food animals. 
Investigating and understanding the role 
of companion animals in the emergence of 
infectious diseases in humans and food 
animals and its implications for 
intervention strategies remains a relatively 
underrepresented area of attention in 
current research, public health and animal 
health policies. Moreover, the knowledge 
that is present is scattered amongst 
various specialists in different areas 
having different perspectives. This leads 
to the current situation where we lack a 
complete overview of the situation in 
FECAVA and the CALLISTO PROJECT
terms of, for instance, incidence, main risk 
species and high risk areas and the 
developments herein. 
Yet this information is necessary to 
develop evidence based, targeted actions 
to prevent reduce and eliminate the 
health risks for humans and food animals 
associated with keeping companion 
animals, in particular resulting from the 
pathogens that they harbour. 
CALLISTO will contribute to this need by 
bringing together specialists from 
different fields of expertise, disciplines 
and sectors – ranging from veterinarians, 
virologists, bacteriologists, 
parasitologists,  epidemiologists, 
ecologists and medical doctors to pet 
traders, farmers, animal welfare 
organisations, sociologists and health and 
food safety authorities –  in a single 
network that will function as an 
interprofessional,  interdisciplinary and 
multisectorial think tank.
The main objectives of the CALLISTO 
think tank are:
•  To provide an overview of the role of 
companion animals as a source of 
infectious diseases for humans and 
food animals;
•  To propose targeted actions that 
contribute to reducing the risk for 
infectious disease outbreaks in 
humans and food animals associated 
with keeping companion animals.
In pursuit of these main objectives 
CALLISTO will:
•  Assemble a balanced 
multidisciplinary, multisectorial and 
interprofessional network of experts 
and representatives from the key 
stakeholder groups relevant to the 
main objectives of CALLISTO;
•  Organise a series of meetings at 
different levels of integration, 
facilitating both interprofessional 
exchange of expert level knowledge 
and cross disciplinary and 
multisectorial integration of 
knowledge and perspectives;
•  Produce and disseminate expert level 
opinion reports containing an 
overview of the current situation and 
proposed actions to reduce the health 
risks to humans and food animals 
associated with infectious diseases 
originating in companion animals.
In total, seven Working Groups will be 
involved in a 3 year during project.  The 
role of FECAVA will be to chair Working 
Group 1 which concerns pets in the 
community.  We will be responsible for 
spreading the message of the CALLISTO 
project to the public and more specifically 
to our clients all over Europe.
The responsibility and challenge in 
delivering this project is huge and we 
will need all our expertise in companion 
animal medicine to convince our clients 
and public opinion that living together 
with animals is a pleasure even though it 
can pose some risks and cause some 
problems. It will be our task to bring the 
correct information without frightening 
people.
The project will start January 2012.
Vet 2011 – La Poste issues a Commemorative 
Stamp
To celebrate the 250th anniversary of the world’s first veterinary school the French 
post office, La Poste, has issued a commemorative stamp.
On August 4th 1761, a decree issued by Louis XV’s Council of State granted Claude 
Bourgelat authorisation to open a veterinary school near Lyon.  This was followed 
by Maison d’Alfort in 1764.  From that time, students from all over Europe came to 
study and then in turn open veterinary schools in their respective countries, most of 
which still exist today.
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You are invited to the 
largest companion 
animal conference 
in Europe – WSAVA /
FECAVA / BSAVA 
Congress,  
12-15 April 2012
 In 2012 the British Small Animal 
Veterinary Association will host the 
WSAVA/FECAVA/ BSAVA Congress. 
This will include the world’s most 
impressive selection of speakers, a huge 
variety of subjects for vets, nurses and 
practice staff, plus a superb exhibition 
and social programme. 
At the 2011 BSAVA Congress there were 
more than 8000 visitors, including 
exhibitors. There were 5,816 delegates (an 
increase by 15% on 2010), including a 
record-breaking 634 visitors from overseas, 
with more than 50 countries represented. 
This figure is expected to rise when the 
BSAVA hosts the World Congress in 2012.
Reasons to attend WSAVA / FECAVA / 
BSAVA World Congress 2012
•  The programme includes over 300 
lectures presented by world class 
speakers, covering a wide range of 
topics, see the programme at  
www.bsava.com/congress 
•  The programme features interactive 
sessions, Controversies, How to… 
lectures, and Masterclasses
•  Provides for all levels and abilities of 
veterinary practice staff and includes 
extended management streams
•  The largest veterinary commercial 
exhibition in Europe with over 250 
exhibitors, with all the latest 
innovations and industry expertise
•  Amazing social events including the 
wonderful World Congress Welcome 
Party, fine dining at the Congress 
Banquet, and the unbeatable Party 
Night
•  Centrally located in the UK  - 
Birmingham has its own international 
airport and is one of Europe’s most 
cosmopolitan cities, with wonderful 
shopping and entertainment, plus 
close to ‘Shakespeare country’ and 
some of the best of British countryside
•  FECAVA and WSAVA members can 
register at the discounted BSAVA 
member rate. 
Online registration began 1st August 
2011. The Early Bird deadline is 12th 
January. For more information visit  
www.bsava.com/congress or email 
congress@bsava.com if you have a 
question. 
The European 
Commission acts to 
protect Member States 
from tapeworm
On 14th July 2011, the Commission 
adopted a regulation permitting, from 1st 
January 2012, a pre-movement treatment 
for dogs travelling to listed Member 
States claiming echinococcus-free status.
Finland, the United Kingdom, Ireland 
and Malta are the Member States 
currently on the list. 
To be on the list, these Member States are 
obliged to introduce surveillance 
programmes and report the results to the 
Commission once a year. Positive 
findings need to be transmitted to the 
Commission and the other Member States 
immediately.
Before travel to one of the four Member 
States, a dog needs to receive a specific 
treatment administered by a vet. The 
details of the treatment should then be 
introduced by the vet in the pet’s 
passport and the owner can travel with 
his pet from 24 hours to five days (120 
hours) after treatment. 
The regulation harmonises treatment 
requirements and travel times following 
treatment for the listed Member States, 
thereby facilitating pet owners’ travel. 
What is Echinococcus?
Echinococcus multilocularis is a 
tapeworm.
The typical transmission cycle of the 
parasite in Europe involves wild carnivores, 
such as foxes, as definitive hosts and 
several species of mammals, notably small 
rodents, as intermediate hosts. The rodents 
become infected by ingesting echinococcus 
eggs that are disseminated through foxes’ 
or dogs’ faeces. 
Dogs can catch the worm by eating 
infected rodents. They may then serve as 
a source of infection for humans and a 
source of contamination of the 
environment. The human infection is 
called alveolar echinococcosis. It is a rare 
zoonotic disease and is considered as one 
of the most severe human parasitic 
diseases in non-tropical areas.
While Echinococcus multilocularis 
infection in animals occurs in the 
northern hemisphere, including the 
central and northern parts of Europe, it 
has never been recorded in certain areas 
of the European Union.
Background
According to the rules laid down in 
Regulation (EC) No 998/2003 (known as 
‘the Pet Regulation’), pet dogs, cats and 
ferrets travelling with their owner for 
non-commercial movements to another 
Member State must be accompanied by a 
passport, or when imported from a third 
country by a certificate, providing proof 
of a valid anti-rabies vaccination. The 
regulation also grants a transitional 
period (to expire on 31st December 2011) 
to Finland, Ireland, Malta, Sweden and 
the United Kingdom making the entry of 
pet animals into their territory subject to 
compliance with certain additional 
requirements in relation to rabies, 
echinococcosis or ticks. 
Sweden is not on the list of Member 
States claiming echinococcus-free status 
because it reported its first echinococcus 
cases in wild carnivores in January 2011. 
The Commission’s action is based on the 
advice of the European Food Safety 
Authority. EFSA considered that the risk 
of the introduction of Echinococcus 
multilocularis into parasite-free areas 
through the movement of infected dogs is 
greater than negligible. That risk, EFSA 
concluded, could be mitigated if dogs 
from endemic areas were to be treated 
prior to entry into echinococcus-free 
areas.
Using its delegated powers conferred by 
Article 290 of the Treaty of Lisbon, the 
European Commission adopted the 
measures mentioned above. They will 
now be transmitted for scrutiny by the 
European Parliament and the Council – a 
procedure that will last about four 
months. If neither Institution opposes, the 
delegated regulation will be published in 
the Official Journal of the European 
Union and will enter into force on the 
twentieth day following that of its 
publication.
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Using the same powers, the Commission 
also adopted another delegated 
regulation amending the technical 
requirements for the anti-rabies 
vaccination set out in Regulation (EC) No 
998/2003. The new rule clarifies that the 
date of vaccination must not precede the 
date of microchipping or tattooing 
indicated in the passport or the 
accompanying health certificate (in case 
of movement from a third country). 
The BASAV Small 
Animal Veterinary 
Conference in Varna
From Denis Novak, SASAP President, 
FECAVA CE coordinator for EE 
The Bulgarian Association of Small Animal 
Veterinarians (BASAV) organized the 
Varna Small Animal Veterinary 
Conference 2011 at the Melia Grand 
Hermitage Hotel, Golden Sands Resort in 
Varna on 2nd -5th June 2011. There were 
241 delegates mainly from Bulgaria but also 
from Romania, Serbia, Greece, Slovenia, the 
Republic of Macedonia, Russia - and even 
one delegate from Australia.
Speakers were well known experts in 
veterinary medicine: Dr. Elke Rudloff, 
USA - Emergency Medicine; Prof. 
Howard Seim, USA - Soft Tissue Surgery; 
Prof. David Senior, USA - Urology; Prof. 
Ron Ofri, Israel - Ophthalmology and Dr. 
Otto Fisher, Austria - Dermatology.
The main programme was accompanied 
by a pre-congress day which included 
neurology lectures given by Dr. Petr 
Srenk from the Czech Republic and 
commercial presentations from industry.
The main sponsors of the Conference 
were Intervet/Schering–Plough Animal 
Health, Pfizer Animal Health and 
Eukanuba. Other exhibitors included 
Royal Canin, Purina, Biomed, Bayer 
Animal Health, Solingen and 5 local 
companies selling veterinary equipment 
and products.
On Saturday 4th June and for the first 
time, BASAV organized a FECAVA Day 
parallel to the main programme. The idea 
was to have a practical workshop in 
ultrasonography and echocardiography. 
The two lecturers for the practical 
seminars on the FECAVA day were from 
Russia: Dr. Alexander Tkachov Jr. - 
Ultrasound and Dr. Andrej Kamolov 
- Cardiology. 
The lectures were given in Russian, 
which was a problem for delegates who 
were not familiar with the language. 
Also, a hotel venue was probably not the 
best choice for such a workshop as many 
delegates were not able to have hands-on 
experience. I hope that this can be 
improved by developing guidelines for 
future FECAVA Day programmes and for 
practical sessions which should be used 
by local member associations in order to 
deliver a high quality CE programme. 
As the FECAVA representative and CE 
coordinator for Eastern Europe I was 
honoured to give a presentation about 
FECAVA in general , detailing also its 
current work.
It is a clear that many delegates were 
familiar with FECAVA’s role in the 
companion animal field. Certainly, there 
is a lot of room for improvement and for 
more proactive work with small animal 
veterinarians and FECAVA member 
Associations within the Balkan region.
The BASAV organising committee should 
be congratulated for producing a very 
good scientific and social programme 
and for setting a very popular 
registration fee which included 
attendance at all social events. A big 
thank you goes to all delegates who came 
to Varna to make it one of the best CE 
events in the region in 2011.
Isabelle Dietrich wins 
the ABCD & Merial 
Young Scientist Award 
2011
From Karin de Lange, ABCD secretary
The ABCD and Merial Young Scientist 
Award 2011 was presented to Isabelle 
Dietrich MRes, a PhD student at the 
Centre for Virus Research of the 
University of Glasgow (UK), on 25 June in 
Vienna, on the occasion of the congress of 
the International Society of Feline 
Medicine.
Isabelle Dietrich (28) received the award 
for her work on a potential gene therapy 
for cats infected with the feline 
immunodeficiency virus (FIV), based on 
restriction of the virus with a synthetic 
feline TRIM5-CypA fusion protein. “In 
our study, we confirmed that such a protein 
was highly efficient at preventing FIV 
infection in vitro”. A TRIM-Cyp-based 
gene therapy approach for FIV-infected 
cats “would offer an effective antiviral defense 
strategy with a very low potential for toxicity 
and the emergence of resistant viral variants, 
and would contribute significantly to animal 
welfare”, she explained.
The award was presented by Professor 
Marian C. Horzinek, Founding Chairman 
of the European Advisory Board on Cat 
Diseases (ABCD), who congratulated the 
laureate. “Isabelle Dietrich has contributed to 
the knowledge of feline infectious diseases by a 
series of studies of high quality and 
originality. Her research into the intracellular 
defense mechanism offers a novel insight into 
the potential control of an often devastating 
disease”. Isabelle had been selected “with 
flying colours” from a pool of “very good 
candidates”, he added. 
The FECAVA Day practical seminar on 
ultrasonography
Dr. Denis Novak addresses the Varna Conference delegates
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for the global surveillance of animal 
diseases, including zoonoses. 
The organisations will collaborate on a 
range of activities including the 
development of global standards and 
guidelines to improve companion animal 
health and the continuing education of 
companion animal veterinarians.  They 
will also implement practical measures 
including developing communication 
campaigns to increase awareness of 
infectious disease surveillance and 
reporting programmes.
The OIE is also the inaugural recipient of 
the WSAVA One Health Award, designed 
to recognise exemplary service by an 
individual, who has promoted the global 
One Health Concept, and, in particular, 
has highlighted an aspect of small 
companion animal relevance to the One 
Health Agenda. They will present the 
international lecture at the upcoming 
WSAVA 2011 Jeju World Congress in Jeju, 
Korea. 
WSAVA Foundation launched
A WSAVA Foundation has been launched 
with a remit to improve global 
companion animal care through science 
and education.  It held its first meeting 
early in 2011 and is identifying potential 
projects, including:
•  initiatives to educate veterinarians 
and the public globally about disease 
prevention and improvement of health 
in companion animals  
•  creating standardization projects in 
key areas of companion animal health 
and welfare
•  supporting the development of 
innovative clinical approaches for the 
diagnosis and treatment of clinical 
diseases in companion animals
WSAVA and OIE join 
forces to promote One 
Health
The World Organisation for Animal 
Health (OIE) and World Small Animal 
Veterinary Association (WSAVA) have 
signed a memorandum of agreement to 
promote increased collaboration between 
the two organisations in the area of One 
Health - a movement which aims to 
encourage human health and veterinary 
professionals to work together to 
eradicate disease.  
Under the terms of the agreement, the 
WSAVA has been granted full observer 
status at the annual OIE General 
Assembly.  The OIE is the 
intergovernmental organisation 
responsible for improving animal health 
and welfare worldwide and is responsible 
From left to right - Professor Marian 
C. Horzinek, Chair of the European 
Advisory Board on Cat Diseases (ABCD), 
Dr Jean-Christophe Thibault, Merial’s 
Technical Director for Biologicals (Europe, 
Middle East and Africa) and Isabelle 
Dietrich MRes.
Isabelle’s work was also “of major 
importance” in the field of human viral 
diseases like AIDS, recalled Jean-
Christophe Thibault, Merial’s Technical 
Director for Biologicals (Europe, Middle 
East and Africa), “As a leading animal health 
company, Merial is very proud to be 
associated to this prestigious European award, 
in association with a recognised expert group 
such as the ABCD.” He also thanked the 
organisers of the ISFM congress, which 
was “the most appropriate venue for 
presenting this award”, created to “highlight 
key research in the field of feline medicine”.
The ABCD and Merial Young Scientist 
Award, created in 2008, is funded by 
Merial and is presented to a young 
scientist in veterinary or biomedical 
sciences, who has made an original 
contribution in the field of feline 
infectious diseases and/or immunology. 
Applicants should have published their 
findings in a journal listed in PubMed or 
Web of Science or have had them accepted 
by another recognised assessing body.
Candidates should be based in Europe, 
have completed a veterinary or 
biomedical curriculum, and be under 35 
years of age at the time of application. 
Applications in the fields of both basic 
and applied sciences are welcome.
For further information, please contact 
Karin de Lange, ABCD secretary, 
karin.delange@abcd-vets.org
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patients. A team approach to continuous 
nutritional education, implementation of 
appropriate protocols and focused client 
communication, utilizing these WSAVA 
Nutritional Guidelines, will be the key 
components to reach this 5VA goal.
The WSAVA Nutritional Assessment 
Guidelines can now be viewed on the 
new FECAVA website.
appetite, activity level, abnormal physical 
exam findings, body condition score, 
unexplained weight change and disease 
status. 
Client compliance with nutritional 
recommendations offered by the 
veterinarian, veterinary nurses/
technicians and their clinic team require 
everyone in the practice to believe in the 
critical importance of nutrition for their 
The Foundation is also identifying 
sources of funding, grants and 
partnerships with the veterinary 
pharmaceutical and pet nutrition sectors 
and other potential donors.   
WSAVA Nutritional Assessment 
Guidelines 
Nutrition is critical because nutrients 
affect every living cell in the body; 
therefore WSAVA recognizes that 
nutrition for dogs and cats requires the 
same attention to detail as all other 
species cared for by our profession. 
Our companion animals are often fed a 
single source of nutrition, either pre made 
or homemade diets. Careful assessment 
of their nutritional needs must be taken 
into consideration in order to maintain 
optimum health and performance, be 
part of a treatment regime for a diseased 
state, or maximize the quality of life in 
the patient with chronic disease. 
To emphasize that point, our goal is that a 
nutritional assessment and specific 
nutritional recommendation be made on 
every patient on every visit. This will 
become known as the 5th Vital 
Assessment (5VA), following the four 
vital assessments of temperature, pulse, 
respiration and pain that are already 
addressed on each patient interaction. 
WSAVA will encourage every veterinary 
teaching institution in the world to begin 
to formalize this approach in their 
curricula as soon as possible. 
Routinely doing a brief screening 
evaluation of the nutritional status 
during history taking and the physical 
examination can be seamlessly 
performed as part of every patient exam. 
An extended evaluation would follow, if 
one or more risk factors is suspected or 
identified on screening. Nutrition related 
risk factors could include age, changes in 
Upcoming WSAVA Congresses:
•	 2011	-	Jeju,	Korea	October	14-17	
•	 	2012	-	Birmingham,	England	April	12-15	(with	Fecava	Congress)
•	 	2013	-	Auckland,	New	Zealand	March	6-9
•	 2014	-	Capetown,	South	Africa	September	14-19
The WSAVA World Congresses will offer a comprehensive scientific programme delivered 
by global experts from around the world in a social atmosphere where veterinarians can 
share information, achievements and build a sense of fellowship. However, the Congress 
is, of course, more than an outstanding clinical experience – it also gives you an 
opportunity to explore a unique part of the world so reach for your guidebooks!
From left to right - Professor Michael Day (Chairman of the WSAVA One Health 
Committee), Professor Jolle Kirpensteijn (President of the WSAVA), Dr Bernard Vallat 
(Director General of OIE) and Dr Alex Thiermann (President of the Terrestrial Animal 
Health Code of the OIE) 
How	to	contact	the	FECAVA	
Office	and	Secretary
Our secretary is Ulrike Tewes. 
You can contact Ulrike:
By phone : +32 (0)2 533 70 20
By e-mail : ulrike@fve.org
The office is open from 8.30 am  
to 4.30 pm Monday to Friday.
Notes	for	Contributors
These can be seen on www.fecava.com and are also printed on page 184 of this issue 
of EJCAP. There is an important change. Submissions should now be sent to:
 
Dr Erik Teske,
Department Clinical Sciences for Companion Animals,
Veterinary Faculty, Utrecht University
PO Box 80.154, NL- 3508 TD Utrecht.
E-mail: e.teske@uu.nl
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rich media is added to the scientific content. It will be easy to 
absorb with the same scientific standard as you expect from 
FECAVA.
Rich media
Scientific articles will be supported by interviews with one or 
more of its authors. More in depth information concerning the 
subject of the article and personal experiences of the author(s) 
will be shared.
VIDEO will make it possible to give practical instructions for 
surgical and other procedures or to educate your clients and in 
that way to convince them of the benefit of a certain procedure. 
AUDIO can be used to demonstrate cardiac murmurs 
corresponding with the content of the specific article on 
Started in 1990 by 12 associations, FECAVA now represents the 
vets of national companion animal associations in 37 European 
countries who receive the journal twice a year in their mailbox 
and have access to an online special edition once a year. To the 
benefit of in excess of 30,000 vets EJCAP makes expertise and 
knowledge available to companion animal vets all over Europe. 
EJCAP comprises reprint scientific articles previously published 
in national journals translated into English, commissioned 
articles often written by European specialists, original work, 
book reviews, European veterinary news and much more. This 
will not change and we guarantee a lot more will be added!
The future is here and now
To strengthen FECAVA’s ambitious vision to be the platform for 
the Companion Animal Veterinarian in Europe, we are 
preparing for a bright future and a considerable part of 
FECAVA’s activity will be online. One of the first steps was taken 
in September 2011 with the launch of a new website meeting the 
new media expectations of the 21st century. Another important 
step, 21 years after the first hard copy was published, will be to 
go completely online with our journal in the spring of 2012. 
EJCAP online will be a multilingual journal with a lot of rich 
media, different to any other online journal in the veterinary 
field. The journal will look like a regular journal with pages you 
can turn and a summary of the article surrounded by relevant 
rich media. If you are interested you can download and read the 
whole article or if preferred easily print it.
Are	you	a	busy	practitioner who does not always have a lot of 
time to read scientific articles? Like many of us, you will be 
juggling your time, but want to stay up-to-date. For that reason, 
FECAVA is transforming EJCAP: it will be an interactive and 
engaging online journal where additional information using 
For	21	years	FECAVA	has	published	a	high	quality	hard	copy	veterinary	journal:	the	European	Journal	of	Companion	Animal	
Practice	-	EJCAP.	Now	EJCAP	goes	digital.	Starting	in	2012,	FECAVA’s	scientific	journal	will	only	be	available	in	digital	format.	
And	with	this	change	come	great	opportunities.
EJCAP online - up-to-date in an interactive 
and engaging way
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cardiology. PHOTOS will be interactive so you can zoom in and 
out, for example to study radiographs better.
SLIDE	SHOWS will be added to articles. 
Through ANIMATIONS certain processes such as surgical 
procedures, diagnostic protocols and disease mechanisms will 
be explained more explicitly.
Rich media will not interfere with the scientifi c content; it will 
support and add to the article and offer even more to the 
companion animal practitioner.
Multilingual – Spanish and English
Although vets can often read English, the language differences 
in Europe do not make EJCAP easy accessible for many vets. The 
language barrier limits the principal aim to bring together the 
expertise and knowledge available in Europe. One of the big 
advantages of going online is the possibility of having a 
multilingual journal. From the fi rst online edition, EJCAP will 
be available in Spanish and English. It is expected that more 
languages will follow in the near future.
Frequency of publication and the special issue
The publication of the journal will initially occur 4 times per 
year, with three regular editions.
The fourth edition each year will concern a specifi c topic. 
Previous issues covered ophthalmology, dermatology, zoonoses, 
and dentistry. It is expected that the topic for December 2012 
will be Diagnostic Imaging, a perfect subject for the use of rich 
media.
Exclusively available to you!
As a member of your national companion animal association 
you are automatically a member of FECAVA. Not sure whether 
your association is a member of FECAVA? Just check at our 
website: www.fecava.org.
Companion animal vets who are not a member of one of the 37 
national companion animal associations cannot get a 
subscription. Your national association will inform you when a 
new online edition is available or you can register directly 
without any obligations at www.fecava.org and get the 
notifi cation through FECAVA. 
Gracias a AVEPA, una de las asociaciones fundadoras de FECAVA, la edición on line de EJCAP desde su 
primer número estará disponible también en español. Una interactiva y comprometida publicación on line, en 
la cual aparte del contenido científi co, una interesante información adicional estará disponible para el clínico 
veterinario Español. Después de 21 años, el español es el primer idioma al cual EJCAP sera traducido. 
Esperamos en un próximo futuro que otros idiomas seguirán esta iniciativa.
Stabilisation of the emergency patient follows the ABC (airway-breathing-circulation protocol). Following the 
stabilisation of respiration and provision of oxygen-saturated blood, perfusion must be ensured. Perfusion is 
evaluated according to heart rate, pulse quality and rate, mucous membrane colour and capillary refill time,  
and temperature. Shock is defined as decreased perfusion leading to hypoxia. Depending on the cause and 
pathophysiologic processes, hypovolemic, obstructive, distributive or cardiogenic shock can be differentiated. All 
lead to a decrease in cardiac output, followed by decreased perfusion of tissues and subsequent cellular hypoxia. 
Therapy includes oxygen supplementation, fluid resuscitation with bolus therapy of isotonic crystalloid or colloid 
solutions, analgesia and haemorrhage control. Intensive monitoring is required for successful stabilisation. 
Key words: shock, hypovolemia, perfusion, fluid therapy
SUMMARY
This paper originally appeared in:
Kleintierpraxis*   55, 3, 2010, 140-154 #
CRITICAL CARE
Introduction
Stabilisation measures of emergency patients concentrate on 
the identification and immediate treatment of live-threatening 
problems based on their importance (ABCD: Airway – Breathing 
– Circulation - Disability) [Aldrich, 2005]. The respiratory tract, 
the heart and circulation and the central nervous system are the 
most important organs to protect. 
The purpose of these organs is the oxygen supply of cells and 
requires adequate oxygen uptake by the lungs (see Part I: 
respiration) and appropriate perfusion of all tissues. Maintaining 
or normalizing the circulation is therefore given priority directly 
after or already during the stabilization of breathing. This 
requires a brief clinical examination of the patient, the correct 
interpretation of the findings as well as an appropriate therapy. 
In many cases, stabilization of circulation will include fluid 
therapy, therefore this issue will be discussed in detail in the 
following review article.     
Definitions 
Le Dran, a french physician, described the condition of an acute 
collapse after a major trauma as “shoc”. Clinically, shock is 
defined as a condition of reduced or absent perfusion that leads 
to metabolic changes [Boag and Hughes, 2005]. At a cellular 
level, shock is defined as insufficient oxygen supply to the cells 
for the maintenance of cellular energy production [Shoemaker, 
1994]. The cellular hypoxia is caused by decreased blood flow 
and not by a decrease in oxygen uptake (lung problems) or 
carrying capacity (anaemia).  Decreased perfusion can  be local 
(eg aortic thromboembolism) or generalized (eg haemorrhage 
leading to hypovolemia). When dealing with the stabilization 
of emergency patients, the generalized form of shock is more 
important. Regardless of whether the cause of shock is due to 
haemorrhage, a heart rhythm disorder, or sepsis, the insufficient 
supply of tissues with oxygen and other nutrients will lead to 
life-threatening cellular changes [Vallet et al., 2005]. 
Evaluation of perfusion parameters in 
emergency patients 
The primary survey of emergency patients should evaluate the 
perfusion status, including the following parameters [Aldrich, 
(1)  Department of Clinical Veterinary Medicine, Vetsuisse Faculty of Bern and Veterinary Emergency and Critical Care Continuing Education 
Längasstrasse 128 CH-3012 Bern  E-mail: nadja.sigrist@kkh.unibe.ch
* Presented by SVK/ASMPA (Switzerland)
** Part I was published in EJCAP 21(1) April 2011 and Part III in this issue
# Copyright permission gratefully received from M. & H. Schaper GmbH, Kleintierpraxis - www.vetline.de/zeitschriften/ktp  
reprint paper (CH)
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2005]: Heart rate and rhythm, pulse rate and strength, 
mucous membrane color and capillary refill time (CRT), rectal 
temperature, peripheral temperature and consciousness (Table 
1). The venous filling (jugular, peripheral) can also provide 
information regarding blood volume and its distribution [Boag 
and Hughes, 2005]. None of these parameters is a sole criterion 
of perfusion and thorough interpretation of circulation must 
include all parameters and consideration of their relationships. 
Determination of arterial blood pressure, central venous blood 
pressure, ECG rhythm, and blood gas analysis including lactate 
measurement may provide additional information [Boag and 
Hughes, 2005]. 
It is important that shock is distinguished from dehydration. 
Both describe a fluid deficit, however, the fluid has been lost 
in different compartments (intravascular vs. interstitial) and 
is therefore treated differently [Sigrist, 2005a]. Clinical signs 
of dehydration include dry mucous membranes, decreased 
skin turgor or enophthalmus. Severe dehydration may lead to 
hypovolemia with the classic signs of tachycardia, pale mucous 
membranes and prolonged CRT, but these are signs of shock 
and are treated accordingly. 
Causes of shock 
Based on the pathophysiologic processes that lead to decreased 
blood flow, shock is clinically divided into four types: hypovolemic, 
obstructive, distributive and cardiogenic [Hinshaw and Cox, 
1972; Schertel and Muir, 1989]. The various causes and their 
pathophysiological consequences result in a reduced cardiac 
output (CO) followed by a decrease in perfusion. Depending 
on the definition of shock, hypoxemic and metabolic shock 
are differentiated on a cellular level [Malouin and Silverstein, 
2009]. Veterinary emergency patients often show combinations 
of different types of shocks. Traumatic shock, septic shock and 
toxic shock are examples of combinations of the above types of 
shock [Otto, 2005]. Pain can lead to the same clinical symptoms 
as shock as well as to a decreased perfusion. Pain in combination 
with shock will also lead to a worsening of clinical symptoms 
[Rudloff and Kirby, 1994]. The classification of the different 
types of shock and possible causes are summarized in Figure 1. 
Hypovolemic shock 
Hypovolemic shock results from a loss of circulating blood 
volume. The normal blood volume in dogs is 90 ml/kg BW and 
60 ml/kg in cats. Losses of more than 15-20% lead to clinically 
apparent shock symptoms [Astiz, 2005]. The volume loss can 
be absolute or relative. An absolute volume loss is seen with 
haemorrhage and massive dehydration after fluid loss through 
vomiting, diarrhoea or polyuria. A relative volume depletion 
results from redistribution of fluid in third compartments 
(ascites, increased permeability leading to edema). Regardless 
of the cause, the loss of volume leads to a reduction in venous 
return to the heart and subsequently to a reduced CO. 
Obstructive shock 
As the name suggests, with obstructive shock obstruction of 
blood flow leads to a decreased perfusion. The obstruction 
of large venous vessels decreases venous return to the heart, 
which subsequently leads to a decreased CO. Causes of venous 
obstruction are gastric dilatation volvolus, severe heartworm 
infection, cardiac tamponade, tension pneumothorax or 
neoplasms and thrombi in the vena cava or large pulmonary 
vessels [Astiz, 2005]. Multiple arterial (micro-) thrombi 
(disseminated intravascular coagulation, aortic thrombosis) can 
also lead to decreased perfusion due to obstruction. However, 
the CO in these cases is normal. 
Distributive shock 
A distributive shock is caused by an abnormal distribution 
of blood in the microcirculation, caused by disturbances of 
the autonomic nervous system (therefore often referred to 
as neurogenic shock), loss of autoregulation, and metabolic 
disturbances on a vascular level [Moore and Murtaugh, 2001]. 
Tissue hypoxia due to decreased perfusion
•	 Hypovolemic	(decreased	blood	volume)
 o Absolute hypovolemia
	 	 •	 Haemorrhage	(internal	and	external)
	 	 •	 Vomiting,	Diarrhoea
	 	 •	 Polyuric	renal	failure
	 	 •	 Hypoadrenocorticism
	 	 •	 Diabetes	insipidus
 o Relative Hypovolemia
	 	 •	 Peritonitis
	 	 •	 Increased	permeability	leading	to	oedema
•	 	Obstructive	(Obstruction	of	venous	or	arterial	
blood	flow)
 o Obstruction of venous return 
	 	 •	 Gastric	dilatation-volvolus
	 	 •	 Pericardial	effusion	with	right	heart	tamponade
	 	 •	 Severe	heart	worm	disease
 o Peripheral arterial or venous obstruction
	 	 •	 Aortic	thrombosis	(saddle	thrombus)
	 	 •	 Disseminated	intravasal	coagulation
	 	 •	 Pulmonary	thromboembolism
•	 Distributive	(generalised	vasodilation)
 o Anaphylactic shock
 o SIRS/Sepsis
 o Brain stem lesions
•	 Cardiogenic	(heart	insufficiency)
 o Decreased contractility
	 	 •	 Dilative	cardiomyopathy
	 	 •	 SIRS,	Sepsis
	 	 •	 Traumatic	myocarditis
	 	 •	 Electrolyte	disturbances
 o Decreased cardiac volume
	 	 •	 Hypertrophic	and	restrictive	cardiomyopathy
	 	 •	 Endocardiosis
	 	 •	 Endocarditis
 o Arrhythmias
	 	 •	 Electrolyte	disturbances
	 	 •	 Brain	stem	lesions
	 	 •	 Primary	heart	disease
	 	 •	 Traumatic	myocarditis
Figure 1: Categorisation and causes of shock
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This results in a disproportionate distribution of blood with 
underperfused as well as overperfused tissues. Vasodilation is 
predominant in most cases, which results in a massive increase 
in blood vessel capacity with the same amount of blood 
volume. This leads to blood accumulation in the peripheral 
microcirculation and a relative hypovolemia with decreased 
venous return and subsequently insufficient CO. 
Cardiogenic shock 
The reduced CO in cardiogenic shock does not result from a 
lack of volume but rather by a reduced cardiac performance. 
Causes include endocardiosis, cardiomyopathy, arrhythmias, or 
decreased contractility. 
Metabolic and hypoxemic shock 
These types of shock lead to cellular hypoxia, regardless of the 
perfusion, are therefore less important for the normalization of 
perfusion in emergency patients and are discussed here only for 
completeness. 
With metabolic shock the available oxygen is not converted 
to ATP due to dysfunction of the cell (mitochondrial enzyme 
damage, or lack of energy production). In hypoxemic shock, 
oxygen deprivation results from reduced lung function or 
decreased transport capacity due to anaemia [Malouin and 
Silverstein, 2009]. 
Other shock types described in the literature are combinations 
of the above types of shock. Examples include toxic shock 
(distributive, possibly cardiogenic), septic shock (distributive, 
hypovolemic, cardiogenic, and often a metabolic component), 
and traumatic shock (distributive, hypovolemic). 
Pathophysiology
The patho- physiological changes in shock have been well studied 
especially in hypovolemic shock [Astiz, 2005]. The hypovolemia 
leads to a reduction in venous return and subsequently to 
decreased cardiac filling and correspondingly lowered cardiac 
output (Starling’s law). The cardiac output (CO) is a function of 
the heart rate (HR) and stroke volume. The stroke volume in turn 
depends on the contractility of the heart muscle and the venous 
return [Guyton and Hall, 2000]: 
CO = SV x HR 
The physiological response of the body to a reduced cardiac 
output is the baroreceptor reflex: the baroreceptors in the aortic 
arch and the carotid bifurcation are less stretched and pass 
this information to the vasomotor center in the brainstem. The 
decreased stretch of the pressure receptors leads to activation 
of the sympathetic and inhibition of the parasympathetic 
nervous system. The release of noradrenaline and other 
vasoactive substances leads to both an increase in heart rate 
and cardiac contractility and an  increase in cardiac output 
[Moore and Murtaugh, 2001; Astiz, 2005]. In addition, venous 
vasoconstriction occurs, which increases blood return to the 
heart. 
In addition, but delayed in time, there is a fluid shift from the 
interstitium into the intravascular space and both ADH as well as 
the renin-angiotensin-aldosterone system are activated with the 
aim of preserving water in the kidneys [Moore and Murtaugh, 
2001] . 
If CO cannot be normalized in this way, continuous activation of 
the sympathetic nervous system occurs, leading to pronounced 
arterial vasoconstriction in order to maintain blood flow to 
the heart, lungs and brain [Moore and Murtaugh, 2001]. The 
arterial vasoconstriction begins in the skin and muscles, but 
progressive vasoconstriction is also seen in vital organs such as 
the gastrointestinal tract, liver and kidneys. Vasoconstriction 
leads to decreased blood flow to these organs, and additional 
oxygen deficiency. 
The baroreceptor reflex is restricted in distributive shock. 
Compensatory tachycardia and an increase in cardiac 
contractility result in a normal to high cardiac output, but the 
vasoconstriction can not occur. The prevailing, mainly nitric 
oxide-mediated vasodilation leads to a redistribution of blood 
to the microcirculation and hypotension [Astiz, 2005]. 
All cell and organ functions need energy (ATP). The production 
of ATP is most effective in an aerobic milieu. Under aerobic 
conditions 38 ATP molecules are produced from glucose and 
oxygen in the Krebs cycle [Guyton and Hall, 2000]: 
  Aerobic: 1 Glc + 6 O2 + 38 ADP + 38 Pi   6 CO2 + 6 H2O 
+ 38 atp 
Under anaerobic conditions, the ATP production is extremely 
unproductive: 
 Anaerobic: Glc 1 + 2 ADP + 2 Pi  2 lactate + 2 atp
This leads to accumulation of lactate and hypoxanthine as well as 
changes in the cell milieu (acidosis, Ca-accumulation), ischemia-
induced release of inflammatory mediators and vasoactive 
substances, which further lead to maldistribution of blood flow, 
myocardial depression and activation of the coagulation cascade 
with formation of thrombi and coagulation abnormalities [West 
and Wilson, 1996; Haljamae, 1993]. Acidosis, energy depletion 
and inflammatory factors will lead to terminal shock with 
vasodilatation of the peripheral arteries and veins, arrhythmias 
and eventually respiratory and cardiac arrest [Wiggers, 1942]. 
Clinical signs of cardiovascular shock 
The clinical signs of shock are given by the activation of the 
sympathetic nervous system and depend, particularly in the 
hypovolemic shock, on the shock stage (Table 1). A reduction 
in blood volume by 10-15% is associated with few clinical 
symptoms (such as seen with blood donation). With a loss of 
up to 20% tachycardia is seen. With a volume loss of 20-35% 
clinical signs of decompensated hypovolemic shock can be 
expected. Losses of more than 35-40% are fatal if not treated 
with appropriate therapy [Schertel and Muir, 1989]. 
Compensated	shock: the first stage of shock is caused by the 
compensatory activation of the sympathetic nervous system 
and manifests itself in an increased contractility (clinically 
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not visible) and tachycardia [Moore and Murtaugh, 2001]. 
Overcompensation, also called the hypermetabolic state, 
with tachycardia, erythematous mucous membranes and a 
short capillary refill time (CRT) can be seen [Otto, 2009]. If no 
overcompensation takes place, mucous membranes and CRT are 
normal. The femoral pulse is normal or throbbing, and the blood 
pressure is normal or increased [Boag and Hughes, 2005]. 
Cats rarely show a compensated shock state [Otto, 2005]. 
Often a compensated shock state with hypermetabolism may 
be seen during shock therapy of decompensated shock. With 
fluid therapy, the mucous membranes are no longer pale but 
reddened and the CRT becomes short (Fig 2a). These animals 
are still in shock and need continued fluid therapy. 
Differential diagnoses of compensated shock are distributive 
shock, sepsis, fever, excitement or stress. 
Early	 decompensated	 shock: with beginning peripheral 
arterial vasoconstriction, which leads to hypoperfusion of the 
less important organs such as skin and mucous membranes in 
order to maintain the blood flow to the vital organs like heart 
and brain (centralization), decompensated shock results [Otto, 
2005]. Due to vasoconstriction, pale mucous membranes and 
a prolonged CRT can be seen in addition to tachycardia. The 
pulse may be weak, the peripheral limbs are cooler and the 
animals may present with hypothermia [Moore and Murtaugh, 
2001]. Blood pressure is normal in the early stages. Hypotension 
manifests only after a volume loss of 40% of the intravascular 
volume [Astiz, 2005]. 
Late	 decompensated	 shock: With ongoing arterial vaso-
constriction, the animals show grey-white mucous membranes, 
prolonged or no longer measurable CRT, tachycardia, tachypnea, 
hypothermia, and stupor. Severe hypothermia or anaemia should 
be considered as differential diagnoses of this shock stage. 
Terminal	 shock: Once vasoconstriction can no longer be 
maintained due to lack of energy, vasodilation with accumulation 
of non-oxygenated blood in the microcirculation occurs. Clinically, 
the mucous membranes become grey-purple with undefinable 
CRT, the animals are showing bradycardia or arrhythmias, are 
stuporous, hypothermic and hypotensive [Moore and Murtaugh, 
2001]. This shock stage ends in cardio-pulmonary arrest. 
Differential diagnoses are cardiogenic shock, other causes of 
bradyarrhythmias (heart problem, hyperkalemia) or brain stem 
lesions. 
In distributive shock, no vasoconstriction occurs (primary 
problem is an uncontrolled vasodilation), which is why the 
division into shock stages is not possible and why it is difficult to 
estimate the extent of the shock level [Otto, 2009]. Cats rarely 
show injected mucous membranes associated with distributive 
shock and SIRS / sepsis and in a retrospective study stupor 
and bradycardia were found as the predominant symptoms of 
distributive shock [Brady et al., 2000]. 
Diagnosis 
In addition to the clinical examination, blood pressure 
measurement, blood gas analysis and lactate measurement may 
help to identify a perfusion deficit. 
The arterial blood pressure is maintained for a relatively long 
time. However, a normal blood pressure does not necessarily 
indicate a normal blood flow. Because of vasoconstriction, the 
blood pressure is maintained for a long time even though the 
blood flow is diminished by the extensive vessel contraction 
[Cohn, 1967; Shoemaker and Czer1979]. More helpful may be 
the interpretation of the blood pressure curve: a high narrow 
curve, respectively a high systolic and low diastolic blood pressure 
may be indicators for vasoconstriction due to hypovolaemia. 
This can also be felt as a throbbing or “bouncing” pulse during 
the evaluation of pulse strength [Boag and Hughes, 2005]. 
An ECG analysis should be performed in patients with 
bradycardia or tachycardia and in patients with clinical signs of 
arrhythmias. 
The determination of hematocrit and total protein should 
be part of the initial diagnostic workup of all emergency 
Figure 2a: compensated shock
Red mucous membranes and a short CRT are the clinical signs of 
compensated shock.
Figure 2b: decompensated shock
Pale mucous-membranes with a prolonged CRT are indicative of 
decompensated shock. Vasoconstriction leads to underperfusion of 
skin, mucous membranes and other organs.
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patients. Anaemia as a cause of tachycardia and white mucous 
membranes can be excluded rapidly by determination of the 
microhaematocrit. Depending on the size and duration of blood 
loss, the hematocrit may be reduced, while it is still normal in 
acute bleeding due to lack of dilution. Fluid losses without red cell 
loss (vomiting, diarrhea, polyuria) lead to haemoconcentration. 
Lactate accumulates in the body during anaerobic metabolism in 
shock and can be detected in blood [Weil and Afifi, 1970; Cady 
et al., 1973]. Lactate levels > 2.5 mmol/L in combination with 
appropriate clinical symptoms are associated with decreased 
perfusion and the lactate levels correlate with the degree of 
shock [Boag and Hughes, 2005]. Lactate may be increased, 
however, by other diseases (neoplasia, diabetes mellitus), and 
with increased muscle activity and is a late marker of hypoxia 
[Boag and Hughes, 2005]. 
Treatment
The main components of shock therapy are fluid administration 
to restore the intravascular volume (except in cardiogenic 
shock), bleeding control, oxygen supplementation and analgesia 
[Mandell and King, 1998; Otto, 2005]. 
Oxygen supplementation 
Shock is a state of oxygen deficiency, therefore animals in 
shock should be supplemented with oxygen, especially when 
an additional lung problem can not be excluded. Oxygen 
supplementation is initially easiest by using oxygen flow-by or 
a mask (see stabilization of emergency patients, Part I). For 
continuing oxygen therapy, it may be more convenient to place 
a nasal oxygen tube, or administer oxygen by an oxygen hood, 
made out of an Elisabethan collar and cellophane wrap. The 
oxygen saturation should be at least 95%. 
The oxygen supply to the tissues depends not only on 
the perfusion and the arterial oxygen content but also on 
haemoglobin, which represents the major part of the transport 
capacity. In the case of massive bleeding blood transfusions 
or substitute products like Oxyglobin® (Biopure, USA) may be 
required for maintenance of oxygen transport capacity [Astiz, 
2005]. In acute bleeding leading to a PCV < 20%, haemoglobin 
should be substituted in the form of whole blood, erythrocyte 
concentrate or Oxyglobin®. The goal of transfusion therapy is 
a PCV of 25-30%, where the rheology of blood is the most 
ideal [Cozette et al., 1979]. Using fresh whole blood, 2 ml of 
blood per kg body weight are needed to raise the hematocrit 
by 1%, with packed red cells 1-1.5 ml / kg  per desired % PCV 
raise are administered  [Sigrist, 2005b]. If time permits, a cross 
test should be performed prior to the administration of blood 
products. In cats, the determination of at least the blood group 
is mandatory. 
Control of haemorrhage 
Visible bleeding should be stopped by pressure bandage or 
ligature of the vessel. In the case of coagulation abnormalities, 
either due to a primary problem (massive haemorrhage), 
complications (DIC, sepsis) or dilution (massive fluid therapy), 
plasma in a dosage of 8-15 ml/kg over max. 6 hours, sometimes 
3 times a day, is indicated [Rudloff and Kirby, 1998]. The 
indications of haemoglobin transfusion are discussed below. 
Fluid therapy 
Venous access: 
Patients with clinical signs of shock will need large amounts 
of intravascular fluids, requiring immediate venous access. 
Subcutaneous fluid will not be absorbed due to vasoconstriction 
of the skin or only very slowly. To ensure a quick infusion 
therapy, the largest possible venous catheter is selected. Short 
catheters are preferred over long central venous catheters 
because the flow rate of a catheter not only depends on the 
radius, but also on the length (Poseuille’s Law) [Marino, 1997]. 
With collapsed veins a skin cut or even a mini-cutdown with 
preparation of the vein may be needed [Dethioux et al., 2007]. 
Intraosseous fluid therapy may be an alternative to intravascular 
administration and may be easier especially in small and young 
animals. An intraosseous access is easiest achieved in the femur 
(intertrochanteric fossa). In young animals, a yellow or pink 
needle can be used while commercially available intraosseous 
needles are handy in larger or older animals. 
Choice of fluid solution: 
The optimal fluid for the treatment of hypovolemic shock is 
still controversial [Schierhout and Roberts, 1998; Choi et al., 
1999]. Intravascular fluid deficits (hypovolemic, obstructive 
and distributive shock) can be replaced with isotonic crystalloid 
solutions, colloids, hypertonic saline solution, blood products 
or combinations of these (Table 2) [Rudloff and Kirby, 1998]. 
Perfusion	Parameter Compensated Early-	decompensated Late-decompensated Terminal
Heart rate Tachycardia Tachycardia Tachycardia  
Bradycardia
Bradycardia
Pulse strength Pounding Weak Weak Weak-missing
Mucous membrane colour Red Pale White-grey Grey-purple
CRT < 1 sec > 2 sec > 2-3 sec Not measurable
Blood pressure Normal-increased Normal-decreased Hypotension Hypotension
Mental status Normal Decreased Depressed Stupor
Peripheral temperature Normal Beginning hypothermia Hypothermia, cold 
extremities
Hypothermia, cold 
extremities
Urine production Normal Decreased Decreased Decreased
Table 1: Shock stages
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The combination of a crystalloid (eg Ringer’s lactate or 0.9% 
NaCl) and colloidal fluid allows the fastest and longest effective 
therapy of hypovolemic shock. Colloids remain in the vascular 
system due to their molecular size, and will draw water from 
the interstitium and keep the crystalloid solution longer in the 
intravascular space [Rudloff and Kirby, 1998]. Isotonic crystalloid 
solutions such as Ringer’s lactate or 0.9% NaCl are distributed 
throughout the extracellular space and only ¼ of the amount 
applied is still available intravascularly after 2 hours. These fluids 
are therefore excellent for the treatment of patients who are both 
dehydrated and in shock (such as with acute gastroenteritis). 
Trauma patients are in most cases only hypovolemic and have 
no pre-existing fluid deficits, so the combination of Ringer’s 
lactate with a colloid such as Haes is preferable. 
Hypertonic saline solution leads to a very rapid redistribution of 
water from the interstitial into the intravascular space, increasing 
the blood volume very rapidly and effectively. However, this 
effect lasts only 15-20 minutes [Rudloff and Kirby, 1998]. The 
administration of hypertonic saline can be lifesaving in late 
decompensated shock, since an immediate effect is achieved 
and time is gained in order to apply other fluids. Because the 
interstitium becomes dehydrated during the application of 
hypertonic saline, these patients must then be rehydrated 
with an isotonic solution and the use of hypertonic saline in 
the already dehydrated patient is contraindicated [Rozanski and 
Rondeau, 2002]. The effect of hypertonic saline solution can be 
extended with simultaneous administration of Haes or dextran. 
The distribution and composition of various infusion solutions 
are provided in Table 2.
Fluid dose:
Due to the physiological understanding and the introduction of 
colloidal fluid solutions,  the “shock dose” of 90 ml/kg/h  is no 
longer indicated and may lead to both under- as well as over- 
infusion of patients. Since the exact amount of fluid cannot 
be accurately determined and the blood volume should be 
normalized as quickly as possible, fluids should  be administered 
by bolus infusion. Clinical symptoms of compensated shock are 
seen with a volume loss of 15-20% and of decompensated 
shock at 20-35% volume loss [Moore and Murtaugh, 2001]. 
In dogs, this corresponds to amounts of 15-30 ml/kg, in the cat 
of 10-20 ml/kg body weight. This results in the proposed bolus 
dose of fluid therapy (see also Table 3). Emergency patients with 
signs of decompensated shock are treated with an initial bolus 
of 20 ml/kg (dog), respectively 10 ml/kg (cat), of an isotonic 
crystalloid solution (eg Ringer’s lactate) together with a bolus 
of 10 ml/kg (dog), respectively 5 ml/kg (cat), of a colloid (eg 
Tetraspan®, B. Braun Vet Care GmbH, D or Voluven®, Fresenius 
Table 2: Comparison of different fluids
Name Compartment pH Na Cl K Ca p Mg Buffer comments
Mmol/L
Crystalloid	isoton
0.9% NaCl Extracellular 5 154 154 no Buffer
Ringer solution® (Braun) Extracellular 147 156 4 2.2 no Buffer
Lactated Ringer’s 
(Fresenius)
Extracellular 5-7 131 118 5.4 1.8 Lactate
Plasmalyte-A® Extracellular 6.5-8 140 98 5 1.5 Acetate, 
Gluconate
Stereofundin® Iso Extracellular 140 127 4 2.5 1 Acetate, Malate
Crystalloid	hyperton
7% NaCl Extracellular 1197 1197 hyperton
Crystalloid	hypoton
5% Glukose Intracellular 4 Glucose  50g
Sterofundin® HEG5 Intracellular 70 66 2 1.3 Glucose 50g
Glukose5%-NaCl0.9% 
2:1 Fresenius
Intracellular, 
interstitial
3-5 51 51 Glucose 33g
2.5% Glc/NaCl Intracellular, 
interstitial
Whole blood Intravascular 140 100 4 COP 20
Plasma Intravascular 140 100 4 2 2 Albumine COP 20
Haes-steril® 6% Intravascular 5.5 154 154 Haes 200/ COP 32
Voluven® Intravascular 154 154 Haes 130/0.4
Venofundin® Intravascular 4-6.5 154 154 Haes 130/0.42 COP 37.8
Tetraspan® Intravascular 140 118 4 2.5 1 Acetate, Malate, 
Haes 130/0.42
Oxyglobin® Intravascular
P: Phosphor; COP: colloid-oncotic pressure; Glc: Glucose
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Kabi AG, Switzerland). The boluses are given intravenously over 
10-15 minutes. The patient is then re-evaluated. If perfusion 
abnormalities persist, the bolus is repeated. Depending on 
the cause and magnitude of shock, several boluses or various 
combinations (crystalloid and colloid solutions or blood 
products) will be necessary. It is important that the boluses are 
given as fast as possible (shock = lack of oxygen!) and not as 
“double maintenance” for several hours. 
The dose of hypertonic saline (7-8%) is 4 ml/kg body weight. 
This, in comparison small amount, has the same effect as a large 
bolus of Ringer’s lactate, but is much faster applied [Schertel et 
al., 1997]. 
In case of suspected internal bleeding, lung contusions or 
hypothermia, a conservative fluid therapy should be applied. 
Small boluses (5-10 ml / kg Ringer’s lactate and 3-5 ml / kg 
colloid) are chosen and the patient is monitored very closely 
[Adamantos and Hughes, 2008]. This conservative fluid therapy 
is referred to as “limited volume fluid resuscitation“, the goal is a 
just sufficient perfusion, ie, a mean blood pressure of 60 mmHg, 
to avoid overinfusion and re-bleeding [Rudloff and Kirby, 1998; 
Hammond and Holt, 2009]. 
Continued fluid therapy: 
Further fluid therapy after normalizing the intravascular volume 
depends on further fluid deficits and losses. After shock 
treatment using fluid boluses, the dehydration is estimated 
again and the fluid loss is calculated according to the formula:
Dehydration (ml) = % dehydration x kg body weight x 10 
[Rudloff and Kirby, 1998]. 
This interstitial deficit is replaced intravenously over 6-12 hours 
with an isotonic crystalloid solution. Maintenance requirements 
(2-3 ml/kg/h) and any future losses from vomiting, diarrhoea or 
polyuria are added to this amount. Depending on the disease, 
the supplementation of potassium, phosphorus, or glucose may 
be necessary. 
Analgesia 
Pain can cause the same clinical symptoms as shock, which 
may make interpretation of the perfusion difficult [Rudloff 
and Kirby, 1994; Day and Bateman, 2004]. All shock patients 
who may potentially be in pain (trauma, diarrhoea, vomiting, 
breathing problems) should be treated as early as possible with 
an appropriate analgesic. The ideal analgesic is potent but 
reversible, does not affect the circulation and respiration, has 
no side effects and can be titrated. This description most closely 
describes the μ-agonist opioids. Methadone 0.1-0.2 mg/kg i. v. 
or i. m. every 1-2 hours or fentanyl 2-5 ug/kg/h as a continuous 
rate infusion (CRI) are possible analgesics for emergency 
patients [Campbell, 2005]. μ-agonists can be titrated as well as 
antagonized and have no major side effects on circulation and 
respiration in the described dosages [Campbell et al., 2003]. 
Other opioids such as buprenorphine (0.01 mg/kg i.v. / i.m. 
every 6-8 hours) or butorphanol (0.2 mg/kg i.v. or i.m. every 
1-2 hours) are also possible, but cannot be repeated in the case 
of insufficient analgesia and are only limited reversible. The 
analgesic effect of butorphanol is much shorter (40 minutes) 
as the sedative effect, which is why a CRI (0.1 mg/kg/h) is 
recommended [Plumb 2004]. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
contraindicated in patients in shock as they reduce renal 
blood flow and can lead to ulceration in the gastro-intestinal 
tract [Campbell, 2005]. Both the kidneys as well as the 
gastrointestinal tract are organs that are inadequately perfused 
during centralization in decompensated shock, and are therefore 
Cardio-vascular	
Problem
Dose	isotonic	
crystalloid
Dose	colloid
Hypovolemic 
shock
Compensated Dog: 10-30 ml/kg 
Bolus# 
Cat 10 ml/kg 
Bolus#
--
Dog: 15 ml/kg 
Bolus# 
Cat: 5 ml/kg Bolus#
Dog: 5 ml/kg Bolus# 
Cat: 5 ml/kg Bolus
Decompensated Dog: 15-30 ml/kg 
Bolus# 
Cat: 10 ml/kg 
Bolus#
Dog: 5-10 ml/kg 
Bolus#
Cat: 5 ml/kg Bolus
10 ml/kg Bolus# + 
Hypertonic sodium: 
4ml/kg
5 ml/kg Bolus
Haemorrhage* Dog: 10 ml/kg 
Bolus# 
Cat: 5 ml/kg Bolus#
3-5ml/kg Bolus whole 
blood / pRBC according 
to needs 
Dog: Oxyglobin 5 ml/kg 
Bolus (max 30 ml/kg)
Cardiogenic 
shock + 
Hypovolemia
5-15 ml/kg Bolus 
slowly
1-3 ml/kg Bolus slowly
Coagulopathy Plasma 8-15 ml/kg
#repeat as required
*  Goal: systolic blood pressure 100 mmHg, or mean arterial blood 
pressure > 60 mmHg
Table 3: Examples of fluid therapy (Rudloff und Kirby, 1998)
Parameter Normal	value	dog Normal	value	cat
Heart rate 60-100 / Min 160-200 / Min
Mucous 
membranes
Pink, moist Pink, moist
CRT 1,5 sec 1,5 sec
Pulse Strong, regular Strong, regular
Mean arterial 
blood pressure
80 mmHg 80 mmHg
Central venous 
pressure
4-8 cm H
2
O 2-5 cm H
2
O
Urine production > 1ml/kg/h > 1 ml/kg/h
Hematocrit > 25% > 25%
Albumin > 20 g/l > 20 g/l
Table 4: Goal of fluid therapy (Rudloff und Kirby, 1998)
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much more sensitive to  any possible side effects of NSAID’s. 
NSAID’s are ideal analgesics for trauma patients with soft tissue 
trauma once adequate renal blood flow (indicated by normal 
urine production) has been established [Campbell, 2005]. 
Support of heart function 
The support of cardiac function has priority in cardiogenic 
shock. Adequate treatment requires the identification of the 
causative cardiogenic problem (contractility problem versus 
volume overload), which is usually only possible by means of 
cardiac ultrasound. 
A reduced contractility as well as various arrhythmias may be 
appearent both in cardiogenic shock as well as other types 
of shocks (due to various inflammatory mediators) [Day and 
Bateman, 2004]. Dobutamine (5-10 μg/kg/min) increases the 
contractility of the heart and may increase cardiac output in 
diseases with reduced contractility (DCM, sepsis) [Plumb, 2004]. 
With an already increased contractility as seen as a normal 
compensatory mechanism of the heart in order to normalise 
cardiac output, dobutamine leads to an undesirable increase in 
the oxygen demand of the heart muscle and is therefore not 
indicated [Plumb, 2004]. 
The most common arrhythmia seen in shock patients are 
ventricular arrhythmias [Day and Bateman, 2004]. Ventricular 
tachycardia can cause hypotension due to the high heart rate 
and decreased contractility. Multi-focal premature beats, severe 
tachycardia or signs of decreased perfusion are indications 
for the medical treatment of extrasystoles [Day and Bateman, 
2004]. Lidocaine (bolus 2 mg/kg followed by 40-80 μg/kg/
min CRI) is the anti-arrhythmic drug of choice for ventricular 
arrhythmias. Causative factors such as hypoxia, hypovolemia or 
electrolyte changes should be corrected as well. 
Vasopressors are generally not indicated in hypovolaemic and 
obstructive shock, since they lead to further vasoconstriction 
and centralization of the blood with subsequent ischemia 
of other organs. Vasopressors are used in distributive shock 
[Schertel and Muir, 1989]. Again, the goal of vasopressor 
therapy is not vasoconstriction but a normalization of vascular 
tone. The replacement of volume has priority and vasopressors 
are only indicated if the vascular volume is normalized (normal 
central venous pressure). 
Dopamine (2-10μg/kg/h) leads to vasoconstriction and 
is therefore indicated in hypotension due to vasodilation 
(distributive shock) [Day and Bateman, 2004]. 
Other therapies 
Trauma patients in shock are often hypothermic and need to 
be warmed up [Rudloff and Kirby, 1998]. Water bottles, warm 
water-filled disposable gloves, warmed fluid solutions, heat 
lamps or hot air supply by means of a Bair hugger are suitable 
to warm patients. The normalization of the temperature is very 
important, especially in cats, as perfusion parameters are not 
interpretable in very hypothermic animals. 
Antibiotic therapy is usually not indicated because of shock. 
Exceptions are indications of interruption of the normal intestinal 
barrier, such as haemorrhagic faeces or melaena. 
Steroids have been promoted for the treatment of shock a few 
years ago due to their membrane-stabilizing effect. Several 
clinical studies have shown no reduction and possibly even 
an increase in mortality and morbidity, indicating that the in 
vitro membrane stabilizing effect either seems to have no 
clinical effect or the side effects of steroids are greater than the 
potential benefits [Lefering and Neugebauer, 1995; Cronin et al, 
1995; Wadell et al, 1998]. Steroids are therefore not indicated. 
The only exception is a patient with sepsis and hypotension 
(septic shock) despite adequate fluid therapy and vasopressors. 
In this case,  steroids are supplemented in a physiological dose 
(Illness related Addison’s disease) [Martin and Groman, 2004]. 
The incidence of septic shock with hypoadrenocorticism is low 
in the dog and not previously been described in the cat [Peyton 
and Burkitt, 2009]. 
Monitoring
Since the exact amount of fluid loss in shock patients can not 
be determined and further fluid losses may occur, repeated 
evaluation of perfusion parameters, both during the stabilization 
and in the subsequent phase, is very important. The goal of 
shock therapy is a normal blood flow and a normal oxygen 
supply to the tissues (Table 4). The blood flow can be verified 
by clinical parameters such as heart rate, pulse quality, mucous 
membrane colour, capillary refill time and urine output. These 
parameters are determined at regular intervals after each bolus 
and after normalization of perfusion. 
Since shock is a state of cellular hypoxia and the clinical 
parameters indeed provide an indication of the perfusion but 
not to the cellular oxygen supply, ongoing search for other 
monitoring parameters is required. Lactate is a marker of 
anaerobic metabolism [Cady et al., 1973] and increases with 
reduced perfusion. Normal oxygen supply to the tissues can be 
demonstrated by decreasing lactate levels and normalization of 
the acid-base balance (accumulation of lactate during anaerobic 
metabolism leads to metabolic acidosis). A decrease of CO2 
can be measured by blood gas analysis, gastric tonometry or 
sublingual, however, this is rarely done in practice. 
SvO2, the saturation of haemoglobin with oxygen in the blood 
of a central vein (ideally from the pulmonary artery) is a marker 
for the balance between oxygen supply and consumption 
[Scalea et al., 1988]. In human medicine, SvO2 is an important 
parameter for the evaluation of fluid therapy in patients with 
septic shock and a rapid normalization of SvO2 by administering 
fluid therapy, blood products, and vasopressors as needed, 
leads to a reduction in mortality [Rivers et al., 2001]. 
The monitoring of haematocrit and total protein is important 
especially in trauma patients, where internal, invisible bleeding 
can not be excluded, as the hematocrit may be normal initially 
and only decrease after normalizing the intravascular volume 
with fluids. Continued fluid therapy with colloids depends on the 
oncotic pressure estimated by the level of albumin. The oncotic 
pressure should be increased by means of synthetic colloids 
(Haes, 1-2 ml/kg/h) when albumin levels are  < 20 g/ l or total 
protein is < 40-50 g/l [Rudloff and Kirby, 1998]. Aggressive fluid 
therapy may cause an iatrogenic hypokalemia. Hypoglycaemia 
should be considered in young animals presenting in shock. 
The rapid and adequate normalization of circulation during the 
stabilization of an emergency patient is important to prevent 
secondary organ changes and complications. After stabilization 
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of respiration (see stabilization of emergency patients, Part I: 
respiration) and normalizing perfusion, the emergency patient is 
stable enough to allow a complete physical examination and a 
diagnostic and therapeutic plan can be established. 
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Efficacy of Advance Veterinary Diets Atopic Care on the management of Canine 
Atopic Dermatitis (CAD): a randomized, doubled-blinded controlled clinical study
CAD is a chronic inflammatory disease of the skin causing pruritus. 
The prevalence is calculated at 10-15% of canine population (Hillier 
&Griffin, 2001), with special predisposition in some breeds such 
as West Highland White Terrier, French Bulldog o Shar Pei, where 
prevalence can reach 30%. Pathogenesys of CAD is complex 
and probably not identical in all cases. Recent studies show two 
main mechanisms of action of CAD: hypersensibility against 
environmental allergens and skin barrier alterations (Marsella & 
Samuelson, 2009; Oyoshi et al, 2009). Development and severity 
of CAD are related to the complex interaction between genetic, 
immunologic, environmental, pharmacologic and physiological 
factors, as well as the functional condition of the skin barrier.
The study evaluated the effect of Advance Veterinary Diets Atopic 
Care on pruritus, cutaneous lesions and steroid-sparing effect 
in dogs with non-seasonal, atopic dermatitis. The dogs enrolled 
were not previously medicated and had undergone an elimination 
diet. Dogs were randomly assigned to either a diet enriched with 
essential fatty acids, vegetal extracts and collagen peptides (A) or 
a commercial diet (B), in a multicentered double-blinded study. 
They all received prednisone initially at 0.5 mg/kg/day, which was 
reduced whenever possible according to a written protocol. Owners 
evaluated pruritus weekly using a visual analog scale. Veterinarians 
performed CADESI-03 at day 0, 28, and 56. 
CADESI and pruritus scores at day 0 were not significantly different 
between groups. Mean pruritus scores were 7.09±0.5, 7.2±0.6; 
2.64±0.4, 5.3±0.9; 0.45±0.2, 4.5±0.8; at days 0, 28, and 56, 
for diets A and B respectively. CADESI scores were 110.64±16, 
99.7±16.7; 48.3±11.5, 78.2±17.7; 14.36±4.9, 56.60±4.8; at days 0, 
28, and 56, for diets A and B respectively. The reduction of pruritus 
and CADESI scores was significant for dogs on diet A from day 0 to 
28 (p=0.017 and p=0.014), and from day 0 to 56 (p= 0.001 and 
p=0.020), but not for dogs on diet B. Total prednisone administered 
(days 0-56) was 13.63 mg/kg ±1.5 and 22.61 mg/kg ± 2.3 for dogs 
in diets A and B respectively (p=0.004). At the end of the study 
none of the dogs on diet A received prednisolone, while 8/11 dogs 
on diet B still received prednisolone.
The results showed that the nutritional approach of Advance 
Veterinary Diets Atopic Care was helpful for dogs with atopic 
dermatitis, achieving a significant reduction of pruritus, skin lesions, 
and prednisone administered.
Hillier A, Griffin CE. The ACVD task force on canine atopic dermatitis (X): is there a relationship between canine atopic dermatitis and cutaneous adverse food 
reactions?. Veterinary Immunology Immunopathology 81, 227-231, 2001.
Marsella R & Samuelson D. Unraveling the skin barrier: a new paradigm for atopic dermatitis and house dust mites. Veterinary Dermatology 20, 533-540, 2009.
Oyoshi MK, He R, Kumar L, Yoon J, Geha RS. Cellular and molecular mechanisms in atopic dermatitis. Advances in Immunology 102, 135-226, 2009.
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The emergency patient with decreased consciousness is identified by clinical examination of pupil size and reaction, 
additional brain stem reflexes, level of consciousness and motor activity. Priority stabilisation of respiration and 
perfusion is mandatory in the management of patients with neurological diseases and is part of the strategy aiming 
at preventing secondary neuronal damage induced by hypoxia, hypercapnia and decreased cerebral perfusion. The 
goal of the emergency stabilisation is maintenance of normal ventilation and oxygenation as well as keeping mean 
arterial blood pressure above 70 mm Hg. Hypertonic saline, Mannitol and sedation may be indicated with signs of 
increased intracranial pressure. Seizures must be treated immediately and some patients may require anaesthesia 
and positive pressure ventilation.
Key words: brain oedema, intracranial pressure, cerebral perfusion, status epilepticus, brain trauma
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Introduction
after stabilisation of the circulation and respiratory problems 
caused by disturbances of ventilation or oxygenation, the 
stabilisation of emergency patients concentrates on the central 
nervous system (CNs). 
Disturbances in the central nervous system affect consciousness. 
The assessment of consciousness and neurological status is 
particularly important in the neurological emergency patient, 
but can only be assessed seriously after stabilisation of 
respiration and circulation, because shock and both hypoxia 
and hypercapnia can also be the cause of a reduced state of 
consciousness. 
Pathophysiology 
Like all organs, the function of the CNs depends on sufficient 
blood flow and oxygen and energy supply. The brain is a 
very active organ with a particularly high oxygen and energy 
demand. It consumes about 20% of the total body oxygen and 
more than 25% of glucose (sokoloff, 1981]. Neurones are also 
not able to retrieve their energy anaerobically to a sufficient 
extent. since the brain has only very limited storage capacity for 
glucose and oxygen, already a minimal lack of energy can lead 
to brain damage. 
Cerebral blood flow depends on the ratio between cerebral 
perfusion pressure (CPP), and the cerebrovascular resistance. 
In a healthy brain, the cerebral perfusion pressure is monitored 
closely to maintain the oxygen and energy supply to the 
nerve cells [Guyton and Hall, 2000]. Through the so-called 
autoregulation, cerebral blood flow is kept constant despite 
changes in blood pressure and cerebral vascular resistance. 
Cerebral blood flow is effectively self-regulated with cerebral 
perfusion pressures between 50-150 mmHg.  at CPP’s above 
or below this range the cerebral blood flow becomes directly 
proportional [Busija et al, 1980]. In various diseases of the 
brain such as in traumatic brain injury, encephalitis, or seizures, 
autoregulation may be impaired focally or generally, which will 
also lead to a direct dependence of cerebral blood flow of mean 
arterial blood pressure (maP): 
   CPP = MAP - ICP 
The intracranial pressure (ICP) is built up by the skull and its 
contents (brain parenchyma, cerebrospinal fluid, blood volume) 
(1)  Department of Clinical Veterinary Medicine, Vetsuisse Faculty of Bern and Veterinary Emergency and Critical Care Continuing Education 
Längasstrasse 128 CH-3012 Bern  E-mail: nadja.sigrist@kkh.unibe.ch
* Presented by SVK/ASMPA (Switzerland)
** Part I was published in EJCAP 21(1) April 2011 and Part II in this issue
#  Copyright permission gratefully received from M. & H. Schaper GmbH, Kleintierpraxis - www.vetline.de/zeitschriften/ktp  
REPRINT PAPER (CH)
Stabilisation of the 
emergency patient part III: 
Central Nervous System**
Nadja Sigrist(1)
144
Stabilisation of the emergency patient part III: Central Nervous System - Nadja Sigrist
[Bagley, 1996]. Normal ICP in dogs and cats is 5-10 mmHg 
[Bagley, 1996]. ICP can rise due to volume increase by brain 
masses, cerebrospinal fluid and blood volume. an increase in ICP 
results in decreased perfusion pressure (CPP) and cerebral blood 
flow, decreased blood flow to and diminished supply of brain 
cells with oxygen and glucose. This leads to secondary changes 
and cell damage. Intracranial hypertension will lead to alterations 
of consciousness, respiratory and circulatory abnormalities, and 
may cause death of the patient by brain herniation. 
Clinical symptoms and localisation 
The initial brief neurological examination should assess the 
responsiveness of the patient, the pupil size and response, other 
cranial nerve functions such as the menace response, and the 
muscle tone of the limbs [sigrist and spreng, 2007]. The clinical 
symptoms of central nervous system disorders manifest in 
abnormalities of mentation, cranial nerve deficits, and abnormal 
posture reactions [Vite and steinberg, 2003]. The consciousness 
may be hyperactive, normal, somnolent, stuporous or comatose 
[Jellinger, 2009]. In a stuporous animal a reaction can be 
triggered by noise or pain stimulus, while the comatose animal 
is unconscious and shows no reaction to stimuli [Pschyrembel, 
1994, Jaggy and spiess, 2007]. Hyperexcitability or seizures can 
also represent clinical signs of an intracranial problem. 
a complete neurological exam is essential to further localise the 
problem and stabilise the patient. Paretic or paralysed patients 
with a trauma history should be carefully manipulated until a 
spinal injury is excluded. The problem can be further localised 
on the basis of specific neurologic deficits [Vite and steinberg, 
2003]. The spinal reflexes are generally normal with an isolated 
central nervous system problem [Jaggy and spiess, 2007]. If 
posture reactions are abnormal in all limbs, the problem can be 
localised cranial to C5 [Jaggy and spiess, 2007]. ataxia, hemi-  or 
tetraparesis may be caused by lesions in the cortex, cerebellum, 
brainstem and spinal cord. Identification of walking abnormalities 
will help identify the localisation [Jaggy and spiess, 2007]. With 
a cortical lesion, paresis or compulsive walking will be seen 
together with abnormal consciousness. Hypermetria, cerebellar 
ataxia and lack of the menace response are characteristic of a 
cerebellar lesion. Once cranial nerve deficits can be identified, 
the brainstem is included in the localisation. In the emergency 
patient, evaluation of the menace response (except for puppies 
younger than 4 weeks), pupillary reflex and pupil size and 
symmetry are particularly helpful. Both miotic and dilated, non-
responsive pupils are a sign of a brainstem problem. anisocoria 
indicates a lateralised or very focal problem [Oliver et al., 1997]. 
Horizontal nystagmus, triggered by lateral head movement, is a 
physiological reflex. The rapid eye movement should take place 
in the direction of head movement. The lack of a physiological 
nystagmus  indicates a brainstem lesion with swelling, bleeding, 
or compression. 
Decerebrate rigidity with limb extension and opisthotonus is 
seen with severe brainstem compression or herniation of the 
brainstem and / or the cerebrum, while an extension of the front 
limbs and flexion of the hind limbs (decerebellate rigidity) is seen 
with herniation of the cerebellum. 
respiratory and circulatory parameters can be altered by 
CNs lesions. Breathing can be changed in many ways and 
is unfortunately not specific for a certain localisation [Vite 
and steinberg, 2003]. The Cushing reflex is seen with 
massive intracranial hypertension due to cerebral oedema or 
haemorrhage. The diminished blood flow to the brain results 
in CO2 accumulation in the brain which leads to activation of 
the sympathetic circulatory centre, followed by generalized 
vasoconstriction. The vasoconstriction results in increased blood 
pressure and a reflex bradycardia, the classic symptoms of the 
Cushing’s reflex [Guyton and Hall, 2000]. Other clinical signs 
of intracranial hypertension are dilated, non-responsive pupils, 
stupor or coma and decerebrate rigidity [Vite and steinberg, 
2003]. 
The Glasgow Coma scale score is a simple scale to assess 
the degree of central nervous system problems [Teasdale and 
Jennet, 1974] and was adapted [shores, 1983] and evaluated for 
veterinary patients [Platt et al., 2001]. The score is most often 
applied in the traumatic brain trauma patient, where it has 
prognostic significance, but can also be used to quantify CNs 
function in any emergency patient. The categories brainstem 
reflexes (pupillary size and response), motor function and 
consciousness are divided into six stages with points from 1-6 
Status epilepticus 
O2 with mask 
IV catheter possible? 
no 
Diazepam 
1mg/kg rectal 
yes 
Diazepam 0.5-1mg/kg iv 
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BUN, Na, K, Ca, blood gas 
Hypoglycaemia? 
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Other blood abnormalities? 
Epileptic activity stopped? 
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kg PO/IV BID Diazepam 0.5-1 mg/kg IV 
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Rule out / treat ARF 
Treat accordingly 
Epileptic activity stopped? 
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repeat after 30 Min if required 
Epileptic activity stopped? 
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Intubation, 100% O2 
Propofol 2-6 mg/kg 
Bolus  2-5mg/kg/h 
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yes 
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Figure 1: Algorithm for seizure control
Adapted from Sigrist and Spreng, 2007
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(Table 1). The higher the score (maximum 18), the better the 
prognosis. a score of <8 points in dogs with traumatic brain 
injury is associated with less than 50% chance of survival during 
the first 48 hours post trauma [Platt et al., 2001]. 
Differential diagnoses 
Depending on the degree of consciousness abnormalities and 
additional clinical symptoms, various differential diagnoses 
should be considered [Vite and steinberg in 2003]. Vascular, 
infectious / inflammatory, traumatic, congenital anomaly, 
metabolic, idiopathic, neoplastic and degenerative (acronym 
VITamIN D) causes are distinguished [Vandevelde, 2007]. In 
emergency patients with CNs symptoms, traumatic brain injury, 
metabolic causes of seizures as well as differential diagnoses 
of reduced consciousness (Table 2) should be ruled out. 
Hypoglycaemia, hypocalcaemia and disturbances of sodium 
haemostasis, as well as many intoxications may lead to both 
decreased consciousness and hyperexcitability or seizures. 
Potential neurotoxins are summarized in Table 3 [Gfeller and 
messonier, 1998, Peterson and Talcott, 2001]. 
Diagnosis 
Due to the different metabolic causes of CNs symptoms, a 
complete blood analysis with CBC, chemistry profile, and if 
indicated blood gas analysis, coagulation profile and urinalysis, 
should be performed. In the emergency situation, at least PCV 
/ total protein, glucose, electrolytes including calcium, urea and 
creatinine, and possibly ammonia should be determined. 
Blood pressure, pulse oximetry, ECG and end-tidal CO2 in 
Mentation Cranial nerves
Pupillary and oculocephalic reflexes (OCr)
Motor activity Points
responsive Normal pupils and OCr Normal gait, normal spinal reflexes 6
responsive but depressed reduced but present pupil reaction and OCr Hemiparesis, Tetraparesis 5
semicomatose, reactive for 
visual stimuli
Bilateral unresponsive miosis with present 
OCr
Lateral recumbency, intermittend 
extensor rigidity
4
semicomatose, reactive for 
noises
Pinpoint pupils with decreased or missing 
OCr
Lateral recumbency, constant 
extensor rigidity
3
stupor, reactive for pain unilateral unresponsive mydriasis with 
decreased or missing OCr
Lateral recumbency, constant 
extensor rigidity with opisthotonus
2
Coma, no reaction Bilateral unresponsive mydriasis with 
decreased or missing OCr
Lateral recumbency, muscle flaccidity, 
decreased or missing spinal reflexes
1
Points of physical exam results of mentation, cranial nerve results and motor activity are added for the Glasgow-Coma-scale 
score (GCs-score).
Table 1: Modified Glasgow Coma Scale (Shores, 1983)
Decreased mentation 
(consciousness)
Hyper-
excitability
Seizures
Intoxication Intoxication Intoxication
Traumatic brain injury Traumatic brain 
injury
Encephalitis Encephalitis
Hypoxia Hypoxia
Hypoglycaemia Hypoglycaemia
Hyperglycaemia
Hypocalcaemia Hypocalcaemia 
(Tremor)
Hypocalcaemia
Hypercalcaemia Hypercalcaemia
Hyponatraemia Hyponatraemia
Hypernatraemia Hypernatraemia Hypernatraemia
renal insufficiency renal insufficiency
Liver failure Liver failure
Hypotension Hypotension
Hypoventilation 
(Hypercapnia)
Thromboembolic 
disease, infarct
Thiamin-deficiency Thiamin-deficiency
Hypothyroidison Hyperthyroidism
Heat stroke
Seizures/Tremor Decreased mentation
amphetamine amitraz
Lead Barbiturate
Bromethalin Benzodiazepine
Carbamate Bromethalin
Drugs (LsD, Cocaine, 
marijuana)
Drugs (Opioids, Ketamine, 
Cannabis)
Ivermectin Ethanol, methanol
Lidocaine Ethylenglycol
methaldehyde Ivermectin
methylxanthine methylxanthine/Theobromine
mycotoxins Opioids
Opioids (high doses) Phenothiazine
Organophosphate
Pyrethroid
Zinc phosphide
Table 2: Causes of CNS symptoms in the emergency patient
Table 3: Neurotoxins 
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intubated patients are not only helpful for monitoring but also 
for the inclusion or exclusion of the differential diagnoses. 
Depending on overall condition and other clinical signs, chest 
radiographs and / or abdominal ultrasound may be indicated. 
Depending on the differential diagnosis specific neurological 
investigations such as CsF analysis, electroencephalogram (EEG), 
magnetic resonance imaging (mrI) or computed tomography 
(CT) of the brain may be indicated. 
Stabilisation
stabilisation of emergency patients with CNs problems focuses 
on the normalisation of breathing and perfusion, followed 
by measures of intracranial stabilization [syring, 2005]. The 
stabilization of breathing and perfusion has been described 
in the first two parts of this series [sigrist, 2010a, b]. specific 
aspects of oxygen supply and fluid therapy will be discussed 
in detail. The reduction of secondary damage to the brain 
by cerebral oedema and / or necrosis, which are favoured 
by hypotension, hypoxia, hypercapnia, hyperthermia and 
inflammatory mediators, is an extremely important treatment 
strategy in neurological emergency patients and is particularly 
important in patients with traumatic brain injury [Chestnut, 
1995]. Normalising oxygenation and ventilation, maintenance 
of intracranial blood flow through adequate infusion therapy, 
reduction of cerebral metabolism and if necessary reduction of 
intracranial pressure and control of seizures are the main goals 
of treatment [Proulx and Dhupa, 1998, syring, 2005] 
Maintenance of oxygenation
Hypoxia must be avoided since hypoxia leads to an increase 
in intracranial pressure [Fortune et al., 1995] and is therefore 
an important mortality factor [Bratton et al., 2007a]. Oxygen 
supplementation is immediately instituted in every patient with 
central nervous system disease and can be applied with different 
techniques [sigrist, 2010a]. Intranasal or intratracheal oxygen 
administration should be avoided in patients with intracranial 
disorders as irritation will lead to sneezing or intensive head 
movements with subsequent massive increase in intracranial 
pressure. The animal with persisting hypoxia (spO2 <90% or 
PaO2 <60-80 mm Hg) despite oxygen supplementation, or 
hypoventilation (PCO
2
> 40-50 mm Hg) should be intubated and 
mechanically ventilated, as both hypoxia and hypercapnia lead 
to intracranial hypertension [Fortune et al., 1995a]. 
Maintenance of intracranial blood 
supply 
as discussed before, the intracranial blood supply depends on 
blood pressure and intracranial pressure. Various studies have 
shown that hypotension (systolic blood pressure <90 mm Hg) 
is associated with increased mortality [Chestnut et al., 1993, 
Bratton et al., 2007a]. The aim of fluid therapy is to maintain 
a cerebral perfusion pressure of at least 50 and a maximum of 
70 mmHg [syring, 2005, Bratton et al., 2007b]. Depending on 
the intracranial pressure, the loss of autoregulation requires a 
mean arterial blood pressure of at least 70-80 mm Hg in order 
to maintain normal cerebral perfusion pressure. Blood pressure 
optimisation is carried out primarily by the application of fluids 
that remain in the intravascular space. While the goal of the 
infusion therapy is clearly defined, a consensus regarding the 
ideal fluid solution in both veterinary and human medicine 
is lacking. The intact blood-brain-barrier is impermeable to 
electrolytes and colloids. However, in neurological emergency 
patients fluid therapy becomes more difficult as the blood-
brain-barrier may show increased permeability, or may even be 
destroyed [Zhuan et al., 1995]. With a damaged blood-brain 
barrier, all fluid types may leak from the vascular system and lead 
to brain oedema. However, the blood-brain barrier is usually only 
locally destroyed and the benefits of  aggressive fluid therapy 
outweigh a potential local increase of intracranial pressure. 
Given the possibility of a generalised increased permeability, the 
isolated use of isotonic crystalloid solutions is less favourable 
and hypotonic crystalloid solutions are ineffective at increasing 
the intravascular volume [Feldman et al., 1995]. Combinations 
of colloidal (5-10 ml/kg) with isotonic crystalloid solutions (10-
20 ml/kg), administered as an IV bolus over 10-20 minutes, are 
given and repeated until normal perfusion parameters and the 
desired mean blood pressure are achieved [Proulx and Dhupa, 
1998; syring, 2005]. 
Hypertonic NaCl (3-8%) at a dose of 3-5 ml/kg is discussed 
as the fluid of choice for traumatic brain injury [Bratton et al. 
2007c]. Due to the high osmolarity, hypertonic saline leads to a 
water shift from the interstitial and intracellular space into the 
intravascular space, leading to both an increase in blood volume 
and blood pressure as well as a reduction of cerebral oedema 
[Bratton et al. 2007c]. Hypertonic saline is therefore specifically 
indicated in patients with hypovolemia in combination with 
oedema [syring, 2005]. Hypertonic NaCl further leads to an 
improved regional cerebral blood flow and oxygen supply to 
the tissues by reducing cell swelling, arterial vasodilation and 
reduction of inflammatory reactions [Doyle. et al. 2001, Bratton 
et al., 2007b]. since it is a crystalloid solution, hypertonic NaCl 
is rapidly distributed in the extracellular space and the effect is 
therefore only very briefly. By combining it with colloids (dextran 
or HEs) the effect can be extended [Qureshi and suarez, 2000]. 
Contraindications for the administration of hypertonic NaCl are 
hypervolemia, pulmonary oedema, hypernatraemia and chronic 
hyponatraemia [Bratton et al., 2007c]. 
after stabilisation of blood pressure and intracranial perfusion, 
further fluid therapy depends on the needs of the individual 
patient [sigrist, 2005]. 
The cerebral blood flow depends also on the tone of the cerebral 
vessels. Hypercapnia due to hypoventilation or seizure activity 
leads to vasodilation and increased intracranial pressure [Fortune 
et al., 1995a] and should therefore be monitored and possibly 
corrected by means of ventilation therapy. The target value of 
PaCO2 is 30-35 mmHg [syring, 2005, Warner et al., 2008]. It is 
important to take into account that hypocapnia is also harmful 
[muizelaar et al., 1991, Fortune et al., 1995]. Hyperventilation 
is therefore no longer recommended [Bratton et al., 2007d]. 
an excessive increase in cerebral blood flow followed by 
increased intracranial pressure and subsequent increased oxygen 
consumption can be seen with increased cellular metabolism 
due to hyperthermia, hypertension, pain, excitement and 
convulsions. Patients should therefore be kept quiet and receive 
adequate analgesia, may be sedated and cooled if necessary. 
147
EJCAP - Vol. 21 - Issue 2 October 2011
analgesia and / or sedation should have no side effects on 
circulation and respiration. Butorphanol (0.1-0.2 mg/kg/h IV), 
buprenorphine (0.01 mg/kg IV) or fentanyl (3 - 5 μg/kg/h IV) can 
be used as analgesics, while butorphanol (0.1-0.2 mg/kg Im or 
IV), diazepam (0.2 mg/kg IV) or midazolam (0.1-0.2 mg/kg Im 
or IV) can be used for sedation [Haskins, 2006; Dyson, 2008]. 
Convulsions should be treated urgently (see below). 
The temperature is kept in the normal range (37-38 ° C) by 
actively cooling or warming the patient. moderate hypothermia 
(32-33 ° C) is used in human patients with massive increase 
of intracranial pressure [Bayir et al., 2009], but requires a 
very intensive monitoring of potential side effects and precise 
protocols and is therefore not recommended in veterinary 
medicine. 
Reduction of intracranial pressure 
an increase in the intracranial pressure is associated with 
increased mortality, which is why the reduction of the ICP, 
respectively its normalisation, is an important part of stabilisation 
[miller et al., 1977]. 
mannitol is an inert sugar with an osmotic effect that is not 
metabolised, filtered renally and excreted unchanged [muizelar 
et al., 1984]. mannitol increases plasma osmolarity and 
therefore attracts water from the cerebral interstitial space and 
has been used for years to reduce intracranial pressure. Besides 
the osmotic effect on the cerebral interstitium, mannitol also 
has favourable effects on the rheology of blood, is a radical 
scavenger, and shows a cerebral vasoconstriction effect, while 
at the same time increasing the intravascular volume [muizelar 
et al., 1983, Bratton et al. 2007c]. 
mannitol not only reduces the intracranial pressure due to 
the hyperosmolarity but also increases blood pressure, both 
resulting in an improved cerebral blood flow [Bullock, 1995]. 
The goal of mannitol treatment is a plasma-osmolarity of 320 
mOsm (normal is 300 mOsm) [Bullock 1995], which is achieved 
with a dose of 0.25-1 g/kg, administered as a slow IV bolus over 
10-20 minutes [Plumb, 2004 ; Bratton et al. 2007c]. Because 
of fast renal excretion and subsequent diuresis, the increase 
in blood-pressure by mannitol is only short-working and it is 
important that the fluid losses are adequately replaced to 
prevent hypotension and re-reduction of the CPP. The potential 
problems of mannitol extravasation with a damaged  blood-
brain barrier are negligible in comparison with the positive 
effect [Bullock, 1995], due to the diuretic effect and potential 
side effects such as kidney failure and disruption of the integrity 
of the blood-brain barrier, mannitol should nevertheless not be 
given without clear evidence or high suspicion of brain oedema 
[Bratton et al. 2007c]. If a positive effect is seen after mannitol 
administration, mannitol can be repeated every 6-8 hours if 
necessary [syring, 2005]. Hypertonic NaCl (3-8%) is also used 
to decrease the intracranial pressure and is partially effective in 
patients who are resistant to the pressure-effect of mannitol 
[Horn et al., 1999]. Elevation of the head by15-30 ° without 
affecting the blood flow to the brain leads to an improved flow 
of cerebrospinal fluid, [Platt, 2009]. It is important to ensure 
that the jugular veins are not compressed (no blood withdrawal 
or jugular catheter). 
Suppression of seizures 
The pharmacological interruption of seizures and prevention 
of consequent damage to the brain are the primary treatment 
goals following stabilisation of respiration and circulation [Platt 
and mcDonnell, 2000]. Different drugs with an anti-epileptic 
effect are used to treat seizures and are often combined due 
to their different onset of action, duration of effect and related 
side effects. 
Diazepam 0.5-1 mg/kg IV is the first choice due to the rapid 
onset of action [Platt and mcDonnell, 2000]. If intravenous 
administration is not possible diazepam can be given rectally (0.5-
2 mg/kg as a suppository or using the intravenous solution) or 
intranasally (0.5-1 mg/kg of the IV solution) [Plumb, 2004]. The 
anti-epileptic effect of diazepam occurs within a few minutes but 
the duration of effect is relatively short [Plumb, 2004]. Diazepam 
may be repeated two times at intervals of 10 minutes or be given 
as a continuous rate infusion (CrI) (0.1-0.5 mg/kg/h diluted in 
5% glucose) [Plumb, 2004]. since diazepam is sensitive to light, 
absorbed by plastic and may lead to thrombophlebitis, a CrI of 
midazolam is preferable, but there is no established dosage in 
veterinary medicine. The recommended dose of midazolam for IV 
or Im application is 0.07-0.3 mg/kg [Platt, 2009]. midazolam, like 
Diazepam, has an anti-epileptic effect by the inhibitory effect of 
stimulated GaBa-a receptors [scott et al., 1998]. 
To further suppress epileptic activity in the brain, patients with 
status epilepticus that responded to diazepam or midazolam, 
should also be treated with a longer-acting antiepileptic 
drug such as phenobarbitone. Phenobarbitone increases the 
threshold potential of seizures by the stimulation of inhibitory 
GaBa-a receptors and the inhibition of amPa receptors 
which will reduce glutamate release [Plumb, 2004]. Due to the 
reduced lipid solubility the time to onset of action may take up 
to 30 minutes [Plumb 2004]. The dosage of phenobarbitone 
is dependent on the pretreatment and the response to 
benzodiazepines. If seizures could be stopped with diazepam 
or midazolam, Phenobarbitone is given as a dose of 2-5 mg/kg 
BID. With status epilepticus unresponsive to benzodiazepines, 
the recommended loading dose of phenobarbital is 10-20 mg/
kg IV [Platt, 2009]. If no effect is seen after 20-30 minutes, the 
dose may be repeated up to a maximum of 24-30 mg/kg/24 
hours [Platt, 2009]. 
at the same time metabolic causes of status epilepticus such as 
hypoglycaemia, hypocalcaemia and other electrolyte changes, 
azotaemia, hypoxia or severe acid-base changes should be 
ruled out by blood analysis and treated accordingly if necessary 
[sigrist 2007]. Hypoglycaemia should especially be ruled out in 
puppies. Glucose values <3 mmol/l (60 mg/dl) are treated by 
means of bolus of glucose (0.5-1 ml/kg of a 50% solution IV, 
at least two times diluted). The maintenance infusion should be 
substituted with 5% glucose after bolus therapy (a 5% solution 
can be reached by adding 50 ml 50% glucose in 500 ml ringer 
lactate or NaCl). Hypocalcaemic animals are substituted with 
calcium. In the case of status epilepticus due to hypocalcaemia 
calcium is given IV with ECG monitring over 15-20 min (e.g. 
calcium gluconate 100 mg/kg). 
Levetiracetam (Keppra®, uZB Pharma aG Zurich) is a newer 
antiepileptic drug that is widely used in human medicine. 
Levetiracetam also appears to be effective and well tolerated in 
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the dog [Dewey et al., 2008; Volk et al., 2008]. Pharmacokinetic 
studies to establish an ideal dose in animals with status 
epilepticus are lacking though. 
If the status epilepticus cannot be controlled with diazepam and 
a loading dose of phenobarbitone, other possible treatment 
options exist (Figure 1). The patient is placed under general 
anaesthesia using pentobarbitone, propofol or gas anaesthesia 
[Claassen et al., 2001]. Pentobarbitone acts like other barbiturates 
as a GaBa-mimetic, inhibits glutamate release and therefore 
appears to have an anti-epileptic effect in addition to inducing 
anaesthesia [Plumb, 2004]. side effects are hypotension through 
vasodilation and reduced cardiac contractility, hypoventilation, 
hypothermia, and accumulation leading to a prolonged recovery 
period and seizure-like activity during recovery [Plumb, 2004]. 
Pentobarbitone is administered to effect (3-15 mg/kg IV) 
and repeated as needed. Propofol also acts on the GaBa-a 
receptor, suppresses the central nervous system metabolism 
and also appears to have anti-epileptic effects [steffen and 
Grasmück, 2002], but EEG-controlled studies are lacking in 
veterinary medicine. Propofol is used as a bolus (1-4 mg/kg) or 
as a CrI (0.1-0.6 mg/kg/min) [Platt, 2009]. Both propofol and 
pentobarbitone can be combined with a midazolam drip in order 
to achieve a dosage as low as possible. The animals should show 
no more seizures, neither generalised nor locally. With both 
pentobarbitone and propofol it is debatable whether the central 
antiepileptic effect is sufficient to suppress the central seizure 
activity and not only muscular activity. anaesthetised animals 
should therefore also receive phenobarbitone (5 mg/kg IV BID). 
Ideally, the suppression of seizure activity is confirmed by EEG 
[Claassen et al., 2002]. The recovery period is also monitored by 
EEG analysis since excitation from the side effects of anaesthetics 
cannot always be distinguished from epileptic seizures. 
Patients are usually anaesthetised for 12-24 hours. This requires 
intensive monitoring. In order to avoid aspiration, patients 
should be intubated. Positive pressure ventilation may also be 
necessary under certain circumstances. However, in most cases, 
the animals breathe spontaneously and are supplemented with 
oxygen (by means of an oxygen tube into the endotracheal tube) 
without being connected to a respirator. The endotracheal tube 
should be suctioned every few hours or changed to prevent an 
obstruction or the ascent of bacteria. Intravenous fluid therapy 
follows the patient’s needs. animals in status epilepticus are 
usually not in shock, but may be, depending on the cause and 
are dehydrated because of the increased metabolism resulting 
in increased fluid requirements. Normally, maintenance dose 
of these animals is at least 5 ml/kg/hr of an isotonic crystalloid 
solution (e.g., ringers lactate).With clinical signs of dehydration 
or desired fluid diuresis (intoxications, renal failure) this dose can 
be doubled [sigrist, 2007]. 
Temperature control 
animals in status epilepticus often present with hyperthermia. 
active cooling can occur with wet towels, ice packs, cold infusions, 
by wetting the fur, or if necessary, bladder or abdominal lavage 
with cool infusion solutions [Platt and mcDonnell, 2000]. active 
cooling should be stopped at a temperature of 39.5 ° C to avoid 
subsequent hypothermia. 
Steroids 
steroids are rarely indicated for central nervous system problems 
[Platt et al., 2005]. With traumatic brain injury or cerebral 
oedema, clinical studies showed no beneficial effect of steroids 
[Bratton et al., 2007e]. High dose methylprednisolone results in 
increased mortality in both patients with traumatic brain injury 
[roberts et al., 2004] and in patients with acute trauma to the 
spinal cord [Carlson et al. 2003]. steroids have various side effects 
such as hyperglycaemia, immunosuppression, gastric ulceration, 
and delayed wound healing and are therefore not indicated in 
emergency patients with disorders of mentation [marshall et 
al., 1977]. In particular, the induction of hyperglycaemia has a 
negative impact on prognosis. 
Glucose control 
Hyperglycaemia leads to reduced neurological outcome and 
increased mortality both experimentally and in human studies 
[Natale et al., 1990, Cherian et al., 1998]. The only (retrospective) 
study in dogs and cats with traumatic brain injury did not find 
any correlation between glucose values and outcome [syring et 
al., 2001]. 
Decontamination 
In case of suspected poisoning with neurotoxins (Table 3) the 
decontamination of the gastro-intestinal tract is an important 
part of emergency treatment [sigrist, 2007]. The induction of 
vomiting is generally not indicated as altered consciousness or 
seizure activity will increase the risk of aspiration pneumonia 
[rosendale, 2002]. Gastric lavage under anaesthesia is indicated 
if the toxin has been ingested less than 2-4 hours ago and severe 
poisoning is very likely. animals should be intubated and the cuff 
inflated for a gastric lavage to prevent aspiration of irrigation 
fluid. The stomach is repeatedly rinsed with 5-10 ml / kg warm 
water until clear liquid is retrieved. The risks of gastric lavage, 
such as anaesthesia risk and aspiration pneumonia, must be 
weighed against the benefits. In animals that are intubated for 
other reasons (coma, convulsions), the benefit of gastric lavage 
outweighs the risks in most cases, and can also be carried out if 
the toxin ingestion is longer than four hours ago. 
after gastric decontamination, the administration of activated 
charcoal (1-4 g / kg PO) to bind remaining toxin is probably the 
most effective decontamination strategy [rosendale, 2002]. 
activated charcoal may be administered orally or by gastric 
tube. activated charcoal binds most of the neurotoxins and 
also oral medications such as phenobarbital. Laxatives such as 
sorbitol or lactulose can accelerate toxin elimination through the 
gastrointestinal tract. 
Monitoring 
animals with central nervous system problems should be 
monitored regularly. respiration, oxygenation, perfusion 
parameters including blood pressure and temperature are 
checked continuously in some patients. Haematocrit, total 
protein, glucose and electrolytes should be checked at least 
daily. after hyperosmolar therapy with mannitol or hypertonic 
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saline, electrolytes (sodium, potassium, and chloride) should 
be measured 30-60 minutes after administration. If abnormal 
findings are found, electrolytes are initially checked every hour 
followed by every 2-3 hours. In hypoglycaemic patients glucose 
is checked every hour after replacement until the glucose level 
has stabilized. The neurological status, in particular pupil size 
and response, or the GCs score respectively, is also verified 
several times a day (depending on the condition of the patient 
every 1-6 hours). stuporous, comatose or anaesthetised 
patients are monitored with heart rate / rhythm, respiratory 
rate, temperature, mucous membrane colour and capillary 
refill time, spO2, blood pressure and end-tidal CO2. The care 
of these patients also includes the application of eye ointment 
and oral hygiene, change of side every 2-3 hours, soft padding 
and control of urination. arterial blood gas analysis, or at least a 
venous blood gas for PCO2 determination should be measured 
every 3-6 hours in stuporous and / or intubated patients to 
detect ventilation or oxygenation problems in time to fix them. 
The measurement of intracranial pressure is one of the most 
important parameters in monitoring a patient with traumatic 
brain injury. The measurement of ICP’s is recommended in 
human medicine in patients with traumatic brain injury and a 
GCs score <8 and CT signs of swelling, bleeding, contusion 
or herniation [Bratton et al., 2007f]. Various methods of ICP 
measurement exist, with the ventricular catheter as the most 
accurate and least expensive method [Bratton et al. 2007g]. 
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This case report describes the computed tomography (CT) and magnetic resonance imaging (MRI) characteristics 
of a canine nasal tumour with atypical intracranial extension in a 10-year-old female large Münsterländer with 
progressing complaints of  difficulties opening her mouth, dullness and weight loss. A presumptive diagnosis 
was made based on CT and MRI. Due to the poor prognosis, the owner opted for euthanasia of the dog. The mass 
was histopathologically examined and diagnosed as a nasal adenocarcinoma with intracranial extension and 
surrounding soft tissue involvement.
Keywords: nasal adenocarcinoma, intracranial, CT, MRI
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Introduction
Nasal and paranasal tumours are uncommon in dogs; they 
account for up to 2.5  per cent of all canine tumours [1,2]. 
among nasal tumours, adenocarcinoma is the most common 
[3]. animals with nasal tumours have a wide range of clinical 
signs such as sneezing, nasal discharge, epistaxis, dyspnoea and 
facial deformity. Dogs with nasal adenocarcinomas have also 
been presented with neurological abnormalities without clinical 
signs related to abnormalties in the nasal cavity [4,5,6]. To 
detect changes in the nasal cavity, CT is superior to conventional 
radiography [7,8,9] and it provides similar information as mrI for 
the evaluation of canine intranasal neoplasia without intracranial 
extension [9]. mrI is superior in visualising brain pathology 
because of its multi-planar capabilities, increased sensitivity and 
better soft tissue characterization. In this case report the CT 
and mr imaging characteristics of a nasal adenocarcinoma with 
intracranial extent are described and discussed. 
Case presentation
a 10-year-old female large münsterländer weighing 27 kg,  was 
admitted to the Department of medicine and Clinical Biology of 
small animals, Ghent university with progressing complaints of 
difficulties opening her mouth, dullness and weight loss. From 
three weeks prior to presentation, opening her mouth was 
painful and she was unable to eat and drink in a normal way. 
atrophy of the masticatory muscles appeared. several antibiotics, 
non-steroidal and steroidal anti-inflammatory drugs were 
prescribed without clinical improvement. Physical examination 
revealed no abnormalities. Neurological examination revealed 
severe dullness, exophthalmia of the right eye, peripheral 
blindness in the left eye, painful reaction when trying to open 
the mouth and on palpation of the right masticatory muscles. 
Bilateral atrophy of the masticatory muscles was present. Due 
to abnormal consciousness, the exophthalmia and the pain, a 
right forebrain lesion with possible retrobulbar expansion was 
suspected.
(1)  Ghent University, Faculty of Veterinary Medicine, Department of Medical Imaging of domestic animals and Orthopedics of small animals. 
Salisburylaan 133, B-9820 Merelbeke. 
(2) Ghent University, Faculty of Veterinary Medicine, Department of Pathology, bacteriology and poultry diseases. Salisburylaan 133, B-9820 Merelbeke.
(3) Ghent University, Faculty of Veterinary Medicine, Department of Small Animal Medicine and Clinical Biology. Salisburylaan 133, B-9820 Merelbeke.
* Corresponding author: E-mail: Kaatje.kromhout@ugent.be
ORIGINAL WORK (B)
Canine nasal adenocarcinoma with 
atypical intracranial extension: 
computed tomography and magnetic 
resonance findings
K. Kromhout(1)*, S. Van der Heyden(2), I. Cornelis(3), T. Bosmans(3), H. van Bree(!), I. Gielen(1)
152
 Canine nasal adenocarcinoma with atypical intracranial extension: computed tomography... - K. Kromhout et al
Fig. 3 Transverse FLAIR image at the 
level of the temporal lobe. Atrophy of 
the masticatory muscles (black arrow) is 
visible on the right side. Normal size of the 
masticatory muscles (red arrow) is visible on 
the left side. An hyperintense signal is visible 
in the temporal lobe (*), oedema is present.
Fig. 4 Dorsal T2W image of the head.  
A retrobulbar heterogeneous mass is 
visible on the right side (black arrow) 
with exophthalmia of the eye. Multiple 
hyperintense regions (*) are visible in the 
right part of the cerebrum.
Fig. 5 Transverse post contrast T1W 
image at the level of the frontal lobe. 
Heterogeneous contrast enhancement 
is visible in the mass (red arrows). 
Rim enhancement (black arrow) of the 
hypointense lesions is visible.
To identify the lesion, an mrI (0.2 Tesla scanner; airis mate; 
Hitachi medical Corporation) of the brain was performed 
with the dog in dorsal recumbency and the head in a human 
knee coil. The mrI procedure was performed under general 
anaesthesia. The dog was premedicated with a combination 
of 0.02 mg/kg acepromazine (Placivet; Codiphar) and 0.1mg/
kg morphine (morphini HCl; sterop), both administered 
intravenously (IV). anaesthesia was induced with 0.2 mg/
kg midazolam (Dormicum; roche) IV, preceding propofol 
(Propovet; abbott animal Health) administration to effect 
(total dose of 50 mg) IV and maintained with isoflurane (Isoflo; 
abbott animal Health) vaporized in oxygen using a rebreathing 
system. Images were obtained in three planes. sequences 
included T1-weighted (T1W), T2-weighted (T2W) spin echo (sE) 
and fluid attenuated inversion recovery (FLaIr). T1W sE were 
also aquired after intravenous paramagnetic contrast medium ( 
0.3 ml/kg;  magnevist; Bayer HealthCare Pharmaceuticals Inc.) 
injection. On the sagittal T2W images an irregular ill-defined 
heterogeneous mass was visible. The mass invaded the conchae, 
lamina cribrosa, olfactory bulb, frontal, parietal and temporal 
lobes on the right side. There was a ventral extension visible in 
the nasal recess and caudal on the transition between the hard 
and the soft palate (Fig 1). Normal outline of several bones of 
the skull was absent. The mass contained multiple hyperintense 
Fig. 1 Sagittal T2W image of the head. An irregular, ill-defined 
heterogeneous mass is visible in the olfactory bulb and frontal lobe 
(black arrow), more ventral (green arrow) and more caudal on 
the transition between the hard and soft palate (red arrow). An 
hyperintense signal is visible in the frontal sinus (*).
Fig. 2 Transverse T2W image at the level of the frontal lobe of a dog. 
A midline shift to the left is visible (black arrow). A hyperintense 
signal is visible in the right frontal sinus (*). An abnormal high 
signal is visible in the region of the medial pterygoideus muscle (red 
arrow) and the temporal muscle on the right side (green arrow).
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signals on T2W images and hypointense signals on T1W images. 
a hyperintense signal was visible in the frontal sinus on T2W 
and T1W images. Transverse images revealed a midline shift to 
the left, an abnormal high intensity signal in the region of the 
right temporal and medial pterygoideus muscle and atrophy 
of the masticatory muscles (Fig 2). On FLaIr images multiple 
hyperintense regions were visible in the muscles, olfactory bulb, 
frontal and temporal lobe (Fig 3).  Dorsal T2W images revealed 
a heterogeneous mass in the right retrobulbar region causing 
exophthalmia of the right eye (Fig 4). Post contrast images 
revealed heterogeneous contrast enhancement of the mass and 
rim enhancement of the hypointense lesions on T1W (Fig 5).
Because there was bone involvement visible on mrI an 
additional CT examination was performed to see the 
extension more clearly. a multi-slice helical CT scanner (GE 
Lightspeed QX/I; General Electric Co.) was used with the 
patient in dorsal recumbency. Images were obtained before 
and immediately after administration of 2 ml/kg intravenous 
contrast medium (ultravist 300; N.V. shering s.a.). Extensive 
destruction of the skull was visible on the right side from the 
region of the parietal lobe affecting two thirds of the nasal 
bone. Thinning and partial destruction of the pterygoid and 
presphenoid bone was present. The right part of the nasal cavity 
was filled with a soft tissue opacity (Fig 6). a partial destruction 
of the turbinates and destruction of the lamina cribrosa was 
also visible (Fig 7). Homogeneous moderate contrast uptake 
was visible in the mass. When using the 3D reconstruction tools 
of a DICOm viewer (OsiriX) the extent of the bone destruction 
becomes clearly visible (Fig 8). after discussing these findings 
with the owner, euthanasia was preferred because of the poor 
prognosis. 
at postmortem examination, there was a multilobular retrobulbar 
mass visible in the right nasal cavity and sinuses. The mass was 
pale, soft and not encapsulated with infiltrative growth into the 
ethmoid, bulbus olfactorius, surrounding bones and soft tissues. 
The right parietal bone showed a 4 by 4.5 cm osteolytic lesion 
associated with invasive tumour growth (Fig 9). microscopically, 
the tumour cells were arranged in simple columnar tubular 
Fig. 9 Postmortem image of the right side of the skull. A pale soft 
mass (black arrow) is visible. An osteolytic lesion at the right side 
of the skull is visible (red arrow).
Fig. 10 Histopathological image of the nasal adenocarcinoma. 
Haematoxylin and eosin staining. A) Normal nasal mucosa (small 
arrow) and a densely cellular neoplasm (*) B) Detail of the neoplastic 
tissue. Neoplastic cells have a predominantly tubular arrangement.
Fig. 6 Transverse CT image at the level 
of the olfactory bulb (*). Destruction of 
the lamina cribrosa (black arrow), nasal 
bone (red arrow) and ethmoid bone 
(green arrow) is visible.
Fig. 7 Transverse CT image at the level of 
the parietal lobe. Destruction of the frontal 
bone (black arrow) is visible. The right 
frontal sinus is filled with a soft tissue 
density (red arrow).
Fig. 8 3D reconstruction (OsiriX) of the 
head.  Destruction of the bony structures on 
the right  side is visible (white arrow). 
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structures, and closely-packed simple non-secreting acini, 
within a fine fibrovascular stroma (Fig 10). The neoplastic cells 
were small cuboidal to medium-sized columnar, with basal or 
central round to oval nuclei and a moderate amount of granular 
eosinophilic cytoplasm. The mitotic index was low (1/high-
power field). Extensive haemorrhages, multifocal necrosis and 
neutrophilic infiltration were noted. Findings were consistent 
with a nasal tubulopapillary adenocarcinoma with infiltration of 
the surrounding soft tissues, rostral part of the brain and skull.
Discussion
Because of the predominance of the neurological signs in this 
dog a lesion in the forebrain and/or retrobulbar region was 
suspected. Previous articles [10,11,12] elected mrI as the imaging 
modality of choice for intracranial lesions. When a mass lesion 
is found on mrI, primary and metastatic tumours, granulomas 
associated with granulomatous meningoencephalitis (GmE) 
or cryptococcocis, infectious/inflammatory diseases such as 
toxoplasmosis or distemper, haemorrhages, abscesses, cysts, etc 
[13] can be included as differential diagnoses. Characteristics 
such as anatomical location, axial origin, shape and margins of 
the lesion, signal intensity and pattern, mass effect and contrast 
uptake could provide a good idea of the nature of the lesion 
[11]. The involvement of the nasal structures and the osteolytic 
content raised the suspicion of a primary nasal tumour with a 
secondary intracranial extension. Nasal tumours tend to extend 
intracranially through the cribriform plate or other cranial bones 
(frontal or presphenoid bones) [14]. They can also extend more 
caudally through the frontal sinuses, nasopharynx and the 
caudal recesses [15]. malignant nasal tumours can invade the 
cranial cavity and cause neurological signs but minimal or no 
clinical signs of nasal disease. Because of this, diagnosis is quite 
difficult [4,5]. The CT features of nasal tumours are described 
previously and include soft tissue attenuating material in the 
nasal cavity which may extend into the ipsilateral frontal sinus, 
pterygopalatine fossa and cranial vault with destruction of 
turbinates, nasal septum and other surrounding bones including 
the cribriform plate. The presence of a mass effect, destruction 
of vomer, the cribriform plate, paranasal bone, invasion of the 
sphenoid sinus by a mass and nasopharyngeal invasion are 
associated with a diagnosis of neoplasia on mrI [16]. High signal 
intensity on T2W and T1W images in the frontal sinuses is typical 
for retained secretions because they contain high protein, fat 
and blood products. accumulation of secretions caudal to a 
nasal mass is consistent with obstructive rhinitis and frontal 
sinusitis [9]. Hyperintense T2W regions in the mass are suspected 
cystic lesions which can be confirmed by rim enhancement after 
contrast uptake. The increased signal intensity in the extracranial 
soft tissues on T2W images and contrast enhancement indicate 
tumour invasion or increased vascular permeability from 
secondary tissue reaction [4]. abnormal signal intensity could 
also be a sign of muscle atrophy. 
Our mr and CT-findings corresponded with those found for 
nasal adenocarcinomas [10,11]. Tissue biopsy is necessary 
for definitive diagnosis [10]. Histological features of nasal 
adenocarcinomas include glandular patterns (papillary, 
tubulopapillary and acinar), cuboidal to columnar cells with 
round or oval nuclei and presence of secretory products [17].
Choosing the right imaging modality for a patient is challenging 
and is based on a detailed history, clinical examination of the 
animal and suspected diagnosis. Lesions and their extension 
seen on both imaging modalities are an important value in 
further treatment and prognosis of the disease. 
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Lymphoma represents the most common malignant tumour in cats. Genetic factors, retrovirus infections, 
chronic inflammation, immunosuppression and passive smoking are discussed as possible causes. Clinical 
signs at presentation normally depend on the anatomic site of the tumour. The alimentary form occurs most 
frequently with an increasing incidence, followed by extranodal, nodal and mediastinal lymphoma. Cytology 
is an important diagnostic tool and samples can be obtained by ultrasound-guided fine-needle aspiration and 
thoracocentesis. In most cases, tentative diagnosis is confirmed by the results of the cytological examination. 
However, a histopathological examination is essential for establishing a state-of-the-art diagnosis. At present, the 
pathohistological classification systems are being reorganized, replacing the older WF (Working Formulation) 
with the newer REAL/WHO (revised European-American Classification of Lymphoid Neoplasms/World Health 
Organisation) Classification. The latter evaluates not only the morphology but also the immunophenotype of 
neoplastic cells.
The cornerstone of the treatment of feline lymphoma, an almost exclusively systemic disease, is chemotherapy, 
which in general is tolerated well by cats. Radiation therapy has proven successful especially in nasal lymphoma. Its 
usefulness in all other forms is not known yet. In addition, the impact of surgery as part of therapy is still unclear, 
with insufficient studies performed. 
Prognosis for nasal or nodal lymphoma appears to be fair to good, with cats showing prolonged survival times of 
about one to two years. Mediastinal, spinal, renal and alimentary lymphoma has a less favourable prognosis, and 
median survival times of less than six months are quite common.
Keywords: feline lymphoma, anatomic classification, staging, pathohistological classification, chemotherapy, 
radiotherapy.
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Introduction
Lymphoma is the most common hematopoietic tumour in 
humans and its term was introduced by the British doctor Thomas 
Hodgkin in 1832. Based on his name, lymphoid tumours were 
accordingly divided into Hodgkin and Non-Hodgkin lymphoma 
in human medicine. While in human medicine both neoplasia 
types play an important role, Non-Hodgkin lymphoma is far 
more common in veterinary medicine. Later, a description 
of lymphosarcoma followed by Virchow in 1863 and in 1871 
Billroth suggested using the term “malignant lymphoma” to 
describe lymphoid tumours.
There is no benign lymphoma, as all are malignant tumours. 
Therefore, today these terms are used as synonyms in human 
and veterinary medicine. Lymphoma is a cancer developing 
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in lymphocytes of the immune system, which can involve any 
organ or tissue. Lymphoma is the most common malignancy in 
the cat, representing up to 41 % of all malignant feline tumours 
[macVean et al., 1978]. 
Aetiology
Genetic factors
The feline leukaemia virus (FeLV), a retrovirus, is a possible 
tumorigenic agent, disturbing either the tumour suppressor 
genes or the proto-oncogenes by insertional mutagenesis 
[Fujino et al., 2008]. The relative risk of developing lymphoma 
was shown to be 62 times greater in cats infected with FeLV and 
77 times greater if the cat was infected with both FeLV and feline 
immunodeficiency virus (FIV) [shelton et al., 1990]. Interestingly, 
although 60-70 % of cats were feline leukaemia virus positive 
between 1960-1980, this FeLV-associated lymphoma rate 
decreased lately, in contrast to the general lymphoma incidence, 
which increased by about 20 % [Louwerens et al., 2005]. 
simultaneously, the age class of affected animals changed from 
younger (<6 years) FeLV-positive cats to older (>10 years) FeLV-
negative cats [Vail et al., 1998], although one has to bear in 
mind that in 22 % of cats, FeLV-negative ELIsa tests showed 
a positive FeLV polymerase chain reaction (PCr) in lymphoma 
tissue [Gabor et al., 2001].
Tumour suppressor genes are also discussed in transforming 
normal cells to neoplastic ones. The cyclin-dependent kinase 
inhibitor p27Kip1 is considered as a tumour suppressor gene and 
was found to be reduced in both B and T-cell feline lymphomas 
[madewell et al., 2001]. Proto-oncogens (e.g. ras from rat 
sarcoma; includes N-ras, H-ras, K-ras), which can be converted 
by mutation into active oncogenes leading to a permanent 
growth-stimulating signal in the cell are a possible cause of 
tumorigenesis. However, in a study of 15 feline lymphoma 
patients only one cat showed a mutation in N-ras [mayr et al., 
2002], so that the importance of this particular proto-oncogene 
seems questionable in cats. 
Telomeres, the regions at the end of chromosomes in normal cells, 
are shortened after each replication cycle and therefore limit cells 
to a fixed number of mitosis. almost all neoplastic cells express the 
nuclear enzyme telomerase, which is able to elongate telomeres, 
a process that leads to immortalization. In a study of Cadile et 
al. [2001], the four examined feline tissue samples (peripheral 
lymph node, nasal, mediastinal and intestinal lymphoma) all 
demonstrated telomerase activity; however, telomerase activity 
appears to be rather an indicator of immortality [Kim et al., 1994], 
an essential step in the development of malignant tumours, than 
the primary cause of tumorigenesis.
Immunosuppression
Cats infected with the feline immunodeficiency virus have a six-
fold higher risk of developing lymphoma [shelton et al., 1990], 
most likely due to an indirect effect of immune dysfunction, 
although a direct role was also discussed in one case where 
integrated provirus was found in tumour DNa [Beatty et al., 
1998]. 
Feline patients receiving immunosuppressive therapy with 
cyclosporine after renal transplantation had 6.1 times higher 
odds to develop a tumour compared with the control group; 
24 % (11 of 45 cats) were diagnosed with post-transplant 
malignant neoplasias, four of them representing lymphomas 
[schmiedt et al., 2009]. 
In human patients, an increased incidence of lymphoma has 
been found after treatment of inflammatory bowel disease with 
immunosuppressive drugs like azathioprine or methotrexate 
[Farrell et al., 2000]. To date no studies concerning IBD therapy 
and risk of lymphoma development have been performed in 
cats. 
Chronic inflammation
Inflammatory bowel disease (IBD) as a cause of lymphomagenesis 
is still controversial in human medical literature as some studies 
demonstrated a higher risk for IBD patients [Jones and Loftus, 
2007], while this could not be observed in other studies.
sound proof is also still lacking in feline IBD patients. One 
cat, diagnosed with lymphoplasmacytic enteritis, developed 
alimentary lymphosarcoma 15 months later [Hart et al., 1994]. 
One cat, which was diagnosed with intestinal lymphoma, had 
concurrent lymphoplasmacytic gastritis and two cats showed 
concurrent colitis [Carreras et al., 2003]. Three cats had been 
treated for IBD for 5, 14 and 24 months prior to the diagnosis 
alimentary lymphoma [Zwahlen et al., 1998].
Bacterial pathogens causing chronic inflammatory diseases seem 
to play an important role in malignant transformations. Only 
recently, an association between Campylobacter jejuni infection 
in humans and mucosa-associated lymphoid tissue (maLT) 
lymphoma of the intestines has been discussed. a causative 
link between Helicobacter pylori infection and development of 
gastric maLT lymphoma has already been firmly established in 
human medicine [Du, 2007]. a significant association between 
the presence of the spiral organism Helicobacter heilmanii and 
lymphoma or gastritis was recently described in cats [Bridgeford 
et al., 2008].
Passive smoking
Cats living in households where at least one package of 
cigarettes was smoked daily, had a significant threefold increase 
in risk for developing lymphoma [Bertone et al., 2002].
Diagnostic approach and staging
after full clinical assessment, abdominal ultrasonography and 
thoracic radiographs are essential steps to evaluate the extent 
of the disease.
For a more specific evaluation of nasal cavities, brain or spine, 
the performance of myelograms, computed tomography or 
magnetic resonance imaging is also indicated.
a complete blood count with thrombocyte count, biochemistry 
profile with calcium, urinalysis and tests for FeLV and FIV should be 
performed. additionally, serum cobalamin concentrations should 
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be assessed as 78 % of tested cats had low concentrations [Kiselow 
et al., 2008]. Evaluation of bone marrow aspirates is necessary to 
complete clinical staging [Table 1, mooney et al., 1987].
Fine needle aspiration of suspected masses, thoracocentesis, 
abdominocentesis and cerebral fluid puncture are elegant, 
cheap and low-risk procedures to obtain sufficient material 
for cytological examination. an experienced veterinary 
cytopathologist is able to differentiate between neoplastic 
and inflammatory disease in most cases. Therefore, cytological 
analysis is the first important step to confirm the tentative 
diagnosis of lymphoma. 
Histological classification systems
Diseases need to be described, defined and named before they 
can be diagnosed, treated and studied; hence a worldwide 
consensus classification system of lymphoid diseases is 
essential to categorize its different entities [swerdlow et al., 
2008]. Histopathology is critical to this process. To perform 
state-of-the-art diagnostics in feline lymphoma, it is most 
important that tissue biopsies of every patient are evaluated by 
histopathologists.
In 1994, a new histopathological classification system named the 
rEaL classification (revised European-american Classification 
of Lymphoid Neoplasms) was instituted by the human medicine 
International Lymphoma study Group. Pathologists did not try 
to stratify lymphomas on the basis of their histological grade 
(as done in the Kiel and Working Formulation classification 
of human and veterinary medicine) but used morphology, 
immunophenotype, genetic abnormalities, clinical presentation 
and course to differentiate the heterogeneous group of distinct 
lymphoid diseases. It appeared that lymphomas were unrelated 
to each other and that they could not be considered as a 
single illness with a spectrum of histological grade and clinical 
behaviour. The successor version of the rEaL classification 
is the WHO (World Health Organization) classification, which 
was developed over seven years, first published in 2001 and 
updated 2008 for human medicine [swerdlow et al., 2008]. 
It emphasises that each disease must be assessed individually, 
that clinical groupings for protocol treatment are not feasible 
and that therapies for one lymphoma type is not necessarily 
applicable to other lymphomas, even if they originate from the 
same cell lineage. In the WHO classification, each lymphoma is 
a distinct disease entity, and therefore it is necessary that both 
clinicians and pathologists learn the histological and clinical 
spectrum of each of these diseases [Jaffe et al., 2008]. 
In veterinary medicine, the older classification system of the 
National Cancer Institute (NCI), the Working Formulation (WF) 
classification, was already compared to the more recent rEaL 
classification system in cats by Valli et al. [2000]. 
To classify the specific tumour correctly in the future 
and determine the cell line origin of the neoplastic cells, 
immunophenotyping will be essential. Immunophenotypes can 
be routinely evaluated by immunohistochemistry on histological 
sections [Zwahlen et al., 1998; Pohlman et al., 2009] or at 
research institutions by flow cytometry. 
sometimes, diagnosis of lymphoma can be very difficult when 
using the usual histological and immunophenotypic assessment. 
For these cases, demonstration of a clonal population of 
lymphocytes is an elegant method that suggests malignancy. 
Clonality is not synonymous with neoplasia, but an important 
hallmark of cancer. much research has been done to develop 
molecular clonality assays to improve diagnostic tools for feline 
lymphoproliferative diseases [moore et al., 2005; Werner et al., 
2005; Henrich et al., 2009].
Anatomical Classification
Alimentary (intestinal, gastrointestinal) lymphoma
The term “abdominal form” is occasionally used and includes all 
gastrointestinal forms plus kidney, liver, spleen, and pancreatic 
lymphoma. sometimes renal lymphoma has been described as 
a separate form. 
Epidemiology
alimentary lymphoma manifests as an infiltrative process, 
which most commonly affects the small intestine (50-80 %), 
the stomach (25 %), the ileocaecal junction and the large 
intestine with or without mesenteric lymph node involvement. 
The reported frequency of the alimentary form ranges from 18-
68 % of all lymphomas [Gabor et al., 1999; Valli et al., 2000; 
Kristal et al., 2001; Teske et al., 2002; Kiselow et al., 2008]. Its 
overall rate has been steadily increasing since 1995 and today 
Table 1: Clinical Staging System for Feline Lymphoma according 
to Mooney et al. (1987)
stage I single tumour (extranodal) or single anatomic 
area (nodal) includes primary intrathoracic 
tumours
stage II single tumour (extranodal) with regional lymph 
node involvement
Two or more nodal areas on the same side of the 
diaphragm
Two tumours (extranodal) with or without 
regional lymph node involvement on the same 
side of the diaphragm
a primary resectable gastrointestinal tumour 
with or without mesenteric lymph node 
involvement only
stage III Two tumours (extranodal) on opposite sides of 
the diaphragm
Two or more nodal areas on opposite sides of 
the diaphragm
all extensive, primary, unresectable intra-
abdomial disease 
Paraspinal or epidural tumours, regardless of 
other tumour sites
stage IV stages I to III with liver and/or spleen involvement 
stage V stages I to IV with tumours with initial 
involvement of the central nervous system and/or 
bone marrow
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alimentary lymphoma appears to be the most common form of 
feline lymphoma [Louwerens et al., 2005].
Clinical presentation
Common clinical signs include loss of body mass, anorexia, 
lethargy, diarrhoea, vomiting [Zwahlen et al., 1998; Kiselow et 
al., 2008; Krick et al., 2008]; in some cases, haematochezia, 
tenesmus [slawienski et al., 1997] and pica [mahoney et al., 
1995] were observed. In most cats, a palpable mass (52-85 
%) or thickened bowel loops could be detected on physical 
examination [mahoney et al., 1995; slawienski et al., 1997; 
Zwahlen et al., 1998].
Diagnostic approach and staging
Loss of structure of gastric wall layers, gastric or intestinal wall 
thickening, decreased echogenicity and loss of motility are typical 
ultrasonographic findings in alimentary lymphoma [Penninck 
et al., 1994; Hittmair et al., 2000]. Cytological examination 
of ultrasound-guided fine-needle aspirations often indicates 
lymphoid neoplasia but for definitive diagnosis of the various 
lymphoma subtypes a histopathological evaluation is warranted. 
samples can be obtained by surgery, laparoscopy or endoscopy. 
Endoscopy is an appealing method as it avoids surgery, and it 
was previously considered as the gold standard for alimentary 
lymphoma diagnosis. However, a study from Evans et al. [2006] 
revealed that although gastric lymphoma could be diagnosed 
on the basis of endoscopic biopsies, these biopsy specimens 
were of no diagnostic value for the differentiation between IBD 
and lymphoma in the small intestine. Full–thickness biopsies 
obtained by exploratory laparotomy or laparoscopy rendered 
superior and more reliable results. It is essential to obtain an 
adequate sample to get reliable histopathological results.
recently, the rEaL/WHO classification was specifically used 
to describe feline gastrointestinal lymphoma [Pohlman et 
al., 2009], subclassifying for example the low-grade diffuse 
small lymphocytic tumour into the B-cell small lymphocytic 
and epitheliotropic T-cell lymphoma, or the high-grade 
immunoblastic lymphoma of the Working Formulation 
into diffuse large B-cell immunoblastic nuclear type, T-cell 
lymphoblastic and large granular lymphocyte lymphoma (Table 
2). Large granular lymphocyte lymphoma is the one kind of 
lymphoma which is very difficult to diagnose on routine HE-
stained tissue sections and it is believed that cytology is more 
sensitive for the identification of the characteristic azurophilic 
cytoplasmic granules [roccabianca et al., 2006]. 
The question whether alimentary lymphomas present more 
often as B-cell tumours or as T-cell malignancies is still under 
discussion. some studies found more T-cell tumours [Zwahlen 
et al., 1998; Carreras et al., 2003; Kiselow et al., 2008], while 
a higher incidence of B-cell lymphomas was observed in 
other studies [Gabor et al., 1999; Waly et al., 2005]. These 
contradictive results may be due to the fact that the examiners 
did not classify the tumours according to their location. In a 
study of Pohlman et al. [2009], all gastric and nearly all (88 
%) large intestine lymphomas were of B-cell origin, while the 
majority of small intestinal tumours originated from T-cells (52 
%); a smaller number of small intestinal lymphomas derived 
from B-cells (38 %) and only a few were nonreactive for B- and 
T-cell markers. Irrespective of the identified immunophenotype, 
all cats tested FeLV-negative on an ELIsa. In contrast, two of six 
paraffin-embedded feline lymphomas showed a positive FeLV 
status by PCr [Jackson et al., 1996]. Large granular lymphocyte 
lymphoma showed either a T-cell phenotype or lacked T- and 
B-cell markers, which is highly suggestive of a cytotoxic T-cell 
or a natural killer cell origin of this distinct type of lymphoma 
[Darbes et al., 1998; Endo et al., 1998; roccabianca et al., 2006].
Therapy and prognosis
Cats with alimentary lymphoma often have additional tumours 
at distant sites [mahoney et al., 1995; Zwahlen et al., 1998]; 
this emphasizes the systemic nature of tumours originating from 
lymphoid cells and that the main pillar of treatment continues 
to be chemotherapy. There are limited studies in which only 
alimentary tumours were included [mahoney et al., 1995; 
slawienski et al., 1997; Zwahlen et al., 1998; Fondacara et al., 
1999; Carreras et al., 2003]. 
Effectiveness of various treatment protocols was assessed by 
calculation of the median survival time. median survival time 
(msT; also called median overall survival or median survival) is 
the time (from diagnosis or from start of treatment) when half 
of the patients have died.
Treating cats with alimentary lymphoma, mostly using the 
COP protocol (cyclophosphamide, oncovin=vincristine, 
prednisolone), resulted in a median survival time (msT) of 1.6 
REAL/WHO WF
T-cell lymphoblastic Lymphoblastic, high grade
Diffuse large B-cell 
lymphoma of 
immunoblastic nuclear 
type
Immunoblastic, high grade
Large granular 
lymphocyte
Immunoblastic, high grade
Diffuse large B-cell 
lymphoma of 
centroblastic nuclear type
Diffuse large, intermediate grade
B-cell lymphocytic 
intermediate type
Diffuse small cleaved, 
intermediate grade
T-cell-rich large B-cell Diffuse mixed, intermediate 
grade
B-cell small lymphocytic Diffuse small lymphocytic, low 
grade
Epitheliotropic small T-cell 
lymphoma
Diffuse small lymphocytic, low 
grade
Table 2: Comparison of the new REAL/WHO (revised European-
American Classification of Lymphoid Neoplasms/World Health 
Organization) and the older Working Formulation (WF) 
classification system in feline gastrointestinal lymphoma according 
to POHLMAN et al. (2009)
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months [mahoney et al., 1995] or 4.5 months [Teske et al., 
2002], while a msT of 2.8 months was observed in cats treated 
according to the VCm protocol (vincristine, cyclophosphamide, 
methotrexate) [Jeglum et al., 1987]. using the VELCaP protocol 
(41 % alimentary lymphoma), the assessed msT was of 2.1 
months [Hadden et al., 2008].
an animal medical Center protocol for cats with colonic 
lymphoma, consisting in a combination therapy with vincristine, 
L-asparaginase, cyclophospamide, doxorubicin, methotrexate 
and prednisone administered over two years, rendered a msT 
of about 3.3 months, a period of time which did not differ 
significantly from that of untreated cats [slawienski et al., 1997]. 
The same drug combination was used in a study by Zwahlen 
et al. [1998] including 21 cats with alimentary lymphoma. The 
treatment resulted in a msT of 9.3 months. unfortunately, 
no histopathology was performed; therefore it is not known 
whether these improved results are due to the fact that more 
low-grade cases were included in this study compared to others. 
In six cats treated with prednisone prior to chemotherapy, 
median survival time was not different from that of cats without 
cortisone pretreatment [Zwahlen et al., 1998].
In feline lymphoma therapy, it is still under debate whether the 
addition of the more expensive and time-consuming treatment 
with doxorubicin (requiring application as intravenous infusion 
over 20 minutes) holds any advantage for the patients. Complete 
remission after single-agent chemotherapy with doxorubicin was 
achieved only in 26 % [Kristal et al., 2001] or 32 % of patients, 
respectively [Peaston et al., 1999]. In a study from moore et 
al. [1996], cats treated according to the COP protocol during 
one month were randomly assigned to two groups. One group 
was maintained on the COP protocol, while the other group 
received a doxorubicin monotherapy. although the doxorubicin 
group showed longer median remission duration, with 281 
days compared to 83 days in the COP group, the doxorubicin 
group included only one alimentary lymphoma out of seven 
patients. The longest remissions were observed in two cats 
treated with the COP protocol. No survival data were described 
in this study. In cats treated with COP plus/minus doxorubicin, a 
significantly longer median remission duration was observed in 
the doxorubicin group, but no significant difference in survival 
times was seen between the two groups [Vail et al., 1998].
In all probability, the varying results of the discussed 
chemotherapy protocols are due to the fact that in none of the 
described studies a subclassification into the different types of 
alimentary lymphoma was carried out and that therefore, no 
comparison between these subgroups could be made regarding 
survival times. strictly speaking, one cannot compare the results 
of those studies at all, as we do not know the tumour subtypes.
Lymphocytic lymphoma (small-cell, well-differentiated, low-
grade) of the gastrointestinal tract was examined by Fondacara 
et al. [1999]. Treating cats only with oral drugs (prednisone 
10 mg/cat once daily and chlorambucil 15 mg/m2 for 4 days 
every 3 weeks) resulted in an excellent msT of 1.4 years. 
Evaluation of 41 cats with low-grade lymphoma (68 % limited 
to the gastrointestinal tract) treated with prednisone (5-10 
mg per cat once or twice daily) and chlorambucil (2 mg per 
cat every second or third day) also resulted in a high msT of 
1.9 years [Kiselow et al. 2008]. This confirms the hypothesis 
that low-grade lymphoma patients treated with prednisolone/
chlorambucil have a good prognosis. However, there were also 
three cats with small lymphocytic alimentary lymphoma, treated 
with cyclophosphamide, vincristine and prednisone, which 
stayed alive for 35, 50 and 641 days, respectively [mahoney et 
al., 1995]. The tumours had not been classified according to 
the new rEaL/WHO classification system, which differentiates 
between the low-grade diffuse small lymphocytic tumour 
and the B-cell small lymphocytic and epitheliotropic T-cell 
lymphoma [Pohlman et al., 2009]. most likely, these different 
subtypes react differently to chemotherapeutic drugs. Feline 
epitheliotropic intestinal lymphoma, also classified as intestinal 
T-cell lymphoma, showed a msT of 11 months after treatment 
(chemotherapy or prednisone monotherapy). Individual long 
term responders, which were still alive after 28 months, were 
observed [Carreras et al., 2003].
The large granular lymphocyte lymphoma seems to be a 
comparatively aggressive disease entity with poor response to 
therapy, therefore carrying a grave prognosis. after treatment 
with a combination chemoprotocol (L-asparaginase, vincristine, 
cyclophosphamide, methotrexate, prednisone), the median 
survival time of cats with large granular lymphocyte lymphoma 
(most commonly affected organs: mesenteric lymph nodes, 
small intestine and liver) was 1.9 months [Krick et al., 2008]. 
Data of different chemotherapy protocols with subclassified 
lymphoma subtypes and median survival times are summarised 
in Table 3.
Neither clinical stage nor FeLV status [mahoney et al., 1995] was 
found to be associated with outcome, and patients achieving 
complete remission did not live longer than cats showing partial 
remission [Zwahlen et al., 1998]. 
Low morbidity was observed during chemotherapy with mild 
gastrointestinal symptoms like inappetence, vomiting and 
diarrhoea being the most common clinical signs. Only in rare 
cases, these symptoms were persistent being most likely due 
to the progression of the disease rather than to the treatment 
itself [Zwahlen et al., 1998]. Neutropenia was most commonly 
reported, while thrombocytopenia and fever was observed 
in rare cases only. most cats on long-term treatment showed 
alterations of the hair coat with loss of guard hairs and broken 
whiskers [mahoney et al, 1995].
It is still unclear whether surgical intervention alone or 
performed prior to chemotherapy results in better survival times. 
No significant difference in survival after surgical procedures 
(mass resection or surgical biopsies) was found in a study by 
slawienski et al. [1997]. Zwahlen et al. [1998] did not see any 
difference in survival times either between patients treated 
with chemotherapy alone versus chemotherapy and surgery. 
However, this result is not surprising as surgery consisted only 
in biopsy and not mass reduction. mahoney et al. [1995] treated 
24 patients with chemotherapy only and four patients with 
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surgery and chemotherapy, resulting in a msT of 5 weeks versus 
17 weeks, respectively. although there is quite a difference 
between these survival times, it is of no statistical significance, 
presumably because of the low number of patients in the 
surgery group.
One cat with colonic lymphoma treated with a subtotal colectomy 
with clear margins survived 3.7 years without receiving any 
additional therapy [slawienski et al., 1997]. another cat with 
a 4 cm ileocaecal mass was treated only with surgery and died 
5 years later without a recurrence, although the margins of 
the surgery were not even clean [Valli et al., 2000]. Therefore, 
besides chemotherapy, surgery could be considered as a 
treatment option for patients with stage II intestinal lymphoma. 
The benefit of radiation therapy in feline alimentary lymphoma 
has not yet been studied. 
Mediastinal (thoracic) lymphoma
Thymus, sternal or mediastinal lymph node involvement 
characterises this lymphoma.
Epidemiology
a prevalence of 6-36 % was reported [Gabor et al., 1998; 
Teske et al., 2002; Louwerens et al., 2005]. most affected 
cats are young (< 2 years) and FeLV-positive; paraneoplastic 
hypercalcaemia is only rarely observed.
Clinical presentation
Cats commonly present with dyspnoea, depression, anorexia 
and regurgitation [Grufydd-Jones et al., 1979; Court et al., 
1997]. Dyspnoea can result from the pressure of the mass in 
the thoracic cavity or from secondary pleural effusion, which 
is common. In rare cases, sympathetic nerve involvement may 
cause Horner´s syndrome. Pressure exerted on the cranial vena 
cava may provoke head oedema.
Diagnostic approach and staging
a mediastinal mass with or without pleural effusion is commonly 
seen on chest radiographs. Computed tomographic evaluation of 
mediastinal masses was not helpful to specify tumour-type [yoon 
et al., 2004]. To confirm the presumptive diagnosis, cytological 
examination of the thoracic fluid or the mass is often sufficient. 
analysis of pleural fluid identified neoplastic lymphoblasts in 79 
% of feline mediastinal lymphomas [Davies and Forrester, 1996]. 
Pathohistological examination revealed that these tumours are 
mostly of T-cell origin [Vail et al., 1998; Gabor et al., 1999]. 
Primary intrathoracic tumours belong to stage I lymphomas; 
however, to complete the staging process abdominal ultrasound 
and bone marrow biopsy are required (Table 1).
Therapy and prognosis
By treating cats with mediastinal lymphoma according to the 
COP protocol, complete remission could be achieved in 92 % 
of the patients, with a median remission duration of 6 months 
[Cotter et al., 1983] and a median survival time of 6.4 months 
[Teske et al., 2002]. COP protocol therapy with or without 
doxorubicin resulted in a survival time of 2.3 months [Vail et al., 
1998], while survival times of 6.6 to 84 months were reported 
of patients on a multi-agent long-term chemotherapy [simon et 
al., 2008].
Combining chemotherapy with radiation therapy in order to 
induce faster remission or to treat chemoresistant cases could 
be an option in the management of mediastinal lymphoma. 
However, the optimum radiation protocol has not been 
established yet [meleo et al., 1997].
Nodal lymphoma
This type of lymphoma is characterised by peripheral lymph 
node enlargement, with abdominal or thoracic lymph nodes not 
being included.
Epidemiology 
Nodal lymphoma is quite seldom seen in cats, only 5-17 % of 
cats showed exclusively peripheral lymph node involvement 
[Gabor et al., 1998; Louwerens et al., 2005]. In human 
medicine, lymphomas are classified into Hodgkin’s lymphoma 
(with large reed-sternberg cells as hallmark) and Non-Hodgkin’s 
Chemotherapy protocol Lymphoma subtypes MST (months) References
COP all 1.6 mahoney et al. (1995)
COP all 4.5 Teske et al. (2002)
VCm all 2.8 Jeglum et al. (1987)
VELCaP all 2.1 Hadden et al. (2008)
amC all 3.3 slawienski et al. (1997)
amC all 9.3 Zwahlen et al. (1998)
Chlorambucil/prednisone Lymphocytic lymphoma 17 Fondacara et al. (1999)
Chlorambucil/prednisone Lymphocytic lymphoma 23 Kiselow et al. (2008)
VCm + L-asparaginase, 
prednisone
Large granular lymphocyte 
lymphoma
1.9 Krick et al. (2008)
Table 3: Survey of various chemotherapy protocols for treatment of analysed lymphoma subtypes and median survival times (MST) of cats 
diagnosed mostly with alimentary lymphoma
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lymphoma. In cats, Hodgkin’s-like lymphoma with mostly one 
cervical mass has only been described in rare cases [Walton et 
al., 2001; steinberg and Keating, 2008]. 
Clinical presentation
In most cases, nodal lymphomas presented as one or two 
palpable masses in the ventral cervical, submandibular or 
prescapular region [Day et al., 1999]; in one cat, the neoplasia 
was located in the inguinal region [Walton and Hendrick, 2001]. 
apart from that, no other striking clinical signs were observed in 
affected cats. The majority of masses were reported to be fast 
growing [Day et al., 1999].
Diagnostic approach and staging
Enlarged peripheral lymph nodes can easily be palpated 
during clinical examination. Fine needle aspiration to obtain 
samples for cytological evaluation is the first step to confirm 
neoplastic disease. Biopsy (core biopsy or excisional biopsy) 
or surgical removal of the entire lymph node is necessary 
for pathohistological confirmation and classification of the 
neoplasia. Thoracic radiographs, abdominal ultrasound and 
bone marrow biopsy are the diagnostic procedures required for 
the staging of the tumour (Table 1).
Therapy and prognosis
It has been discussed that feline Hodgkin’s-like lymphoma may 
be a less aggressive form of the tumour, as cats receiving no 
chemotherapy at all (n=11) survived from one week to four 
years, compared to cats receiving chemotherapy (n=4), which 
showed survival time between six months and 1.3 years [Walton 
and Hendrick, 2001]. after treating cats with lymphoma in 
peripheral nodes (most likely non-Hodgkin’s lymphoma as no 
Hodgkin’s-like appearance was described) following the COP 
protocol, complete remission was achieved in 80 % of the 
patients, with a median remission duration of 28 months [Cotter 
et al., 1983] and a median survival time of 20.8 months [Teske 
et al., 2002]. 
There is some evidence that surgery alone could be an effective 
treatment for cats with nodal lymphoma. a case was reported 
where a single mass in the region of the parotid gland recurred 
6 months after initial removal, was again excised and recurred 
after 9 months; the mass was operated again with no recurrence 
observed 13 months after the third surgery [steele et al., 1997]. 
In two cats, no recurrence occurred after excising a single mass 
in the neck [Day et al., 1999]. a third cat showed a recurrence 
6 months after surgical removal of the single tumour, which 
was excised again and recurred after 6 months. The mass was 
again removed and a COP protocol was started; 18 months 
after diagnosis no recurrence was observed. Local radiation 
therapy can be considered if only one mass is present. However, 
at present it is not known whether radiation therapy is more 
advantageous than conventional chemotherapy or surgery.
Peripheral lymph node hyperplasia
The most important differential diagnosis for nodal lymphoma 
is the histologically similar looking distinctive peripheral lymph 
node hyperplasia of young cats. The aetiology of this mostly 
transient hyperplasia is still unknown; retrovirus infection has 
been discussed as a possible cause. In one study, 67 % of 
affected cats were FeLV-positive, but only one of these cats 
developed lymphoma [moore et al., 1986]. In another study 
including six cats, lymphadenopathy resolved without any 
treatment in five animals. The sixth cat was euthanized due 
to wrong diagnosis. all six patients had tested negative for 
FeLV, although two cats had transient FeLV infection because 
FOCma (feline oncornavirus-associated cell membrane antigen) 
antibodies were found [mooney et al., 1987b].
Extranodal/atypical/unclassified form 
Lymphomas are tumours of the immune system and can 
originate from lymphatic tissue, such as lymph nodes, spleen 
and bone marrow or in atypical locations such as the nasal 
cavity, central nervous system, kidneys, liver, skin, eyes, and 
actually in any tissue. The most common extranodal lymphomas 
were found in the nasal cavity, the central nervous system (CNs) 
and the kidney [Vail et al., 1998; Valli et al., 2000].
Nasal lymphoma
Epidemiology
The most common nasal disease described in cats is neoplasia, 
with 70 % diagnosed as lymphoma [Henderson et al., 2004]. 
a prevalence ranging from 2 to 13 % was reported for nasal 
lymphomas [Valli et al., 2000; Teske et al., 2002]. Patients were 
mostly FeLV-negative.
Clinical presentation
The most common clinical signs in cats with nasal lymphoma 
include nasal discharge (bloody or mucopurulent), sneezing, 
increased upper respiratory noise, ocular discharge, epistaxis 
and facial deformity [Henderson et al., 2004; Little et al., 2007; 
sfiligoi et al., 2007].
Diagnostic approach and staging
In order to assess location and extension of the primary tumour, 
skull radiographs and computed tomography scans should be 
performed; the latter is also necessary to plan radiotherapy. 
rhinoscopy is an elegant method to obtain multiple biopsies 
for pathohistological evaluation to confirm tentative diagnosis. 
Tumour cells were all [sfiliogi et al., 2007] or predominantly 
[Little at al., 2007] of B-cell origin.
sometimes a mass can be dislodged during nasal flushes and 
used for pathohistological examination [Henderson et al., 2004]. 
To obtain a flush biopsy the cat is anaesthetized and intubated. 
One nasal cavity is flushed with saline in a retrograde manner 
using, for example, a bulb syringe, while the contralateral nostril 
is occluded. The specimen is flushed through the pharynx out of 
the oral cavity [Vail, 2007].
Nasal lymphoma has often been categorized as a localized 
disease. If only local radiation therapy is planned, a thorough 
staging of the tumour has to be performed to rule out any 
systemic dissemination (Table 1). In a study of Little et al. 
[2007], 67 % of the necropsied cats showed an extension of 
the neoplasia beyond the nasal cavity and in 31 % of completely 
staged cases multiorgan involvement was present. 
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Therapy and prognosis
Considering these findings, it seems suboptimal to restrict 
therapy for cats with nasal lymphoma to local treatment, 
although there are no studies supporting that a combined 
radiation and chemotherapy yields better results than radiation 
therapy alone. a multi-institutional retrospective study of 97 cats 
with nasal lymphoma showed no significant difference in survival 
times between patients treated with chemotherapy alone (10.7 
months, n=18), radiation therapy alone (47.7 months, n=19) or 
combined radiation and chemotherapy [15.8 months, n=60; 
Haney et al., 2009]. In another study, patients were treated 
with various megavoltage radiation and chemotherapy (COP 
or LCHOP protocol) resulting in a median survival time of 31.4 
months [sfiligoi et al., 2007]. 
median survival time after treating nasal lymphoma in cats 
with a COP-protocol was 3.3 months [Henderson et al., 2004], 
11.9 months [Teske et al., 2002] and 15.2 months with a COP-
protocol with or without doxorubicin [Vail et al., 1998]. survival 
time was reduced to 28 days if cats received no treatment or 
only prednisolone monotherapy [Henderson et al., 2004].
Bony destruction and facial deformity, which can be severe, 
were no prognostic factors. In contrast, tumour transgression 
of the cribriform plate was proven to have a poorer prognosis 
[sfiliogi et al., 2007].
CNS lymphoma
Epidemiology
after meningioma, lymphoma was the second most brain 
tumour [Troxel et al., 2003] and the most common spinal 
neoplasia in cats [marioni-Henry et al., 2004]. It seems that, 
in the past, affected cats were younger, often FeLV-positive 
(84-100 %) and predominantly affected by extradural spinal 
lymphoma [spodnick et al., 1992; Lane et al., 1994], whereas 
more recently, the mean age of cats with lymphoma has been 
increasing and intradural lesions have become more common 
[marioni-Henry et al., 2004]. However, the latest study found 
extradural and intradural components (in 88 % of the cases), 
with 57 % of cats being FeLV-positive [marioni-Henry et al., 
2008]. 
Clinical presentation
The most commonly affected site was the lumbosacral region 
resulting in paresis or paralysis of the hindlimbs, a typical clinical 
sign at presentation. However, in 40 % of cats the lymphoma 
extended to multiple other regions of the spinal cord, while the 
brain was involved in 50 % of the cases [marioni-Henry et al., 
2004]. Other common clinical signs of patients with spinal and 
intracranial lymphoma were nonspecific like anorexia, lethargy 
and loss of body weight. Cats with lymphoma of the brain also 
showed ataxia, altered consciousness and aggression [Troxel et 
al., 2003].
Diagnostic approach and staging
In patients with suspected spinal cord lymphoma, plain 
radiographs seldom showed a soft tissue mass or lytic vertebral 
lesion. advanced imaging techniques such as myelography, 
computed tomography or magnetic resonance imaging were 
needed for visualization of masses [marioni-Henry et al., 2008]. 
Cerebrospinal fluid analysis demonstrated a nonspecific increase 
of neutrophils and protein in most cats, but positive findings of 
specific neoplastic lymphocytes were also observed in a variable 
number of cases, i.e. in 83 % [singh et al., 2005], in 67 % 
[spodnick et al., 1992], in 35 % [Lane et al., 1994] or in 9 % of 
affected cats [marioni-Henry et al., 2008].
In order to assess involvement of other organs beside the CNs, 
complete staging of the tumour must be performed (Table 1). 
On post-mortem examination of cats with spinal lymphoma, the 
most common extraneural locations of the neoplasia were bone 
marrow and kidneys [spodnick et al.; 1992; marioni-Henry et 
al., 2008].
Therapy and prognosis
Nine cats with intracranial lymphoma received palliative therapy 
with systemic corticosteroids; median survival time was 21 
days with a range of nine to 270 days [Troxel et al., 2003]. 
Four cats with extradural spinal lymphomas were treated with 
chemotherapy (combination of vincristine, L-asparaginase and 
prednisone) after local radiotherapy (three cats) or surgery (one 
cat). Only one patient improved long-term, being still alive after 
13 months, while the other three cats died within five months 
[Lane et al., 1994]. after a single dose of radiation and COP 
chemotherapy, one cat was euthanized after 38 days, another 
one survived for two months after decompressive surgery and 
chemotherapy [marioni-Henry et al., 2008]. six cats treated 
according to the COP protocol showed a median remission 
duration of 14 weeks with complete remission and of six weeks 
with partial remission. Of three cats treated with prednisone 
monotherapy, one showed no response to treatment, while 
partial remission of four and 10 weeks was achieved in the other 
two animals. In one cat, which had been treated surgically (dorsal 
compressive laminectomy) and had received postoperative COP 
chemotherapy, complete remission of neurologic signs for 1.2 
years was observed. after recurrence, therapy with doxorubicin 
(30 mg/m2) again led to total remission, but the cat died in a car 
accident [spodnick et al., 1992]. 
Renal lymphoma 
Epidemiology
about 5 % to 10 % of cats showed primary renal involvement 
[Jeglum et al., 1987; Gabor et al., 1998; Valli et al., 2000] but in 
31 % of the cats the kidneys were affected in addition to other 
organs [Gabor et al., 1998]. 
Clinical presentation
On physical examination, renomegaly is the most conspicuous 
finding. Depending on the severity of azotaemia, unspecific 
clinical signs like inappetence, vomiting, polyuria and polydipsia 
are frequently observed.
Diagnostic approach and staging
abdominal radiographs or ultrasound examination findings 
confirming renomegaly should always raise suspicion of renal 
lymphoma. ultrasonography has shown an association between 
hypoechoic subcapsular thickening and renal lymphoma 
[Valdes-martinez et al., 2007]. To confirm the tentative 
diagnosis, fine needle aspiration of the kidney was described 
as a useful, non-invasive diagnostic tool [Borjesson, 2003]. 
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samples for histopathological examination can be obtained by 
transabdominal core biopsy, laparoscopy or laparotomy. The 
majority of tumours were of B-cell phenotype [Gabor et al., 
1999].
Therapy and prognosis
as renal lymphoma is always bilateral, nephrectomy does 
not represent a treatment option [mooney et al., 1987]. 
Chemotherapy has the advantage of being a systemic treatment, 
which is especially beneficial as cats with renal lymphoma often 
show involvement of the central nervous system [mooney et 
al., 1987]. For treatment, different chemotherapy protocols 
have been used yielding similar survival results. median 
survival times of cats with renal lymphoma were five months 
after treatment with a VCm protocol [Jeglum et al., 1987], 
4.8 months with a COP plus/minus doxorubicin [Vail et al., 
1998] and 5.6 months [mooney et al., 1987] on a treatment 
consisting of an induction therapy (vincristine, L-asparaginase, 
cyclophosphamide, methotrexate) and a maintenance protocol 
(vincristine, methotrexate and cytosine arabinoside). Cats with 
only slightly increased renal parameters survived longer than 
those with moderately to severely elevated levels, but some 
of the cats with nearly normal values did not survive longer 
than patients with severely increased renal parameters. some 
patients with extremely elevated kidney parameters (creatinine 
5.9-14.4 mg/dl) responded well to chemotherapy. Therefore, 
severely increased renal parameters should never be reason to 
exclude a cat from therapy [mooney et al., 1987]. 
Conclusion
In the future, it will be of utmost importance for feline lymphoma 
management to obtain a correct, accurate and specific 
diagnosis, with veterinary histopathologists, cytopathologists 
and oncologists working together and speaking the same 
language worldwide. This is an essential premise to evaluate 
different therapeutic measures and to advance research in the 
clinically relevant field. Therefore, a state-of-the-art diagnostic 
approach is mandatory. 
Diagnosing lymphoma only by fine needle aspiration without 
histopathological examination and immunophenotyping does 
not provide adequate information. The first important step must 
be evaluating tumours histopathologically in a uniform manner, 
preferably applying the new rEaL/WHO classification system, 
which provides important information about morphology and 
immunophenotype of neoplastic cells. additional research will be 
necessary to detect biological variabilities in order to understand 
in what ways the respective lymphoma diseases differ from each 
other at a molecular level. This knowledge will be essential to 
initiate innovative therapeutic approaches with the potential of 
improving prognosis and survival in feline lymphoma patients. 
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Animal Assisted Therapy (AAT) is a method of complementary treatment in the rehabilitation of many human 
illnesses and conditions. Although the dog is the most widely used therapy animal that is used in AAT programmes, 
the rabbit can also be used as an alternative animal species and complementary therapy for many diseases. It is an 
intelligent, human friendly and playful small animal, easily socialised and transported. Also, the rabbit has very 
good communication through its body language. A special bond also exists between children and rabbits, and in 
the animal world of children, the rabbit is a very popular animal mainly because of children’s literature. As a result, 
rabbits elicit positive feelings in children and enhance their imagination. Based on previous experience from an 
AAT programme with rabbits in a children’s hospital, the rabbit can be easily accepted by children with emotional 
or physical problems. In order for an AAT programme with a rabbit to be a success, it is very important to guarantee 
the good health and normal behaviour of the rabbit, as well as its proper welfare. The contribution and participation 
of a veterinarian during the design and the implementation of the programme are also very important for assuring 
the success of an AAT programme with rabbits.
Keywords: animal assisted therapy, children, rabbit, welfare
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general
Introduction
animal assisted therapy (aaT) is a therapeutic intervention in 
which the physical and/or emotional needs of an individual 
are met through the use of an animal. It is based on the 
growing knowledge of benefits that animals can provide to 
sick, handicapped, old or socially-isolated individuals. The Delta 
society is a human services organisation that is dedicated to 
improving people’s health and well-being through positive 
interactions with animals. In an attempt to promote the 
standardisation of terminology, the society has defined aaT 
as a goal-directed intervention in which an animal that meets 
specific criteria is used as an integral part of the treatment 
process. aaT is directed and/or delivered by a health or human 
services professional with specialised expertise [Delta society 
1992].
The incorporation of an animal in therapy is beneficial, because 
animals have a natural tendency to create a bond with people. 
a good therapy animal will seek affection and interact with the 
patient. Thus, animals promote a warm and safe atmosphere 
that can be therapeutically beneficial for a patient and help the 
patient accept interventions that are offered by the care provider 
[Carmack 1991, anonymous 1996, Dimitrijevic 2009].
The 1998 Prague Declaration of the International association 
of Human-animal Interaction Organisations urges all persons 
and organisations that are involved in animal-assisted activities 
and/or aaT and all bodies that govern the presence of such 
programmes in their facilities to consider and abide by the 
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following points: (a) only domestic animals which have been 
trained using techniques of positive reinforcement, and which 
have been, and will continue to be, properly housed and cared 
for, are involved, (b) safeguards should be in place to prevent 
adverse effects on the animals involved, (c) the involvement of 
assistance and/or therapy animals is potentially beneficial in each 
case and (d) basic standards should be in place to ensure safety, 
risk management, physical and emotional security, health, 
basic trust and freedom of choice, personal space, appropriate 
allocation of programme resources, appropriate workload, 
clearly defined roles, confidentiality, communication systems 
and training provision for all persons involved [IaHaIO 1998].
Compared to service animals, which must be trained to do 
work or perform tasks for the benefit of a disabled individual, 
therapy animals are usually the personal pets of their handlers, 
who use them to provide aaT to patients [anonymous 2009]. 
although the dog is the most widely used therapy animal in 
aaT, other species, such as cats, horses or birds may, also, be 
used depending on the medical condition that requires curative 
treatment. During the last few years, there is an increasing 
trend to have a rabbit as a pet animal. This increasing use of 
pet rabbits prompted us to think about the possibility of using 
rabbits in aaT programmes. The aim of the present article is to 
present the role of rabbit as a therapy animal and to highlight 
the main rabbit welfare issues. These welfare issues, which have 
been taken from the published veterinary literature and our 
personal experience, should be considered when a rabbit is used 
in an aaT programme.
The use of rabbits in AAT programmes
Depending on the illness, the rabbit could be considered as an 
appropriate animal species to incorporate in an aaT programme. 
It is an intelligent, human friendly and playful small animal, easily 
socialised and transported [adbill and Juppe 2000, Kaminski et 
al. 2002]. Furthermore, the rabbit has very good communication 
through its body language. a unique bond also, exists between 
rabbits and children In the animal world of children, the rabbit 
is a very popular animal, mainly through children’s literature, as 
well as songs, drawings and zoo and pet farm visits [mallon 
1992].
In view of the above mentioned characteristics of the rabbit, we 
decided to use rabbits as complementary therapy for children 
with emotional or physical problems, as well as for abused and 
neglected children. This decision was taken despite the fact that 
the available literature on the use of rabbits in aaT programmes 
is limited. The aaT programme was organised and implemented 
in the Department of Oncology of the P & a Kyriakou Children’s 
Hospital in athens, greece. Preliminary results of this study 
clearly show that there is a positive feedback from all children 
that participated in the programme and their accompanying 
persons [loukaki et al. 2009].
Animal welfare issues in the use of 
Rabbits in an AAT Programme
an aaT programme is mainly managed from an anthropocentric 
point of view. In most cases, the focus of aaT is the patient and 
the therapeutic result, irrespective of whether it is beneficial or 
not, and this depends on the physical and mental health of the 
participating therapy animal. When rabbits are used in an aaT 
programme, there is a moral and legal obligation to safeguard 
the welfare of these animals. Discomfort and distress before, 
during and after their use may seriously affect the animal itself 
and, consequently, the expected results for the patients.
Defining animal welfare is a complex issue and different 
definitions have been proposed at various times. One of the 
first definitions was published as a minimal standard for farm 
animals by the Brambell Committee in 1965. This definition has 
since become known as the “five freedoms”: freedom from 
thirst, hunger and malnutrition; freedom from discomfort; 
freedom from pain, injury or disease; freedom to express 
normal behaviour; and freedom from fear and distress [Brambell 
Committee 1965]. Others have proposed that the ability of an 
animal to cope with its environment, and thus exert control over 
its life, may be more important than any of the five freedoms 
of animal welfare [Webster 1994]. This definition is in line 
with Broom and Johnson’s definition of animal welfare who 
defines it as “its state as regards its attempts to cope with its 
environment”[Broom and Johnson 1993].
since “pet” rabbits retain many of their wild-type behaviour 
traits and express them when they are given the opportunity, 
it is very important for those planning an aaT programme with 
rabbits to consider their behaviour and biology in the wild, 
especially when designing rabbit housing and care programmes 
[lehmann 1991, stauffacher 1992]. In fact, the Delta society 
emphasizes that aaT may be inappropriate for the animal when 
(a) injuries from rough handling or other animals may occur, 
(b) basic animal welfare, which includes veterinary care and 
access to water and exercise areas, cannot be assured, and 
(c) the animal doesn’t enjoy visiting the human patient [Zamir 
2006]. It is also important to determine whether the animal 
can be appropriately monitored for signs of stress. monitoring 
signs of stress is probably the most important consideration for 
any species that is used as therapy animal, because the aaT 
environment can be stressful for them. Critical for the success 
of an aaT programme is whether an animal has the capacity to 
recover from its perception of encroachments, cope comfortably 
in the aaT environment and enjoy the human interaction. The 
main animal welfare issues for rabbits in an aaT program 
are their housing and husbandry conditions, human-animal 
interactions and veterinary care.
Housing and husbandry conditions
The rabbits which are used in an aaT programme are usually pet 
animals brought in by the pet’s owner or the vet or the person 
organising the therapy, to the hospitals or the institutions where 
the patients reside. Depending on the internal regulations of 
the institution where the patients are living, rabbits may be with 
their owner, the vet or the person organising the therapy, or the 
companion of the rabbit housed in the same building where the 
aaT sessions take place. If transportation is needed, the rabbit 
could be confined in a proper cat carrying cage or basket for the 
journey. If no suitable carrying cage is available, the rabbit can 
be transported in a secure cardboard box with holes punched in 
the walls for ventilation.
an acclimatisation period should be provided after its arrival at 
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the location of the aaT, depending on the journey time and the 
frequency of each journey. Once the rabbit is no longer stressed 
and becomes familiar with the journey between its home and 
location of the therapy, the acclimatisation period could be 
shortened.
special concern should be given to provide proper housing for 
the rabbits based on their behavioural and physical requirements. 
The cage should be a pleasant place to spend time for the 
rabbits and the bigger, the better. a general rule of thumb in 
selecting the cage is to choose one that is at least four times the 
stretched out size of the adult rabbit [royce 1996]. If rabbits are 
kept in a hospital or institution where the aaT programme is 
taking place, they can be housed either individually or in groups 
in either cages or floor pens. In the case of group housing, the 
group must be stable and harmonious. male rabbits are difficult 
to house in groups as they fight vigorously. If group housing 
is not possible, frequent human contact should be provided. 
The guidelines for the accommodation and care of animals that 
are used for experimental and other scientific purposes of the 
european Commission could be used for rabbits that participate 
in an aaT programme. [european Commission 2007].
environmental enrichment items within the cage will increase 
the rabbit’s behavioural repertoire and reduce stereotypic 
behaviours. Hay and grass cubes will prevent boredom and 
provide roughage. a wide range of enrichment items is 
commercially available for rabbits and it includes mirrors, plastic 
or rubber objects and stainless steel rattles and balls (morton et 
al. 1993, Johnson et al. 2003). each enrichment item should be 
carefully evaluated to ensure that there is sufficient evidence of 
use, they are not toxic and are not capable of causing any injury.
Human-rabbit interactions
although rabbits usually enjoy interacting with humans, they 
need to be handled with great care, because they are easily 
frightened [Brewer 2006]. Therefore, proper handling by 
humans is very important for these animals. rabbits that are 
used as therapy animals are routinely manhandled during an 
aaT session and, as a result, a small number of animals get 
injured. even when gently handled, rabbits can become anxious 
when they are exposed to strangers who caress them. Therefore, 
before using a rabbit in an aaT programme, it is very important 
to train it for each project, such as daily presentation to a large 
number of people especially children, unusual noises and smells, 
and transportation.
Human-rabbit interactions are less likely to cause stress to the 
rabbit during husbandry or aaT when the behaviour of the staff 
and patients is compatible with the animal’s natural behaviour. 
rabbits can recognise and discriminate between different 
humans. Therefore, positive contact with familiar humans in the 
form of handling, training and general habituation to human 
contact will reduce stress when they are handled during an aaT 
session [Davis and gibson 2000]. rabbits that are to be used in 
an aaT programme should also be exposed to the staff that will 
run the programme before its start. Based on our experience, 
special concern should be given when incorporating rabbits into 
an aaT programme for children. most rabbits do not like to be 
held or handled and may try to escape a well meaning child’s 
arms by biting and scratching. In addition, a rabbit’s back may 
be easily broken as a result of improper handling [royce 1996].
Before starting any aaT session, it is important to inform the 
patients about the animal species that will be used in the session. 
This can be done using photo - graphs or videos depending 
on the age of patients. The animal’s natural behaviour and 
needs and ways of safe contact with the animal should be 
properly explained to the patient by the participating animal 
care givers or veterinarian. Introducing the animal to the group 
gives the opportunity to the animal to become familiar with 
the new environmental conditions. For this purpose, another 
‘vital ingredient’ in the aaT programme is the pet helper. 
This individual should be very skilled, because he/she acts as 
the interpreter between the possibly terrified animal and the 
frightened patients [Kobayashi et al. 2009].
Veterinary care
all rabbits that are to be used in an aaT programme must 
have a veterinary check in order to ensure that they are in good 
physical and mental health before incorporating them into a 
therapeutic process. In addition, a clinical examination should 
be performed on the rabbit(s) before each aaT session. special 
concern should, also, be given to the temperament of the rabbit 
towards humans.
To avoid aggression and any troublesome behaviours, as well 
as for medical reasons, rabbits must be spayed or neutered. 
studies have shown that 50 to 80% of unspayed female rabbits 
develop uterine and/or mammary tumours by five years of age 
[green 1958, Toft 1992].
special concern should be given to the possibility for disease 
transmission from the rabbit to the patients and from the patient 
to the rabbit, as well as the development of allergic reactions in 
patients who are participating in the aaT programme [morrison 
2001, mani and maguire 2009].
Assessment of rabbit welfare
When using rabbits in an aaT programme, It is important to 
establish a mechanism for assessing its welfare during the 
programme and the early recognition of behavioural changes 
which are often signs of poor welfare. Behavioural signs of stress 
in rabbits may be subtle and may not be immediately obvious 
to an untrained human observer. Thus, the assessment of rabbit 
welfare should be conducted by a person with considerable 
knowledge on the biology and normal behaviour of rabbits, 
including its ability to cope and adapt with its environment 
[Fraser 1993]. Behavioural and physiological changes, such as 
unexplained aggression, hiding, chewing cage bars, excessive 
grooming or reduced grooming, increased or decreased food 
consumption and unusual movements, such as repeated 
circling within the cage, could be expressions of stress, fear 
or depression [mayer 2007]. Therefore, an assessment of the 
rabbit’s behaviour should be made before, during and after the 
aaT session by a well-trained person.
Based on our experience, rabbits should be interchanged in 
an aaT programme, so that they are not separated from their 
home/group for long periods. For this reason, the use of two 
different rabbits in the same aaT programme is preferred. 
rabbits should not be used if they need to cope with adverse 
environmental conditions, such as heat or large temperature 
differences (outside housing in winter and working in heated 
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rooms). special attention should be made for signs of stress-
related behaviour, such as freezing from fright. If such signs 
appear, the therapy session must be stopped.
In order to guarantee the proper use of rabbits in an aaT 
programme, specific institutional guidelines should be in force. 
In addition, the institution, in collaboration with a veterinarian, 
should establish a code of good practice for its aaT programms 
that includes animal welfare issues. This code should include 
the following requirements: (a) rabbit welfare must be a priority 
for the therapist, (b) the rabbit to be used in the programme 
must never be forced “to have to leave home in order to go to 
work” or to perform actions that it is reluctant to perform, (c) 
the rabbits should be given time to acclimatise before each aaT 
session, and (d) rabbits must be protected from individuals that 
are carrying transmissible diseases to rabbits [Preziosi 1997].
Conclusions
aaT is a novel therapeutic interventional programme with 
important benefits in the management of patients with chronic 
diseases and a prolonged hospitalisation. although the dog is the 
most widely therapy animal, a rabbit can, also, be used in most 
aaT programmes, as it is an intelligent, human friendly small 
pet animal that can be easily socialised. In most cases, an aaT 
programme is mainly managed from an anthropocentric point 
of view and ignores the important role of the animal’s physical 
and mental health in the treatment. Therefore, special concern 
should be given to animal welfare in an aaT programme. The 
assessment of rabbit health and welfare before, during and after 
an aaT session is very important and should be performed by a 
person, preferably a veterinarian, with considerable knowledge 
of the biology and behaviour of this animal. Behaviour of the 
rabbit should be evaluated regularly in an aaT programme and 
during an aaT session. as soon as behavioural changes are 
observed and compromised welfare is recognised, the treatment 
should be postponed. Institutes that have an aaT programme 
with rabbits should create a code of good practice in order to 
guarantee the rabbit’s welfare in the programme
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Non-steroidal anti-inflammatory drugs (NSAIDs) are currently the fastest growing class of drugs in both human 
and veterinary medicine [1]. This is mainly due to their effectiveness as convenient anti-inflammatory, analgesic and 
anti-pyretic agents across a range of species.  They are used to provide surgical analgesia peri-operatively and in the 
control of soft tissue pain and inflammation, however their greatest use is in the management of osteoarthritis.  
Recently there has been a great deal of interest in using them in the management of cancer patients.  In the UK 
the market value for NSAIDs in small animal use has more than doubled in the last decade, from an estimated 
£17 million in 2001 to £38 million currently in 2011.  The market value for small animal pain management in USA 
in 2008 was estimated as being worth $200 million with 94% occupied by NSAIDs [2].  The number of animals 
receiving NSAID medication was estimated at 26 million dogs and 6 million cats with the main indications 
identified as osteoarthritis (44.6%); peri-operative use (24.1%) and non-surgical soft tissue trauma (11%). 
There are an increasing number of licensed NSAID drugs appearing in the veterinary market in response to this 
growing clinical demand.  These are a combination of generic versions of existing established products and a 
range of newly developed NSAIDs.  It is useful to consider the development and appearance of NSAIDs into the 
clinical market as occurring in phases or generations (Table 1).  The first generation drugs (aspirin; phenylbutazone; 
meclofenamic acid) were the first agents used and these were generally replaced by the second generation drugs 
(carprofen; meloxicam; etodolac) which dominate the market at present.  More recently a third generation of new 
products has being introduced (firocoxib; robenacoxib; cimicoxib; mavacoxib; deracoxib and tepoxilin) which offer 
new opportunities for clinical management.  This article will concentrate on the newer NSAIDs  available and how 
these can enhance current clinical practice. 
INTRODUCTION
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How NSAIDs work; Cox inhibition
NSAIDs achieve their beneficial clinical results  through inhibition 
of cyclo-oxygenase enzyme (COX) [3].  Cyclo-oxygenase enzyme 
plays a key role in the Arachidonic Acid(AA) cascade, resulting 
in the production of an array of pro-inflammatory prostanoids 
(Fig 1).  Arachidonic acid is produced when the phospholipid 
cell membrane is degraded as a normal physiological process, 
which is accelerated in the presence of injury or inflammation. 
The action of cyclo-oxygenase on AA results in the production 
of the prostanoids of PGE2, PGI1 (prostacyclin), PGF2α and PGD2 
in addition to thromoxane, TXA2. These can act in certain 
locations and tissues to initiate and prolong inflammatory 
processes, enhance pathological consequences and cause pain. 
NSAID drugs can modify these actions by blocking the action of 
cyclo-oxygenase enzyme. 
However many of the products resulting from this cascade have 
important constitutive functions under normal circumstances 
and reducing the availability of these by using a NSAID can 
result in problems in certain areas recognized as the toxic effects 
of the drug.  These effects are most commonly manifested as 
gastro-intestinal problems but damage can also be seen in the 
renal mechanism and in the liver.  
(1)  Vets Now Referrals, Penguin House, Castle Riggs, Dunfermline, Fife GB-KY11 8SG  E-mail: stuart.carmichael@vets-now.com
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COX -1 and COX-2
A key advance in better understanding the actions and toxic 
effects of NSAIDs resulted from the discovery that cyclo-
oxygenase was produced as at least 2 iso-enzyme forms, COX-
1 and COX-2.  These are produced from two entirely different 
genes [4] and expression occurs under different circumstances 
with COX-1 being more ubiquitous and having a physiologically 
constitutive function. The COX-2 iso-enzyme is not widely 
expressed under normal physiological conditions but appears 
with injury or inflammatory reactions in which it plays a central 
role [5].  This led to COX -1 being labeled ‘Constitutive’ and 
COX-2 being termed ‘Inducible’.  The logical progression from 
this knowledge was that it would be more sensible to produce 
and use NSAIDs which only blocked COX-2 and had a minimal 
effect on COX-1.  It is certainly true that most of the toxic side-
effects observed when using NSAIDs are due to the removal 
of COX-1 activity but experimental studies using exclusive 
COX-2 inhibitors were very disappointing and often these 
agents had fatal consequences.  Therefore the ‘good COX / bad 
COX’ approach was not the complete answer.  COX-2 has some 
very important physiological functions that we now understand, 
including repair of existing gastric lesions, CNS nociception, 
essential renal function, reproductive function and probably 
many that we are yet unaware  [4;6;7;8].  A further COX iso-
enzyme has been identified, COX-3 [9], whose function is still 
uncertain although it has been suggested that it may play a role 
in central pain transmission in dogs [10].  It seems that rather 
than each iso-enzyme having clearly defined roles and actions 
there is likely to be an overlap of COX iso-enzyme function 
required for normal physiological activity and this may vary 
depending on the site that they are functioning in at a point in 
time [11].  
 
Targeting COX Activity for Clinical Use
Classification of NSAIDs based on their activity levels against 
COX-1 and COX-2 respectively is useful in differentiating their 
activity and, more importantly, understanding the risk of toxic 
side-effects. Individual drugs can be described as COX 1 or 2 
sparing, preferential or selective.  It has been proposed that it 
may be more useful to use consistent terms such as preferential, 
selective or specific, based on actual values rather than more 
subjective descriptions although there is as yet no clearly 
accepted scheme for this [12]. The usual way of determining this 
is by identifying the action against COX-1 (IC50) and dividing by 
the activity against COX-2 (IC50) to give a number. Alternatively 
this can be expressed as a ratio.  The higher the number then 
the higher the relative activity against COX-2. Drugs with high 
values should be less likely to show COX-1 dependent problems 
such as gastro-intestinal toxicity and this has been demonstrated 
to be the case in human medicine [13].  Unfortunately the actual 
ratio can vary depending on the study quoted as there is, at this 
point in time, no consistent method of determining it.  However 
broadly, Aspirin is regarded as COX-1 selective; carprofen, 
meloxicam as COX-2 preferential and newer agents firocoxib 
and rabenocoxib as COX-2 selective (Table 2).  
Developing 3rd Generation NSAIDs
Many of the new generation of NSAIDs developed are coxib 
class determined by their chemical structure. Coxib class NSAIDs 
are usually COX-2 selective drugs specifically designed to 
try to reduce toxicity profile. These are the first NSAID drugs 
developed due to their COX-2 selectivity and are specifically 
designed in humans to reduce gastrointestinal toxicity. It is 
important to remember this in relation to the potential of renal 
toxicity and effect on other major organs and each individual 
Figure 1. Phospholipid cell membrane releases Arachidonic Acid 
which through the action of cyclooxygenase enzyme results in the 
formation of pro-inflammatory prostanoids.
Generation Drugs
First Generation Aspirin
Phenylbutazone
Meclofenamic Acid
Second Generation Carprofen
Etodolac
Meloxicam
Tolfenamic Acid
Ketoprofen
Third Generation Tepoxilin
Deracoxib
Firocoxib
Mavacoxib
Robenacoxib
Cimicoxib
Table 1  Introduction of NSAID drugs
Cell membrane
phospholipids
Phospholipase
Lipoxygenase
Cyclo-oxygenase
PGG2
PGH2
Prostaglandins
(PGE2, PGD2, PGF2α)
Prostacyclin
(PGI2)
Thromboxanes
(TXA2, TXB2)
Arachidonic acid
Leukotrienes
Table 2 COX 1: COX-2 Activity Description
COX-1: COX-2 Ratio Description
< 1 COX-1 Selective
1< but < 100 COX-2  Preferential
100< but < 1000 COX-2  Selective
1000< COX-2  Specific
173
EJCAP - Vol. 21 - Issue 2 October 2011
seem that firocoxib is an effective COX-2 selective drug with a 
high safety profile as evidenced by published results. 
Robenacoxib
Robenacoxib (Onsior® ; Novartis) is a new COX-2 selective NSAID 
with indications in both the dog and cat.  It is available in a 
wide range of flavoured tablet strengths for dogs and as a 6mg 
flavoured tablet for cats. Recommended dose is 1mg/kg once 
daily for both species. Tablets should be given without food 
in the dog as combining with a meal reduces absorbtion and 
availability. Better efficacy was reported if food was withheld 
for 30 mins before or after administering tablets.  In cats the 
recommendation is to give tablets with a small meal.  There 
is also an injectable product available.  Robenacoxib attains 
peak plasma levels quickly but has a relatively short plasma half 
life.  There is evidence that there is rapid passage into inflamed 
osteoarthritic joints and that concentrations within joints were 
three times that of plasma 10 hours after administration [24]. 
The drug demonstrates tissue selectivity, being concentrated 
at the site of inflammation, a characteristic that was predicted 
for drugs displaying specific biochemical behaviour [24;25]. 
Robenacoxib was demonstrated to posses these in trials done 
in the cat [26]. The advantage of such a quality may be that 
a higher concentration of the drug in the target inflamed 
tissue would lead to sustained and enhanced action while 
the relatively low plasma concentrations may serve to avoid 
exposing normal organs to high levels of the drug.  Resulting 
slow clearance would explain an observed long duration of 
action in inhibiting PGE2 [26;27].  Another interesting feature 
described is that while the COX-1 binding of robenacoxib shows 
almost instant de-binding, the COX-2 de-bind is much slower 
with a half-life of 25minutes [27].  All of these properties would 
predict enhanced action at the site of a problem with a good 
safety profile.  Robenacoxib displayed a good combined safety 
index in laboratory Beagle dogs [28] and non-inferiority, both 
in efficacy and adverse effects, when compared with carprofen 
in a study in client owned dogs suffering from osteoarthritis 
over a 12 week period [29]. In the cat high safety index was 
demonstrated in 28-48 day administration study [30] and similar 
efficacy to ketoprofen was seen in a shorter study using an acute 
pain and inflammation model over 5-6 days [31].  Although this 
is a relatively recent entrant into the market there is already 
evidence of good efficacy and safety in both dog and cat and 
an interesting variation in mode of action proposed.
drug should be monitored to evaluate other potential problems 
particularly as COX-2 is essential to renal function and in 
other key areas.  COX-2 selective drugs can cause significant 
side-effects in the same way as COX-1 selective in particular 
circumstances and acute renal failure, thromoembolic disease 
and gastrointestinal problems have all been seen as a direct 
result of their use [14;15]. These findings are consistent with 
COX-2 having an important constitutional role in the body. 
Recently this class of drugs were also associated with fatal 
cardiovascular complications in humans due to artherosclerosis 
which is not a major problem in dogs [16].  There are a crop of 
newly available coxib class NSAIDs for use in companion animals 
in Europe namely firocoxib (Previcox®; Meriel); robenacoxib 
(Onsior®, Novartis) and cimicoxib (Cimalgex®; Vetoquinol).  The 
characteristics of each of these will be described individually in 
addition to another interesting NSAID that has been introduced, 
mavacoxib (Trocoxil®; Pfizer) (Table 3).
Firocoxib
Firocoxib (Previcox®; Meriel) is a highly COX-2 selective NSAID 
developed for use in the dog.  It is available in chewable tablets 
in two sizes, 57 and 227mg (Table 3).  Recommended dose is 
5mg/kg once daily.  There is currently no injectible form available 
but the drug is rapidly absorbed after oral ingestion achieving 
peak plasma concentration in one hour after administration. In 
an experimental model of induced synovitis, dogs treated with 
firocoxib had lameness scores that were significantly better 
than placebo or carprofen at both 3 hours and 7 hours post 
administration and similar to  dogs treated with vedaprofen 
(Quadrisol®; Intervet) [17].  Extensive clinical trials have indicated 
that it has a good safety profile [18;19;20] and good efficacy 
when compared with both carprofen [21] and etodolac [19]. In 
both of these studies, which were conducted over a period of 
30 days treating dogs with clinical osteoarthritis, firocoxib was 
demonstrated to be superior to both carprofen and etodolac as 
evidenced by owner and veterinary assessment of clinical signs 
and force plate analysis of weight-bearing [19;21].  Firocoxib 
was also shown to be well tolerated in a study in dogs over 
7 yrs of age with osteoarthritis where treatment effects were 
monitored for 90 days.  In a much longer study, extending 
over 52 weeks also involving client owned animals with clinical 
osteoarthritis, a drop out rate of 5.1% was reported due to GI 
signs, compared to 2.9% drop out in an earlier 40 day study 
[18;22]. Improvement rates of 82% at 15d, 84% at 90days and 
96% at the conclusion of the study were reported.  It would 
Generic Trade Name COX-1:COX 2 Dose Admin Range of tablets Injectable Cat
Firocoxib Previcox 
(Meriel)
COX-2 
Selective
5mg/kg sid Chewable 
tablets
57mg 227mg No No
Robenacoxib Onsior 
(Novartis)
COX-2 
Selective
1mg/kg sid Flavoured 
tablets
5, 10, 20, 40mg Yes Yes 
6mg tab
Cimicoxib Cimalgex 
(Vetoquinol)
COX-2 
Selective
2mg/kg sid Ce Chewable 
tablets
8, 30, 80mg No No
Mavacoxib Trocoxil 
(Pfizer)
COX-2 
Preferential
2mg/kg 
monthly
Triangular 
tablet
6, 20, 30, 75, 90mg No No
Table 3  New Coxib class NSAIDs- characteristics
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suppression of prostanoids in the clinically affected animal are 
interesting.  Trials demonstrated a clear improvement at each 
time interval in dogs treated with mavocoxib with changes seen 
from the second day after treatment started.  This has been a 
consistent feature of long term administration of NSAID [34;35]
but it is clearly much easier to achieve this with mavocoxib.  
Using NSAIDs Safely and Successfully
General
With an increasing set of drugs and a wide range of application 
it can be confusing to the veterinarian trying to plan what 
medication to use in what situation. When faced with a choice 
of selecting a particular NSAID there are factors to be considered 
and these can be prioritized as follows:
1. Safety
2. Effectiveness
3. Ease of administration
4. Cost
Using NSAIDs safely
Safety of a particular drug and avoidance of adverse effects 
is the factor that most influences choice. Most veterinarians 
are aware of the relatively high occurrence of problems with 
regular NSAID use and these concerns restrict both the use of 
drugs and the period they are used for.  Side effects reported 
with all NSAIDs are mainly gastrointestinal (64%) with renal 
events (21%) and hepatic problems (14%) the other main 
toxicities reported [36]. The majority of these are not serious 
and reversible with early attention.  Almost all of the second 
and third generation of NSAIDs that we have available are much 
safer than their predecessors offering greater comfort in this 
area.  The coxib group have been developed with their COX-
1 sparing profile to try and minimize gastro-intestinal adverse 
events.  Sadly although there are some individual dogs which 
are very sensitive to NSAID use, many of the problems seen 
are due to misuse or poor communication with the owners. 
Common mistakes seen include 
1. using the incorrect dose (overdose)
2. using in combination with another NSAID 
3. using in combination with corticosteroids
Using an incorrect dose can be due to a genuine mistake or 
increasing the dose above the recommended one in the 
mistaken belief that this will improve the effect by vet or owner. 
These are both avoidable with appropriate understanding and 
communication.  Cumulation of drug due to reduced clearance 
or altered metabolism can be more difficult to avoid completely 
but can be predicted by knowing of other health issues or 
screening patients who are believed to be at risk for problems 
by blood sampling or performing other diagnostic tests pre-
treatment.  The challenge is to make these drugs and their 
benefits more available to risk groups such as geriatrics rather 
than to deny them access.
When using NSAIDS peri-operatively to control surgical 
pain it is imperative that the patient is adequately hydrated 
throughout the procedure. Failure to achieve this can lead to 
problems with renal perfusion and subsequent serious renal 
damage or death.
Cimicoxib
Cimocoxib (Cimalgex® Vetoquinol) is a new coxib that has just 
appeared on the market. It is available as a range of chewable 
tablets for dogs given at a dose of 2mg/kg once daily.  There is 
very little published data available at the present time but two 
field studies are described. 
These field studies involved dogs of different age groups, 
genders and breeds.  A study in dogs (average age 8.8 years 
old) with chronic osteoarthritis lasted for up to 90 days. Dogs 
were given either cimicoxib or firocoxib once daily. Effectiveness 
was determined based on examinations by a veterinarian and 
assessments by the animal’s owner.  A second study involved 
dogs (various ages from four months upwards) undergoing 
either orthopaedic or soft tissue surgery. The dogs received 
either cimicoxib or carprofen. The first dose was given two hours 
before surgery, and treatment was continued for several days. 
Pain was assessed by the veterinarian (up to 24 hours after surgery 
and at the end of the follow-up treatment). The owner also 
noted pain-related observations. Given daily, Cimalgex reduced 
pain and inflammation and lameness in dogs with chronic 
osteoarthritis, and was as effective as firocoxib.  Cimalgex was 
also shown to be as effective as carprofen, in the management 
of peri-operative pain due to orthopaedic or soft tissue surgery 
during the first 24 hours after surgery.  At present it is suggested 
that great care be taken in dogs less than 6 months old and that 
use in puppies up to 10 weeks of age should be avoided.
Mavacoxib
Mavacoxib (Trocoxil®; Pfizer)is a coxib by chemical structure but 
is a preferential COX-2 inhibitor rather than a selective one.  It 
is unique among the NSAIDs currently available in having a very 
long half-life of 40days, meaning that dosing is once monthly. 
Trocoxil is available in a variety of tablet strengths (6,20,30,75 
and 90mg) to be administered at a dose of 2mg/kg.  The tablets 
are triangular in shape and chewable.  They can be given with 
food as this increases bioavailability but it is important to ensure 
that the tablet(s) are ingested.  Dose regime suggested is a 
‘jump start’ one with the second dose given at 14 days and 
then monthly dosing thereafter for a total treatment of 7 doses 
maximum.  Treatment can be resumed after a break of one 
month.  This drug is indicated where continuous treatment in 
excess of one month is required, usually in osteoarthritic dogs. 
It has not got a license for use in cats.  Both safety and efficacy 
were comparable to carprofen at this dose level which was 
determined by field trial studies [32;33].
Initial studies in laboratory beagles had indicated a dose of 
4mg/kg but this was modified after field trial in dogs with 
osteoarthritis to 2mg/kg when half-life was found to be 
longer in target breeds.  Interestingly no increased toxicity was 
seen in these trials where the higher dose of 4mg was used. 
Toxicity was mainly gastro-intestinal and there were some 
initial concerns about toxicity as the active drug could not be 
withdrawn as is common practice when this occurs.  In reality 
the adverse events lasted no longer than the same events seen 
with carprofen despite the fact that the drug was still active in 
the system.  As this type of toxicity is often predisposed to by 
other inciting factors, these must be looked for and, if present, 
removed or corrected eg hydration in dehydrated animals.  The 
advantages, rather than disadvantages, of having continual 
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effective suppression of peripheral and central pain mechanisms 
may lead to altered disease progression [40;41].
These findings have altered the basic management of 
osteoarthritic cases and produced new challenges in this 
area. In simple terms NSAIDS are being used increasingly and 
for more prolonged periods.  Several studies have indicated 
that prolonged use of NSAIDs has resulted in improved 
outcomes compared with shorter periods of treatment [34;35], 
presumably in line with the reasons identified above, and this is 
becoming more common practice.  This raises concerns about 
possible toxicity but as yet, there has been no evidence that 
prolonged use has resulted in increased or new adverse events 
(Pfizer; Trocoxil Study).  Many of the newer drugs have long-
term license indications.
There are three major situations that veterinarians have to deal 
with when using NSAIDs to manage OA.  
The first one deciding what NSAID to use, which is becoming 
increasingly complicated with a greater variety of choices. The 
newer second and third generation drugs all demonstrate good 
safety profiles and have good evidence of efficacy therefore 
choice is really based on personal preferences. Most of these 
also come in formulations that are easy to administer and are 
in once daily dose regimes, both of which increase compliance. 
The coxibs hold promise with increased GI safety profiles and 
all of these are perfectly suitable for first line use.  Drugs like 
mavacoxib offer an easier method of delivering prolonged 
therapy in cases which are stable and would benefit from this 
approach.  Increasingly NSAIDs are not used as single agents 
to treat OA but as part of a multi-modal approach supplying 
analgesia along with alterations in diet, lifestyle, exercise and 
mobility in addition to possible surgical intervention. [2] This 
approach recognizes the complex nature of a chronic lifelong 
disease like OA and produces better and more sustained results.
The second main challenge is that presented by an animal that 
shows a poor response to NSAID treatment, the slow responder. 
This situation has to be dealt with logically and a multimodal 
approach assists with this.  In this situation a number of 
questions have to be posed and answered. 
1.  Is the joint too altered to respond to medication? In these 
cases there may be a surgical salvage solution if a single joint 
or pair of joints is involved eg Total Hip Replacement.
2.  Could the animal have a poor response to that NSAID? 
Although all of the modern NSAIDs show good efficacy 
in the test populations it is widely accepted that there are 
individually determined variations in response. This means 
that one NSAID may work better than another in an individual 
case. Unfortunately there is no way to find this out other than 
by using trial and error.  However this may be the simplest 
way to resolve the problem and obtain a good response.
3.  Has the NSAID had long enough to have an effect?  This is 
a common situation where a drug is removed too quickly 
before it has had time to make a difference.  Again a 
multimodal approach can help and promote a degree 
of patience. Clearly it depends on the degree of pain or 
suffering but that is not the usual reason for poor response 
being recognized. Usually the expectations for improvement 
are wrong and false hopes of a complete recovery in a short 
period of time lead to frustration and disappointment.
NSAIDs must never be used in combination and never used 
with corticosteroids.
Monitoring for any signs of problems is an important part of using 
these drugs.  A clear set of instructions to owners explaining the 
risk and advising them what to look out for can avoid serious 
complications.  Most adverse events, especially gastrointestinal 
ones, can be contained and resolved if the animal is presented 
early.  The majority of gastrointestinal problems occur early, 
usually within the first two weeks of treatment. Vigilance 
should be higher during this period for any signs of vomiting 
or diarrhoea. 
Coping with Gastrointestal (GIT) events
In the majority of cases early recognition with withdrawal of 
the NSAID and supportive therapy is adequate to allow an 
early return to normal.  In more severe events gastric ulceration 
and perforation can result.  Unfortunately side-effects have 
been reported even with the third generation coxibs. Sadly 
in the events documented it seems that the main reason for 
serious adverse events with these drugs was again down to 
inappropriate use [36;37].  It is much better to try and avoid 
these consequences rather than treat them and this emphasizes 
the importance of owner vigilance and making early contact 
with the veterinarian if there are concerns about toxicity. 
Advised practice in cases showing possible adverse events is 
to withdraw NSAID, ensure that animal is properly rehydrated 
and try to establish if there are any other reasons for the signs. 
Various medical interventions are available if gastric ulceration 
is suspected but few are very effective at quickly resolving an 
NSAID induced ulcer [2].  H2-blockers such as Cimetidine can be 
used to try and decrease the acidity in the gastric lumen, which 
can reduce secondary damage, but cimetidine will not prevent 
the formation of an ulcer. Omeprazole (protein-pump inhibitor) 
may be a more practical and effective choice as it is a much more 
potent antacid and is given once daily.  Misoprostal, which is a 
synthetic PGE1 analog which can be used to prevent ulceration 
but requires dosing 3-4 times daily and side-effects are common. 
In the absence of any satisfactory method of either preventing 
or healing drug induced ulceration best practice is to try to avoid 
their formation by using NSAIDs sensibly and only using gastro-
protectives in extreme circumstances or proven intolerance 
cases. Even in these cases, results can be unpredictable.
NSAIDs in the management of Osteoarthritis
Osteoarthritis is the most common cause of chronic pain in 
small animals and one of the most common indications for 
NSAID use.  NSAIDs are becoming increasingly important in 
the management of osteoarthritis with the realization of how 
important control of pain is to deliver an improved outcome. 
This is coupled with increasing disappointment over the results 
of so-called chondro-protective drugs in alleviating the clinical 
signs.  Recently the understanding that peripheral and central 
sensitization in the sensory system in chronic osteoarthritis could 
play an important part in suffering and disease progression has 
prompted increased interest in the actions of COX-2 in the 
nervous system, in particular, the CNS.  COX-2 seems to play an 
important role in sensory perception in OA and sensitization [38]
and COX-2 inhibition has been demonstrated to decrease central 
sensitization [39].  There is also speculation that prolonged and 
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toxicity, difficulty in ensuring accurate dosage because of the 
smaller bodyweights and difficulty in administering medication 
[46].  There are three Second Generation NSAIDs which are 
licensed for use in the cat and which have clinical evidence of 
both safety and efficacy.  These are meloxicam, ketaprofen and 
tolfenamic acid.  The only Third Generation product to have 
an indication in cats at this time is robenacoxib (Table 4). It is 
outwith the scope of this article to expand in detail on the use 
of these drugs in cats but there is an excellent set of guidelines 
which have been produced by the ISFM and AAFP for long term 
use of NSAIDs in cats to which the reader is directed [46].
Concluding summary
NSAIDs carry considerable advantages in the management of 
both acute and chronic pain in both dogs and cats as a result 
of their mode of action and the fact that they are easy to 
use.  Recent introduction of a new range of third generation 
coxibs increase the choice available to the veterinarian.  A full 
understanding of the drugs and the diseases they are used to 
treat allows safe and effective use avoiding unnecessary adverse 
events. Clear communication to the owners is a key part of this. 
This is especially important for the increasing numbers of older 
cats and dogs who may benefit from the proper use of NSAIDs 
to alleviate pain and suffering as a result of chronic disease.  
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A 30-months-old neutered male Airedale Terrier presented with depressed mental status and anisocoria. A space-
occupying suprasellar lesion was visualised by magnetic resonance imaging. The lesion appeared isointense relative 
to the brain parenchyma on T1-weighted images and hyperintense on T2-weighted images and had a moderate 
homogeneous enhancement. The dog was euthanased and the histopathologic diagnosis was a suprasellar germ cell 
tumour. 
Key words: Airdale Terrier, intracranial germ cell tumour, immunohistochemistry, magnetic resonance imaging. 
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Introduction
Germ cell tumours are a group of primitive gonadal neoplasms 
but they may also occur in extra-gonadal sites [1, 2]. In man 
and in dogs, these tumours have been rarely observed in the 
central nervous system, often in the suprasellar region [1-12]. 
Intracranial germ cell tumours (IGCT) have been described in 
young adult Doberman Pinschers, although this neoplasm has 
also been reported in other breeds [3,4,6,7,12]. This is the first 
report of an IGCT in an airedale Terrier. In human patients, 
magnetic resonance imaging (mrI) has been reported as the 
investigation of choice for the presumptive diagnosis of IGCT 
and for planning the surgical approach [13]. In dogs there is 
sparse data on mrI features of IGCT [12]. The present report 
describes the clinical, mrI and histopathologic features of IGCT 
in a young airedale Terrier.
Case report
a 30-months-old neutered male airedale Terrier was referred 
for investigation of progressive drowsiness and anisocoria noted 
one week before presentation. On neurological examination the 
dog had low neck carriage and depressed mental status. Direct 
and consensual pupillary light reflex was considered normal in 
the left eye and absent in the right eye. In particular, the right 
pupil appeared constantly dilated. Palpebral, corneal and gag 
reflexes, facial sensation, menace response, eyes movements, 
spinal nerve reflexes, proprioception and muscle tone were 
normal. Fundoscopic examination of both eyes revealed no 
gross abnormalities. The neurological findings supported 
involvement of the brain and the parasympathetic portion of 
the right oculomotor nerve. Haematology, biochemistry and 
cerebrospinal fluid profiles were normal. The dog had reduced 
total L-Thyroxine (6.44 nmol/l; reference 15.0 to 50.0 nmol/l) 
and low-normal basal cortisol (24.8 nmol/l; reference 27.5 
to 125 nmol/l). Thyroid-stimulating hormone was also low-
normal (0.036 ng/ml; reference 0 to 0.6). mrI scans (Vet-mr 
Grande, Esaote s.p.a, Genova, Italy) of the dog’s brain were 
obtained under general anaesthesia in transverse, dorsal, and 
sagittal planes of orientation before and after the intravenous 
administration of 0.1 mmol/kg gadolinium (magnevist®, 
schering, Germany). On T1-weighted (T1-W) images (Tr: 850 
ms, TE: 26 ms) an isointense ill-defined space-occupying round 
lesion was visualised in the diencephalon, compressing the 
surrounding brain parenchyma and lateral ventricles. On T2-
weighted (T2-W) images (Tr: 3110 ms, TE: 80 ms) the lesion had 
uniform high signal intensity, demarcated margins and appeared 
to compress the hypothalamus. after intravenous administration 
of contrast medium there was moderate homogeneous 
enhancement (Fig. 1, Fig. 2). In particular, sagittal post-contrast 
T1-W images showed that the lesion was dorsally displacing 
the rostral portion of the mesencephalon (Fig. 2). Differential 
diagnoses for the lesion included glioma, meningioma, IGCT, 
pituitary tumour and craniopharyngioma. Before planning any 
treatments, diagnostic needle biopsy of the mass was offered 
but the owner elected for euthanasia of the dog. Post-mortem 
examination was confined to the brain that was fixed in 10 per 
cent formalin and submitted for histopathological evaluation. 
The fixed brain ventral surface had an irregular rough pale 
area (20x15 mm diameter) dorsal to the pituitary gland. Cut 
surfaces revealed an overlying suprasellar hypothalamic firm 
pale area (20 mm diameter) that was poorly demarcated from 
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the adjacent compressed neuropil. The cerebrum, cerebellum, 
brain stem and ventricles were otherwise unremarkable. The 
hypothalamic mass (Fig. 3) consisted histologically of abnormal 
tissue with three intermingled areas: 1) organoid clusters of 
pleomorphic germ cells (Fig. 4); 2) multilocular cysts lined by 
columnar epithelial cells (Fig. 5). Cysts and surrounding neuropil 
contained cell debris, stands of basophilic mucinous material 
and cholesterol clefts (Fig. 6); 3) Foci of lymphocytes and 
macrophages with foamy pale cytoplasm. also present were 
foci of acidophilic pituitary epithelial cells (Fig. 7). Compressed 
neuropil around the suprasellar mass contained reactive 
gemistocytes. Immunohistochemical staining was carried out 
using commercial antibodies linked to horseradish peroxidase 
(HrP) (DaKO Corporation, Glostrup, Denmark) as follows: alpha-
fetoprotein (aFP)-polyclonal rabbit antihuman; human chorionic 
gonadotrophin (HCG)-polyclonal rabbit antihuman; epithelial 
cytokeratin 5/6-monoclonal mouse antihuman cytokeratin; 
CD30-monoclonal mouse antihuman germ cell (embryonal 
carcinoma) marker. Immunostaining with antibodies linked to 
horseradish peroxidase gave a strongly positive reaction for aFP 
(Fig. 8) and a less strong focal reaction for HCG in the suprasellar 
pleomorphic cells (Fig. 9). There was positive immunostaining of 
these cells with antibody (CD30) against embryonal carcinoma. 
Cells lining cysts were positively immunostained for epithelial 
cytokeratin 5/6 (Fig. 10). On the basis of the anatomic site, 
histological appearance and positive immunostaining for aFP 
and HCG the lesion was considered to consist of germ cells, 
pituitary acidophils and epithelial cysts with secondary 
degenerative changes.
Discussion
Germ cell tumours are a group of primitive gonadal neoplasms 
but they may also occur in extra-gonadal sites [1, 2]. In man 
and in dogs, primary central nervous system germ cell tumours 
are rare [3-7, 9, 10, 12]. In man IGCT occur predominantly in 
Transverse (Fig 1) and sagittal (Fig2) post-contrast T1-weighted 
MR images of the brain at the level of the interthalamic adhesion. 
The lesion shows homogeneous contrast enhancement, a round 
shape and demarcated margins. In addition, note how the lesion is 
dorsally displacing the rostral portion of the mesencephalon.
Fig. 4: Organoid clusters of pleomorphic germ cells in a suprasellar 
mass. Haematoxylin & Eosin X80
Fig. 3: Section of a suprasellar mass (m) in a 30 months 
old Airedale Terrier. There is compression of the overlying 
hypothalamus. Haematoxylin & Eosin X6
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children and adolescents [5, 9]. affected dogs are usually 2 to 
5 years of age and it seems that IGCT may be over-represented 
in Doberman Pinschers, although this tumour has also been 
reported in other breeds [3, 4, 6, 7, 12]. This is the first report of 
an IGCT in an airedale Terrier. 
The polymorphic histological nature of the suprasellar mass 
in this report was interpreted as consisting of 3 separate 
intermingled components: primitive germ cells; epithelial 
cysts resembling craniopharyngioma; pituitary acidophils. 
Post mortem examination was limited to the brain and 
histological examination of the pituitary was not undertaken 
but the presumption is that the lesion originated there. Case 
reports of primary intracranial tumours at this anatomic site 
and with this histological appearance have been published 
as craniopharyngioma in dogs, but are now classified as 
germ cell tumours on the basis of these criteria: 1) anatomic 
location, 2) the presence within the tumours of several distinct 
cell types, 3) positive staining for aFP [3, 4].
Human patients with this tumour may have clinical signs of 
headache and visual disturbances that may be related to 
raised intracranial pressure and optic chiasmal compression. 
In addition, because these neoplasms are usually located in 
the suprasellar region of the brain, tumour growth may cause 
endocrine dysfunctions such as diabetes insipidus, amenorrhoea, 
growth retardation, and precocious puberty [8, 11]. Clinically, 
our patient had depressed mental status and anisocoria with 
constant dilatation of the right pupil. These neurological findings 
supported involvement of the brain and the parasympathetic 
portion of the right oculomotor nerve. Lesions of this nerve may 
cause a dilated pupil that is unresponsive to light because of loss 
of the parasympathetic preganglionic neurons that innervate 
Fig. 7: A cluster of eosinophilic pituitary epithelial cells 
(arrows) in a suprasellar germ cell tumour. Haematoxylin 
& Eosin X160
Fig. 6: Suprasellar mass showing degenerate germ cells and 
cholesterol clefts around an epithelial cyst. Haematoxylin & Eosin 
X100
Fig. 8: Suprasellar germ cell tumour with strong multifocal AFP 
staining. HRP-AFP/Haematoxylin & Eosin X100
Fig. 5: Suprasellar mass showing multilobular cysts (arrows) with 
surrounding germ cells. Haematoxylin & Eosin X100
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the iris constrictor muscle [12]. In this particular case it is likely 
that the suprasellar mass was compressing the right oculomotor 
nerve and the diencephalon with secondary involvement of the 
ascending reticular activating system, a network of neurons 
responsible for maintaining the state of wakefulness [12]. Because 
IGCT can extend from the olfactory peduncles to the pons and 
pyriform lobes, other neurological deficits caused by enveloping 
of other cranial nerves and compression of the surrounding brain 
parenchyma may be expected and can include head pressing, 
circling, blindness, partial or total ophthalmoplegia externa and 
bradycardia [3, 7, 12]. rarely, in dogs IGCT have been associated 
with pituitary dysfunction [3]. In the case under study, the reduced 
L-Thyroxine and low-normal basal cortisol and thyroid-stimulating 
hormone was thought to reflect incipient panhypopituitarism. It 
is possible that these neoplasms may behave differently: in some 
cases sufficient pituitary tissue may persist to maintain adequate 
pituitary function, [3, 4] whereas in other cases tumour may 
invade and destroy the pituitary impairing normal physiologic 
function of the gland. In human patients computed tomography 
or mrI, with and without intravenous administration of contrast 
medium, may be employed to establish the presumptive 
diagnosis of IGCT. However, mrI is preferred under most 
circumstances, providing superior resolution and multiplanar 
imaging capabilities, and avoiding the “spray” artefact from the 
petrous ridge that may obscure computed tomography images 
of the base of the brain [8]. moreover, in man mrI has been 
reported as the investigation of choice to presumptively diagnose 
IGCT and to plan the surgical approach [13]. In this particular 
case mrI was very helpful to precisely locate the anatomical site 
of the suprasellar mass and to delineate the extent of the tumour 
and its involvement with the surrounding brain. The tumour was 
localised in the diencephalon and this finding is in accordance 
with previous studies in dogs as well as in people where IGCT 
are often visualised in the suprasellar region [8, 12, 13] although 
they have also been identified in the pineal region [2] and in 
the midbrain [14]. mrI features of IGCT have been reported in 
dogs where a homogeneous moderately enhancing mass was 
detected on T1-W post-contrast images corresponding to the 
suprasellar region [12]. However, there was no mention of the 
signal intensity in the other mrI sequences. In accordance with 
human literature, the tumour in our patient appeared isointense 
relative to the adjacent brain on T1-W images, hyperintense on 
T2-W images and had moderate homogeneous enhancement 
after intravenous administration of the contrast medium [13]. 
several lesions including meningioma, pituitary tumour, glioma 
and craniopharyngioma may mimic IGCT. all these brain lesions 
may appear iso- to hypointense on T1-W images, hyperintense 
on T2-W images and they usually show enhancement on 
postcontrast T1-W images. In addition, they may be associated 
with mass effect and they can be localised in the suprasellar 
region [15-21]. However, meningioma and glioma were 
considered to be less likely because these primary brain tumours 
are rarely located in the diencephalon and would be uncommon 
in a dog of this relative youth [18, 20, 21]. Pituitary tumours may 
impinge on the ventral aspect of the forebrain at the level of the 
diencephalon and may be adenomas or adenocarcinomas. These 
secondary brain tumours might be suspected as they usually 
appear as fairly sharply marginated masses that can displace and/
or invade the overlying brain [17-19, 22, 23] but they would be 
unusual in a dog of this young age [22, 23]. at present there 
are no data on the mrI findings of craniopharyngioma in dogs. 
In one study craniopharyngioma was suspected in a dog on 
the basis of clinical findings and computed tomography images 
[24]. mrI features of craniopharyngioma have been reported 
in a cat: an ovoid mass invaded the hypothalamus and optic 
chiasm but there was no mention of the magnetic resonance 
signal intensity features [25]. In man craniopharyngioma tends to 
have a suprasellar location and the most common mrI pattern of 
this tumour is that of iso- to hypointensity on T1-W images and 
high signal intensity of variable homogeneity on T2-W images. 
The tumour usually shows enhancement on T1-W postcontrast 
images [15, 16]. On the basis of mrI findings in this report we 
were unable to definitively diagnose the exact nature of the 
lesion. ante-mortem diagnosis by surgical biopsy was declined 
by the owner. In man stereotactic surgery (a surgical intervention 
which makes use of a three-dimensional coordinates system 
to locate small targets inside the body and to perform on 
them biopsies or other procedures) is the preferred surgical 
approach both for diagnostic and therapeutic reasons, because 
Fig. 9: Suprasellar germ cell tumour with focal HCG staining. 
HRP-AFP/Haematoxylin & Eosin X100
Fig. 10: Suprasellar germ cell tumour showing cytokeratin positive 
cyst epithelial cells and surrounding germ cells. HRP-cytokeratin/
Haematoxylin & Eosin X200 
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of the low associated morbidity [26]. In dogs, transsphenoidal 
hypophysectomy may be used to achieve a final histopathological 
diagnosis of pituitary masses and is expected to have the best 
outcome when used in case of nonenlarged or moderately 
enlarged pituitaries [27]. In man gross resection of IGCT is not 
recommended in view of the potential morbidity associated with 
this procedure [13] and these suprasellar tumours are treated 
with craniospinal irradiation and chemotherapy. However, even 
with aggressive therapy, the 5-year survival is less than 50% [28, 
29]. at present, there are no data on treatment and outcome of 
IGCT in dogs. One recent study of 46 dogs with pituitary masses 
showed that dogs that underwent radiotherapy had significantly 
longer survival times than untreated dogs: but pre- and post-
mortem histological evaluation of the pituitary lesions was not 
carried out [30]. It may be that conventional radiotherapy could 
be effective for controlling and inhibiting IGCT growth in dogs 
but further studies would be required to assess the benefits and 
risks of this medical approach. In conclusion we report the first 
case of IGCT in a young male airedale Terrier. The lesion was 
detected by mrI and confirmed histologically. On the basis of 
mrI findings alone we were unable to definitively diagnose the 
exact nature of the lesion and histopathological evaluation was 
necessary for morphologic diagnosis of the complex nature of 
the suprasellar mass.
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Three cases of canine pyoderma associated with a lichenoid reaction are presented. These three dogs were 
dolichocephalic and were used regularly for hunting. Lesions observed in the three cases were similar and had the 
same localisations: clusters of papular and nummular plaques and plaques frequently covered by thick crusts, on 
the ear pinnae, face and limbs. Skin biopsies revealed a dense band-like infiltrate of lymphocytes, plasma cells and 
histiocytes associated with epidermal basal cell lesions, and subcorneal and/or follicular pustules. The response 
to antibiotic therapy was excellent and rapid, the lesion disappearing in 3 weeks. This presentation of pyoderma is 
rare. Lichenoid dermatitis is probably due to a particular reaction pattern.
Key words: Dermatology – Dog – Pyoderma – Lichenoid reaction.
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DErmaTOLOGy
Introduction 
Pyoderma is a very common canine disease. Pustular lesions are 
frequently a symptom of this disease but a wide diversity of 
symptoms have been observed [1,2].
Lichenoid dermatites are rare diseases whose origin is often 
unknown in dogs. The clinical characteristics are papular lesions 
which can coalesce and form plaques [3].
In this article, we present three retrospective cases of pyoderma 
with a lichenoid aspect from a clinical and histopathologic point 
of view. In addition they show epidemiological similarities.
These three animals were brought for consultation in 1985, 
1987 and 2003 respectively.
Case Number 1
a 3 year old neutered female Pointer was brought in for 
consultation with chronically evolving scabby lesions on the 
ventral aspect of the ear pinnae. The dog lived freely in the 
countryside and was regularly used for hunting.
The lesions had appeared six months previously. a systemic 
antifungal treatment (griseofulvin) and local treatment 
(enilconazole, Imaveral®) had been administered, without result. 
a fungal culture did not show the presence of dermatophyte. 
The use of benzoyl peroxide (Peroxydex®) led to a partial 
improvement of the lesions.
a clinical examination of the dog did not show any anomalies 
other than cutaneous .
several clusters of scaly papular and nummular plaques and 
plaques, sometimes coalescent, were present on the ear pinnae 
and limbs (figures 1 and 2). some of the lesions were ulcerated 
and covered with crusts.
a new fungal culture and several skin biopsies were performed. 
No fungal colony developed. The histopathologic examination 
had showed the presence of sero-cellular crusts, an important 
follicular orthokeratotic hyperkeratosis, and a dense band-
like infiltrate of lymphocytes and plasma cells. We reached the 
conclusion that it was a superficial pyoderma of bacterial origin.
(1) Aqvivet Clinique Vétérinaire, Avenue de la Forêt, Parc d’ Activitiés Mermoz, F-33320 Eysines (Bordeaux). E-mail: dncvetderm@aol.com
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Case Number 3 
a 4 year old male Pointer was brought in for consultation for a 
multifocal crusting dermatosis.
The dog lived in a house and had access to a garden. He was 
regularly used for hunting. The lesions had appeared 1 month 
before the consultation. Local treatment using Panolog® 
(nystatin, neomycin, triamcinolone) had not resulted in an 
improvement.
a clinical examination of the dog showed only the cutaneous 
anomalies.
Numerous nummular erythematous papules and plaques of 
varying sizes, frequently eroded and covered by a thick crust, 
were observed on the ear pinnae, the head and the front legs 
(figure 5).
skin scrapings, a trichogram and a fungal culture all gave 
negative results.
a cytological examination obtained by skin smear revealed 
numerous neutrophils, macrophages and Cocci, frequently 
phagocytised by the polymorphs.
The bacteriological examination enabled the identification of 
a strain of Staphylococcus intermedius susceptible to different 
antibiotics (penicillins, cephalosporins, aminoglycosides, 
macrolides, sulfonamides, quinolones).
The histopathological examination revealed several subcorneal 
pustules in the process of drying up, some signs of hydropic 
degeneration and apoptosis in the basal layer of the epidermis 
(figure 6) and a marked pigmentary incontinence. a dense and 
diffused infiltrate of lymphocytes, plasma cells and histiocytes 
was observed in the superficial dermis and some areas of 
suppurated folliculitis were noted (figure 7). We concluded that 
this was a superficial pyoderma of bacterial origin.
systemic antibiotic treatment using cefalexin (rilexine®, 600 mg 
PO, BID) was started. a marked improvement in the lesions was 
observed after 15 days (figure 8). The treatment was continued 
for 15 more days and resulted in the complete disappearance 
of the skin lesions. No relapse had been reported during the 
following year.
Discussion
These three cases presented several similarities (table 1). In all 
three cases, the dogs were dolichocephalic and used regularly 
for hunting. The lesions observed and their localization were the 
same, papular and nummular plaques and plaques covered with 
thick crusts on the ear pinnae and limbs. The histopathological 
examination showed a dense band-like sub-epidermal infiltrate, 
mainly composed of lymphocytes and plasma cells, associated 
with epidermal basal cell lesions. subcorneal and follicular 
pustules were often present. The response to antibiotic therapy 
was excellent and rapid.
antibiotic treatment with oxacillin (Bristopen®, 500 mg PO, BID) 
was prescribed together with benzoyl peroxide shampoos. The 
dog made a complete and rapid recovery and a check-up 3 weeks 
later showed no further skin lesions. Two relapses occurred 
2 months and 2 years respectively after the first episode and 
responded to the same treatment. There was a clear relationship 
between these relapses and use of the dog for hunting.
Case Number 2
a 2½ year old neutered male German pointer was brought for 
consultation with recurrent and generalised scabby lesions.
The dog lived in a house and had access to a garden. He was 
regularly used for hunting. The lesions had appeared 3 months 
earlier, shortly after the dog was used for hunting. The lesions, 
at first localised and consisting of crusty papules, had been 
treated orally with amoxicillin and hydrocortisone. The lesions 
totally disappeared but a relapse was observed one month later.
a clinical examination of the dog showed only the cutaneous 
anomalies.
Clusters of papular and nummular plaques, frequently covered 
by scales and thick crusts, were observed on the ear pinnae and 
limbs (figure 3). some hyperpigmented macules surrounded by 
epidermic collarettes were also observed on the abdomen.
skin scrapings, a trichogram and a fungal culture all gave 
negative results.
a cytological examination obtained by skin smear revealed 
numerous neutrophils, macrophages and Cocci, frequently 
phagocytosed by the polymorphs.
The bacteriological examination identified a strain of 
Staphylococcus intermedius susceptible to different antibiotics 
(penicillins, cephalosporins, aminoglycosides, macrolides, 
sulfonamides).
The histopathological examination revealed numerous 
serocellular crusts with colonies of Cocci, an important 
follicular orthokeratotic hyperkeratosis, and signs of basal cells 
degeneration associated with some apoptotic cells. a dense 
and diffuse infiltrate that included lymphocytes, plasma cells 
and histiocytes was observed in the superficial and periannexial 
dermis (figure n°4). In some areas, neutrophils and signs of 
suppurative folliculitis and furunculosis, with free keratin in the 
pyogranulomatous infiltrate, were observed. We concluded this 
confirmed a superficial and deep pyoderma of bacterial origin.
a systemic antibiotic treatment with amoxicillin potentiated 
clavulanic acid (synulox®, 500 mg PO, BID) was started. a 
marked improvement of the lesions was observed within 10 
days. The treatment was continued for an additional 25 days 
and at the check-up the lesions had completely disappeared. 
The case was not seen again and follow up was not possible.
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The symptoms of lichenoid dermatitis are scaly and flat papules 
and plaques usually localised on the external face of the ear 
pinnae, on the ventral region of the thorax and the abdomen. 
Other locations are less frequently described [3, 7, 8]. In our 
three cases, these flat papules and plaques, sometimes covered 
by thick crusts, were found on the ear pinnae (and in one case, 
on the head) and the limbs.
In these three cases the term lichenoid dermatoses can be used.
Lichenoid dermatoses are rare diseases whose cause is unknown. 
In human dermatology the hypothesis currently regarded as the 
most plausible by certain authors is of an auto-immune cause, 
possibly triggered and localised by a viral infection (hepatitis 
C virus) [4,9]. In dogs, an immunological mechanism is also 
considered likely [10]. In certain cases, genetic determinism 
and the intervention of infectious or traumatic factors are also 
evoked. These diseases are described in the Doberman but also in 
other breeds [3, 7, 8, 11, 12]. Our three cases concern 2 Pointers 
and 1 German Pointer all of about 3 years old, used regularly 
for hunting. It could be imagined that regular use for hunting 
increases the risk of trauma and bacterial infections on the 
face, the ear pinnae and the forelimbs. The head conformation 
(dolichocephalic breeds) could be another factor which leads to 
auricular trauma during hunting sessions.
The lichenoid dermatitis diagnosis is based upon the case history, 
the type and localisation of the lesions, and the histopathological 
examination. In our cases, in view of the clinical aspect, we have 
suggested two main groups of dermatoses for the differential 
diagnosis: pseudoneoplasms (bacterial, fungal, parasitic or 
sterile) and neoplasms [13].
The supportive investigations to be carried out are skin scrapings, 
cytological and bacteriological examinations using exudates, 
and fungal cultures. Histopathological examination is essential 
for a definitive diagnosis: it shows in the epidermis a more or 
less regular hyperkeratosis and acanthosis and signs of hydropic 
degeneration of the basal layer cells, as well as some apoptotic 
keratinocytes. In the superficial dermis, a dense infiltrate is 
Table 1: Summary of the three cases 
Breed 2 Pointers and a German Pointer
sex 2 males (1 neutered) and 1 female (neutered)
age Young adults (approximately 3 years)
Way of life Hunting
reason for consultation Crusting dermatitis
Dermatological examination Several nummular erythematous papules and plaques, frequently covered by crusts, 
on the ear pinnae and limbs
Cytological examination Neutrophils, phagocytosis of Cocci (2/3)
Histopathological examination Hydropic degeneration and apoptosis in the basal layer of the epidermis (2/3) 
Lymphoplasmocytic subepidemal band-like infiltrate (3/3) Suppurated folliculitis 
(2/3) Perifolliculitis (1/3)
Treatment ß-lactamine antibiotics 20 – 30 days
Follow-up Recovery in 2-3 weeks (In 1 case: 2 relapses at 2 months and 2 years)
The term “lichenoid” means “of lichen-like appearance”. In 
human dermatology, lichenoid dermatitoses are inflammatory 
diseases characterised, clinically by papular lesions resembling 
botanical lichen and histopathologicaly by a band-like infiltrate 
of mononuclear cells in the superficial dermis, associated with 
lesions in the lower layers of the epidermis, which suggest a 
cell-mediated autoimmune reaction against the epidermis [4]. 
The skin conditions which match this definition are : idiopathic 
lichen planus , lichenoid drug reactions, lichenoid contact 
dermatitis, lichen striatus, solitary lichenoid keratosis, graft 
versus host disease, lupus erythematosus, lichen nitidus and 
prurigo pigmentosa [4].
In veterinary dermatology there is a certain amount of confusion 
surrounding this term. some entities present both the clinical 
and histopathological sides of a lichenoid dermatitis in the true 
sense: lichenoid keratosis, psoriasiform lichenoid dermatitis 
and idiopathic lichenoid dermatitis¹. But several histopatologist 
authors have used the term “lichenoid” to define a band-like 
mononuclear infiltrate in the superficial dermis associated with 
epidermal basal cell lesions, independent of the clinical aspect [5]. 
For some of them, damage to the lower layers of the epidermis 
(known as interface dermatitis) is not an essential criterion 
[6]. In this case, it can be considered that many dermatitoses 
reveal a “lichenoid” reaction on histopathological examination. 
a “lichenoid” infiltrate, that is to say in a sub-epidermal 
band, is effectively present in numerous conditions such as 
mucocutaneous pyoderma, cutaneous lupus erythematosus, 
systemic lupus erythematosus, pemphigus erythematosus, 
uveo-cutaneous syndrome, vitiligo, erythema multiforme, 
actinic keratosis, mycosis fungoides [6].
In terms of clinical nosology it would be logical to restrict the 
use of the term “lichenoid” to dermatitis which show signs both 
on a clinical and histopathological level. In the same way, on 
the histopathological level it would be preferable to use the 
term “lichenoid” for a sub-epidermal infiltrate, whether it has 
interfacial dermatitis or not.
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Figure 1: 
Lightly scaly and erythematous papules and plaques frequently 
confluent on the internal aspect of ear pinnae (Case Number 1).
Figure 2:
Erythematous plaques 
on a forelimb (Case 
Number 1).
Figure 3: 
Multiple localised scaly papules with crusts on 
the face and ear pinnae (Case Number 2).
Figure 4: 
Histopathological examination of a lesion (from Case Number 2) 
(HES, x 40): sub-epidermal dense band-like infiltrate
Figure 5: 
Close-up of lesions on ear pinnae: plaques covered with a thick 
crust can be observed (Case Number 3).
Figure 6: 
Histopathological examination of a lesion (from 
Case Number 3) (HES, x 250): interface dermatitis 
characterised by a mainly lymphocytic (L) infiltrate 
associated with an hydropic degeneration of cells of 
the basal layer of the epidermis (small arrows).
Figure 7: 
Histopathological examination 
of a lesion (from Case Number 
3) (HES, x 40) : suppurative 
folliculitis associated with a 
dense periannexial infiltrate.
Figure 8: 
Close up of the lesion illustrated in figure 5 after 15 
days of antibiotic treatment (cefalexin): a marked 
improvement in the lesions can be seen. Some areas 
of alopecia remain.
L
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Conclusion
Lichenoid dermatoses are rare and still poorly understood. 
A good response to antibiotic treatments, in certain cases, 
would suggest the involvement of infectious factors in their 
pathogenesis. They are increasingly considered as a reaction in 
the skin tissue to various antigenic stimulations [7, 10].
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visible, composed mainly of lymphocytes and plasma cells and 
a marked pigmentary incontinence [5, 6]. This histopathological 
feature is dominant in our three cases. Modifications in the 
basal layer with images of apoptosis and hydropic degeneration 
were observed in two cases (for the first case – in 1985 – we 
were unable to re-evaluate the histopathological examination). 
In the affected areas, serocellular crusts with colonies of Cocci, 
sub-corneal pustules and follicular pustules are often visible. 
It is therefore possible to conclude to a superficial pyoderma, 
presumably of bacterial origin, associated with a secondary 
“lichenoid” reaction which accounts for the unusual clinical 
aspect of the lesions.
There is no specific treatment for lichenoid dermatitis. The 
evolution can alternate between phases of improvement and 
worsening. An antibiotic therapy using cefalexin has resulted 
in an improvement in the lesions in some cases [3,7]. Surgical 
removal of the lesions has provided a cure in other cases [12].
In our cases, a systemic antibiotic treatment has led to a 
complete and rapid recovery in 2 – 3 weeks, which is in favour 
of a bacterial origin.
The development of pulmonary oedema is subdivided into cases of cardiogenic and non-cardiogenic origin. 
Cardiogenic oedema pathogenically is caused by elevated hydrostatic pressure in the pulmonary capillaries 
due to left sided congestive heart failure. Non-cardiogenic pulmonary oedema is categorised depending on the 
underlying pathogenesis in low alveolar pressure, elevated permeability or neurogenic oedema. Some important 
examples of causes are upper airway obstruction as in laryngeal paralysis or strangulation for low alveolar pressure, 
leptospirosis and ARDS for elevated permeability, and epilepsy, brain trauma or electrocution for neurogenic 
oedema. The differentiation between cardiogenic versus non-cardiogenic genesis is not always straightforward, but 
most relevant, because treatment markedly differs between the two. Of further importance is the identification of 
the specific underlying cause in non-cardiogenic oedema, not only for therapeutic but particularly for prognostic 
reasons. Depending on the cause the prognosis ranges from very poor to good chances of complete recovery. 
Keywords: alveolar pressure, re-expansion, airway obstruction, ARDS, neurogenic
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Introduction
The physiological movement of fluid through a vascular 
membrane into the surrounding tissue depends on 3 factors: 
membrane permeability, oncotic pressure gradient and 
hydrostatic pressure gradient. an additional factor, lymphatic 
drainage, counteracts extravascular fluid accumulation. Oedema 
develops if one of these 4 factors is disturbed to a degree that 
cannot be compensated. For pulmonary oedema to develop, 
essentially an increased intravascular hydrostatic pressure or 
a disturbed vascular permeability is always responsible [1]. 
For clinical purposes, pulmonary oedema is divided based 
on pathophysiology into cardiogenic and non-cardiogenic 
oedema. The exact differentiation and diagnosis is made based 
on a combination of clinical and radiological findings and 
considerations. 
Whereas in human medicine a vast amount of literature on 
non-cardiogenic pulmonary oedema is available [e.g. reviews, 
2-6], in dogs and cats only a few case reports [7-10] and original 
articles have been published [11-17]. This article will review 
the pathophysiological mechanisms, known causes, variable 
prognosis and briefly, therapy of pulmonary oedema.
Pathogenesis and causes of cardiogenic 
pulmonary oedema
Cardiogenic pulmonary oedema develops secondary to a rise 
of hydrostatic pressure in the pulmonary capillaries (normal 
<12 mmHg). When the rise in pressure is gradual, pressure may 
exceed 20 mmHg before pulmonary oedema develops, because 
the capacity of lymphatic drainage can be increased [18]. Left-
sided congestive heart failure as a result of an identifiable 
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underlying cardiac disease must be present for cardiogenic 
pulmonary oedema to develop. The most important acquired 
diseases are advanced degenerative mitral valve disease and 
dilated cardiomyopathy. The single most important congenital 
disease is patent ductus arteriosus. rarely pulmonary oedema 
may also develop in cases of ventricular septal defect (VsD) and 
subaortic stenosis (sas). most VsDs are restrictive (resistive), 
and only rarely lead to congestive heart failure [19]. In severe 
Causes according to pathophysiology * Time interval
Low alveolar pressure, postobstructive 
oedema
0-2 hours
Laryngospasm, e.g. post extubation 
Laryngeal paralysis
strangulation
Tracheal collapse
Tracheoscopy
Low alveolar pressure, re-expansion 
oedema
0-24 hours
Post-expansion oedema after 
thoracocentesis and fast removal of pleural 
effusion or pneumothorax 
Post surgical correction of (chronic) 
diaphragmatic hernia
Post pneumonectomy
Neurogenic Minutes to hours
Electrocution 
seizure, during postictal phase
skull / brain trauma, 
Cerebral haemorrhage
meningoencephalitis
Hunting dogs
Cerebral oedema secondary to 
hyponatraemia in endurance athletes 
Abnormal permeability / vasculitis Hours to days
arDs
Leptospirosis
Others Hours to days
High altitude pulmonary oedema (HaPE)
*These causes should be considered in small animals, even if not all of these 
have been published in the scientific literature.
Table 1: Causes of non-cardiogenic pulmonary oedema and time 
interval from insult to its development
Fig. 2: Radiographs of a 6-year old male Doberman with coughing and gagging.
The caudodorsal lung areas show marked opacification (arrows); there is severe left atrial dilation and cardiomegaly, particularly prominent 
on the DV- projection. Cardiac changes and localisation of increased pulmonary densities make cardiogenic oedema probable. The 
echocardiographically documented underlying disease of dilated cardiomyopathy provides a plausible cause of cardiogenic oedema.
Fig. 1: Radiographs of a 11-year old Dachshund with cough due to 
advanced degenerative mitral valve disease. 
There is radiological evidence of left-sided cardiomegaly (dorsal 
displacement of trachea) and severe left atrial dilation (small 
arrows) causing dorsal displacement and compression of the left 
stem bronchus (white arrow). The pulmonary veins are enlarged 
(large arrow) and the caudo-dorsal lung field is mildly opaque, to 
be interpreted as early stage cardiogenic oedema. From a clinical 
standpoint the diagnosis is plausible if a loud typical murmur of 
mitral insufficiency is auscultable.
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sas congestive failure is an equally rare incident; affected dogs 
may die suddenly [20]. 
radiologically, congestion is manifested by dilated pulmonary 
veins and cardiogenic oedema that initially is characterised 
by an increased interstitial lung pattern progressing to an 
alveolar pattern. Typically, the oedema starts in the perihilar 
area progressing to the caudo-dorsal lung fields (Fig. 1 & 2). In 
addition, there should generally be clear radiological signs of left 
sided cardiac disease with distinct left atrial dilation as well as 
clear clinical signs of an underlying cardiac disease that concurs 
with the radiograph findings [21].
Pathogenesis and causes of non-
cardiogenic pulmonary oedema
Various mechanisms are responsible for non-cardiogenic 
oedema to develop; i.e. low alveolar pressure, increased vascular 
permeability, increased hydrostatic pressure and a combination 
of these. The various causes, according to pathophysiology are 
summarized in Table 1. The risk of developing non-cardiogenic 
pulmonary oedema seems to be higher in younger animals [16]. 
Low alveolar pressure develops after fast removal of pleural 
effusion, pneumothorax, or lung lobe torsion, called re-
expansion oedema. mortality of this rare complication in 
humans is described as 20% [22]. In veterinary medicine, 2 
feline cases have been described in which both died [8,9]. Low 
alveolar pressure also results from upper airway obstruction, 
called postobstructive oedema; e.g. in brachycephalic syndrome, 
laryngeal paralysis, tracheal collapse, strangulation (Fig. 3), and 
iatrogenic causes during intubation and bronchoscopy (Fig. 4) 
[3,14,15,23]. The non-cardiogenic oedema in some hunting dogs 
may partially be caused by obstruction, specifically laryngeal 
oedema associated with prolonged and constant barking. more 
likely in these dogs it is neurogenic oedema associated with a 
very high catecholamine level (see below) [17]. Postobstructive 
pulmonary oedema in dogs and cats is probably much more 
common than diagnosed. many cases may be misdiagnosed 
as cardiogenic oedema, because dyspnoea and oedema are 
associated with exercise or a stress situation, e.g. in laryngeal 
paralysis or oedema associated with anaesthesia, or because 
affected animals may have two concomitant diseases, e.g. 
tracheal collapse and degenerative mitral valve disease [24]. 
a further important cause of non-cardiogenic oedema is 
neurogenic oedema. Pathophysiologically, excessive sympatho-
adrenergic activation in the medulla oblongata plays the central 
role. This results in pulmonary venous constriction shifting 
blood from the systemic to the pulmonic circulation, increase in 
pulmonary hydrostatic pressure and finally oedema [25]. Causes 
described in dogs are brain trauma, epileptic seizures and 
electrocution [11,13,15]. Pulmonary oedema occurs in hunting 
dogs during or after the hunt and is thought to be a neurogenic 
oedema caused by excessive catecholamine secretion [17]. a 
Fig. 3: Radiographs of 
a 7-month old Labrador 
with severe dyspnoea after 
strangulation. 
The dog was tied to a 
leash and unobserved 
for a short moment, and 
subsequently developed 
severe dyspnoea. The 
radiological correlate 
is a diffuse alveolar 
pulmonary opacification, 
most prominent in 
the caudo-dorsal lung 
field (3a & b).The heart 
appears hypovolaemic. 
Treatment with artificial 
respiration (PEEP) 
over 36 hours resulted 
in gradual stabilisation 
of the critical state. 
Radiographs obtained 
48 hours after admission 
show marked regression 
of the oedema; however, 
as a consequence of 
PEEP an extensive 
pneumomediastinum can 
be recognized (3c & d).  
a b
c d
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Pulmonary oedema and low oncotic 
pressure
Oncotic pressure, primarily dependent on plasma albumin 
concentration, is one of the important factors in keeping fluid 
inside the vasculature but it does not play an important role 
in the lungs. The pulmonary interstitial space normally has 
a higher albumin concentration than other interstitial tissue 
and a small oncotic gradient, because the permeability of 
pulmonary capillaries is higher than in other capillaries. When 
plasma albumin drops, the interstitial albumin concentration 
drops as well, therefore not markedly affecting the oncotic 
gradient. Thus, it is unusual to find pulmonary oedema when 
hypoalbuminaemia is the only abnormality [1].
Therapeutic principles for treating  
pulmonary oedema
In cardiogenic pulmonary oedema the central therapeutic focus 
is to decrease preload by aggressive diuresis using loop diuretics. 
In contrast, the various mechanisms of non-cardiogenic oedema 
are not affected by diuresis. Furthermore, in some diseases, 
fluid therapy is indicated rather than diuresis to supportively 
treat the underlying disease, e.g. in sepsis, pancreatitis and 
leptospirosis. However, in these cases, infusion therapy must 
be defensive/cautious. The primary supportive measure is 
optimised oxygenation. Depending on the cause and severity 
particular pathogenesis of neurogenic pulmonary oedema 
is the one in endurance athletes caused by cerebral oedema 
elicited by hyponatraemia [6]. Prognosis for complete recovery 
in neurogenic oedema is good with adequate supportive care. 
acute (formerly adult) respiratory distress syndrome, arDs [2] 
is an important factor in the development of non-cardiogenic 
oedema. The underlying cause is severe and diffuse damage 
of the lung parenchyma resulting in endothelial and epithelial 
disturbance of permeability and exit of protein rich fluid. 
Complicating factors are coagulation disturbances, perfusion 
disturbances and loss of surfactant. arDs may be a complication 
of primary lung damage, e.g. after inhalation of toxic gas 
(smoke intoxication), aspiration of gastric content, inhalation of 
hyperbaric oxygen (oxygen intoxication) or pneumonia. arDs 
may also be a complication of a severe systemic disease like 
sepsis, extensive burns and acute pancreatitis. The prognosis even 
with intensive supportive care is poor [16]. Pulmonary oedema 
similar to arDs can be elicited by multiple blood transfusions; 
even though this complication is life threatening, the prognosis 
is much better than in arDs [2,5]. a further important cause 
of protein-rich pulmonary oedema is vasculitis and disturbed 
vascular permeability well recognised in dogs with leptospirosis 
[26]. This may be complicated by prognostically important 
pulmonary haemorrhages that may not be differentiated 
radiologically from oedema [27]. 
Finally, high altitude above around 3000 m may cause non-
cardiogenic pulmonary oedema in susceptible individuals [28]. 
Fig. 4: Radiographs of a 3-year old 
cat with non-cardiogenic oedema 
occurring during bronchoscopy. 
During a bronchoscopic exam, a 
dramatic drop in oxygen saturation 
was observed on the pulse oximeter, 
and loud crackles were auscultable. 
The radiological correlate was 
a severe generalized alveolar 
pulmonary opacity, pronounced 
in the caudo-dorsal lung fields (4a 
& b). An echocardiographically 
normal heart excluded a cardiogenic 
cause. After 48 hours of absolute 
rest in an oxygen cage there was 
nearly complete resolution of the 
pulmonary changes (4c & d). The 
suspected pathogenesis was airway 
obstruction by the endoscope. 
a b
c
d
195
EJCAP - Vol. 21 - Issue 2 October 2011
of the oedema, keeping an animal quiet in an oxygen-rich 
environment may suffice, or artificial respiration using positive 
end exspiratory pressure (PEEP) may be needed [4]. The use of 
glucocorticoids is controversial. In a recent human study, low 
dose and early application of methylprednisolone had a positive 
effect on the course in arDs [29]. Furthermore, extrapolated 
from human medicine, steroids seem useful in the pulmonary 
oedema in leptospirosis [30].
In summary, cardiogenic and non-cardiogenic causes may lead to 
the development of pulmonary oedema. The exact identification 
of the underlying cause is of paramount importance for therapy 
and prognosis. more and more so-called hopeless cases may be 
cured with progressive specialisation in intensive care medicine 
and with the dedication of veterinarians and animal owners 
allowing time consuming and costly treatments.
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How to create responsive 
clients
Caroline Jevring-Back,
Published by Saunders Elsevier,
(http://intl.elsevierhealth.com.vet) 
(April 2010) E-Book Further details: http://
saunderssolutions4vets.com/ 
ISBN-9780702040542 € 42 99 £ 35
How to create responsive clients is an 
“online” based educational programme for 
vets and practice managers who wish to 
learn more about client communication skills. 
This programme can also easily be used by 
nurses and receptionists. The format of this 
“e-book” is quite interesting as it mixes text, 
images, animations and sound. It reminds 
me very much some of the CD Roms and 
DVDs that were proposed in the 90s when 
LifeLearn wanted to launch their “Veterinary 
Staff Training Series”.
The interactive component is clear, pleasant, 
and makes the learning experience educa-
tional and fun. The content is “scientifi cally 
sound” and of a good standard. Vets will 
acquire a solid basic understanding of client 
education features, including client compli-
ance (a popular topic in the last few years). 
The author insists on the central role played 
by the client, which is crucial. Clients are 
indeed the “life-blood” of our business and 
are NOT “an incidental encounter vets have 
to (unfortunately) experience a few times 
through their working day”
The programme nicely mixes theory and case 
studies and makes the application of the 
lesson immediately relevant. It reinforces the 
impact of the messages. Examples are mostly 
interesting and pertinent. Some examples 
and quite “extreme” and could unfortunately 
make readers think they are “way out”, thus 
losing their credibility as they listen to some 
poor answers and behaviour. However, one 
should not be put off by this initial impres-
sion, as things get better.  It is probably a 
good learning experience for most of us to 
see and listen to “the very bad” and then to 
“the excellent” as the difference is striking 
and the point is well made.
Assessments are also inserted at each step 
of the module, helping the reader “check” 
his or her learning curve and fully understand 
the course. The narrative component is excel-
lent and professionally produced: the speech 
is clear and well paced. The “post-its” that 
are placed on the screen are a good idea 
and an effective way to emphasize some key 
points throughout the segment. When the 
wrong answer is given, a correct answer is 
then provided and explained in detail. For 
case study N°3 it was NOT striking to me that 
that dog was overweight (but maybe it is 
because I own a fat Labrador!). Still, I would 
have picked an obviously obese example in 
such case. 
Conclusion and Summary
How to create responsive clients is an interest-
ing and good programme in many respects. 
The module will certainly contribute effec-
tively by helping staff to better use open and 
closed questions and also understand what 
compliance is all about. Readers will learn to 
adopt “active listening techniques” as well 
as “checking” with clients to make sure they 
have captured your message. I recommend 
this excellent basic programme to introduce 
your staff to client communication skills.
Philippe Moreau, DVM, MS, DECVIM, DECVN 
(F)
Textbook of Veterinary Internal 
Medicine Expert Consult, 7th 
Edition
Edited by Stephen J. Ettinger, DVM, DACVIM 
and Edward C. Feldman, DVM, DACVIM
Published by Elsevier Saunders
(http://www.elsevierhealth.com.vet) (2010 )  
2208 Pages, Hardback 2 Volumes
ISBN: 978- 1-4160-6593-8
ISBN  978-1-4160-6593-7 € 221  £ 181
When I received and opened this edition I 
was pleasantly surprised by the colourful 
appearance, making manoeuvring through 
this book more exciting and fun then in the 
earlier editions. 
In the introduction the reader gets as usual 
the list of outstanding contributors, most of 
them from the USA and Canada, but also 
quite a lot from Europe and Australia. 
The fi rst section is somewhat new and 
contains the latest information on genom-
ics. After this comes the second more well 
known section containing some really good 
illustrated algorithms and up to date differ-
ential diagnostic lists which are very practical 
when working up a patient’s problem list. 
Leading on from these two chapters there 
is an extremely well documented section on 
different techniques used in the different 
fi elds of internal medicine. Following these 
introductory sections the reader will fi nd 
chapters focusing on specifi c disease entities, 
all well updated.
Those used to reading this textbook will be 
surprised by the many changes compared 
with the fi rst six editions. Some changes may 
surprise readers unable to fi nd certain infor-
mation in its usual place- for example the 
section on haematology and immunology 
which is now in the fi rst book.
I agree with the Editors, it was really good 
to remove some older subject matter making 
this edition a really good textbook keeping 
up with the explosive changes we meet every 
day in internal medicine.
The layout of this edition is made extremely 
user friendly through the use of colour, the 
enormous amount of very practical algo-
rithms, tables and boxes, and the wide range 
of clear and relevant photographs. 
If I had to be really picky, I have some issues 
with some aspects of the headings, especially 
in the second volume. They can be somewhat 
confusing: subtitles are sometimes larger 
than main headings (e.g. diagnosis, treat-
ment). I personally prefer the main headings 
to be larger to have a better overview of the 
plain text.  
As the editors point out, this seventh edition 
has become quite “electronic” making 
this textbook an ideal teaching resource.  I 
really wish this had been available when I was 
studying!
References have been omitted in an attempt 
to be “green” (i.e., to save trees by not wast-
ing paper). I understand the editors view 
completely although I personally like to have 
the references in the book.
Thus there is much in this edition making it 
not only extremely valuable for vets with a 
special interest in internal medicine but also 
for anyone in general practice and for veteri-
nary students learning their way in internal 
medicine. 
A must-have book with an enormous amount 
of recent information put together by a lot 
of well known contributors, in an extremely 
pleasant way to use and read.
 
Dr Greet Junius (B)
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BSAVA Manual of Canine 
and Feline Reproduction and 
Neonatology, 2nd edition
Edited by Gary England and Angelika von 
Heimendahl
Published by BSAVA 2010 Distributed by 
Wiley-Blackwell 240 pages Paperback 
ISBN- 978 1 905319 19 0 90 €  £75 
Available from www.wiley.com/go/vet
BSAVA members should order from
www.bsava.com for member prices
Well known authors from France, Italy, 
Norway, Spain, Sweden, Turkey, the UK and 
the USA have contributed to this enlarged 
2nd edition. It comprehensively covers the 
following topics.
•  endocrinology and physiology of female 
and male reproduction, 
•  prevention of breeding in both the female 
and male,
•  the clinical approach to the infertile bitch, 
queen and infertile male, 
• artiﬁ cial insemination in dogs,
•  pregnancy diagnosis, normal and abnormal 
pregnancy and parturition in the bitch and 
queen, 
•  the clinical approach to unwanted mating 
and pregnancy termination,
•  management and critical care of the 
neonate,
•  the clinical approach to neonatal condi-
tions.
•  The last chapter covers the clinical approach 
to common conditions such as mammary 
gland disease, conditions of the non-
pregnant and neutered bitch and queen, 
to conditions of the male and the clinical 
relevance of biotechnology advances.
This book is fi lled with many pictures and 
schematic  diagrams and gives the reader a 
very good overview and a wealth of informa-
tion covering all aspects of the approach and 
treatment of reproductive disorders of dogs 
and cats. It can be warmly recommended to 
veterinarians, veterinary nurses and students.
Dr. Hans-Klaus Dreier, (A)
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Slovak
201
6 December VICAS Dublin CE Ultrasound - Intermediate/Development Level English
6 December BSAVA Kettering Old dogs and new tricks: Canine Geriatrics English
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ISFM Hong Kong International Feline Symposia ‘Feline Diagnostic - Clinical pathology 
and diagnostic imaging’
English
24-25 March AVEPA Cordoba Veterinary Specialities Congress Spanish
5-8 April HVMS Annual Congress Greek, English
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24-26 May ECVD Lisbon (P) 21st European Congress of Veterinary Dentistry English
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30 Nov-2nd Dec AFVAC Paris - La Defense Annual Congress French
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